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Abstract 
With the incidence of many cancers, including brain tumours, increasing worldwide, the 
diagnostic pathway and new innovative treatments have often failed to keep pace. The 
main stay of cancer diagnosis remains at the Histopathologists’ microscope, with little 
change in light microscopy within recent times. Research promises many new diagnostic 
tools, aiming to improve turn around times and provide instant accurate answers. One 
such tool is vibrational spectroscopy. This thesis aims to use spectroscopy as a proof of 
concept within brain tumour diagnostics to demonstrate its abilities within the cancer 
diagnostic pathway. 
Proof of concept studies aimed at targeting both biofluid and tissue diagnosis of primary 
and metastatic brain tumours has been performed, along with involvement of Patients’ 
and Clinicians’ to aid development of diagnostic tools. Spectrochemical methods 
including Raman and attenuated total reflectance- Fourier transform infrared 
spectroscopy (ATR-FTIR) have shown an ability to diagnose primary and metastatic 
tumours; with fresh frozen tissue ATR-FTIR proved superior with a classification 
accuracy of non-tumour brain versus primary brain tumours of 97.2%, though this 
decreased when comparing tumour types (79% accuracy); when differentiating 
metastatic brain tumours from formalin fixed tissue accuracy was similar for both 
spectroscopic techniques at 60% for colorectal adenocarcinomas, 68% for lung 
adenocarcinomas and 70% for melanoma; finally, with biofluids, using ATR-FTIR to 
determine a primary versus metastatic tumour and the type of each tumour, accuracy was 
low at  non tumour 85%, high grade glioma 92%, low grade glioma 61%, meningioma 
43%, melanoma metastasis 21%, colorectal adenocarcinoma metastasis 50% and lung 
adenocarcinoma metastasis 24%.  The final, novel study, trialled a handheld Raman 
spectrometer within the histopathology department at Royal Preston Hospital, Lancashire 
Teaching Hospitals NHS Trust, to determine if the benefits of spectroscopy lay within 
the intraoperative diagnosis. The final results demonstrate accuracies from 64-94% 
depending on tumour type, demonstrating that with further training, Raman spectroscopy 
may provide a clinically useful diagnostic tool within the operating theatre, to replace the 
need for intraoperative smear preparations and diagnosis by a Neuropathologist. 
Overall, this thesis highlights the need to involve Patients’ and Clinicians’ within 
research to ensure uptake and accurately targeted diagnostic tools. It also demonstrates 
the potential of spectroscopy, when well targeted within the diagnostic pathway. Moving 
forward, further work to move Raman spectroscopy into the operating theatre, is likely to 
prove beneficial to patients.  
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1. Introduction 
	  
The diagnosis and treatment of cancer has taken great steps forward in recent years, with 
earlier diagnosis and improved treatment, though little has changed around the 
pathological diagnostic process. Techniques invented hundreds of years ago are still in 
use today and are held up as the gold standard. Many new diagnostic tools are now in 
production aiming to improve accuracy, reproducibility and speed of diagnosis. The aim 
of this thesis is to use one such tool as a proof of concept within brain tumour diagnostics 
to demonstrate that whilst new developments may be useful as an adjunct within the 
diagnostic pathway, the gold standard of histopathology remains as important as ever.  
 
1.1 Pathology 
 
Pathology is a medical speciality whose name refers to the study of disease. It is derived 
from three Greek words meaning tissue, suffering and study of (IvyRose Holistic, 
accessed 23/1/18). It encompasses nineteen disciplines, including; histopathology, 
virology, microbiology, biochemistry and immunology. Histopathology as a sub-
speciality has been around for many years and is practised by medical doctors with 
specialist training to become a Histopathologist. It encompassed the microscopic 
examination of tissue, often used to diagnose disease. Tissue is examined, following 
fixation with formalin, and then processed and embedded within wax. Following this, 
sections several microns thick are cut and stained with Haemotoxylin and Eosin (H&E). 
The sections are then examined using conventional light microscopy, a technique that has 
changed little since the time of Virchow, widely known as the ‘Father of modern 
pathology’ in the mid 1800’s (Schultz, 2008). Histopathology usually provides the 
patient with a diagnosis and is a crucial stage within most patient pathways, with 70% of 
all diagnoses within the NHS attributable to pathology (RCPath, 2017).  Figure 1.1 
shows the flow of specimens through a pathology laboratory prior to examination.   
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Figure 1.1: A flow diagram demonstrating the workflow through a pathology department. 
Starting with formalin fixation, which takes 24-48 hours. This is followed by processing and 
embedding which for large specimens takes another 24 hours. This is then cut and stained, 
ready for microscopy. (St Michaels Hospital, accessed 12/12/17) 
 
This process has been in place for many years and results in a tissue sample being out of 
the patient for over 48 hours before it can be adequately examined by a pathologist and a 
report issued.  In contrast to this frozen sections were brought in to circumvent this 
process for an urgent specimen with diagnosis provided during an operation. This is used 
primarily as an intraoperative aid, often to determine margin clearance or if the area 
resected contains a malignant tumour. This cannot provide as detailed an answer as full 
fixation and examination, but it does, in most cases, answer the question of benign versus 
malignant in under half an hour of the tissue arriving into the pathology laboratory. This 
is achieved via snap freezing the tissue and cutting it in a cryostat which allows the tissue 
to be cut frozen without defrosting. This is then stained in the same manner as a fixed 
tissue section with H&E. 
Formal histological examination often provides a definitive diagnosis and the paraffin 
tissue block created can then be used for molecular testing if needed. During the 
diagnostic process, special techniques such as immunohistochemistry (IHC) are often 
used in order to support the morphological examination. IHC uses antibodies directed at 
specific antigens in order to detect their presence within a specific tissue. When used to 
determine the origin of a tumour a panel is used to encompass those expected to be 
positive and negative to ensure accuracy. A reagent (such as DAB, 3.3’-
diaminobenzidine) indicates a positive presence with a brown stain, within either the cell 
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cytoplasm or nucleus (see Table 1.1, page 15 and table 1.2, page 16). The combination of 
positive and negative stains, chosen depending on the tissue type, helps to determine the 
tissue of origin when combined with morphological appearances.   
One of the main pitfalls within histopathology is the widely reported inter-observer error. 
As so much of pathology is performed independently it can be subject to human error. In 
complex cases or difficult areas, such as dysplasia in the upper GI tract, cases are shown 
to colleagues, which can lead to disagreement. These cases are then sent to specialists, 
who tend to look solely at this area of pathology in order to reach a consensus. In some 
cases, this may still not be possible and clinical correlation is crucial to provide the best 
management for the patient. Given these complexities, it is not surprising there are intra 
and interobserver differences. These can range from a change in dysplasia grade to 
difficulty in identifying early invasive lesions (Coco et. al., 2011). This can be 
demonstrated within the thyroid with discrepancy between invasive and non-invasive 
lesion within 57% of minimally invasive thyroid follicular carcinomas (Franc et. al., 
2003).   
In order to meet Government targets, for example for cancer care, histopathology output 
is measured in turn around times. This is the time taken from the tissue being removed 
from the patient to the time for an authorised report within the hospitals system. The 
Royal College of Pathologists make suggestions as to how long this should take based 
upon the sample and the urgency determined by the requesting Clinician. This can range 
from 5-10 working days depending on if this is a biopsy (e.g. a small piece of tissue, 
usually less than 5mm) to a resection specimen (e.g. a segment of bowel) and if this is 
deemed clinically urgent by the requesting Clinician.  
This contrasts with cytology, which is the study of cells. Cytology specimens can be 
taken from anywhere in the body, they usually are from abnormal fluid collections, such 
as pleural effusions or from fine needle aspiration (FNA) of a lump, lymph node or organ 
e.g. thyroid. The cells are either smeared directly onto a slide and fixed with an alcohol 
spray prior to staining or they are suspended in an alcohol based fixative, such as 
cytorich red, and then spun using a centrifuge onto a slide. Special inserts are used within 
the centrifuge to ensure the cells are focused onto one spot. This technique is known as a 
cytospin preparation (see Figure 1.2). This is then traditionally stained with a 
Papanicolaou (PAP) stain.  Direct smear preparations are stained with either May-
Grünwald Geimsa (MGG) or PAP stain. This is done to best visualise the nuclei of the 
cells and the cytoplasm. These specimens have no architecture to assess and the 
diagnosis is made purely on the appearance of the cells and nuclei. This can be prepared 
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in 24 hours, improving turn around times. It has its own limitations due to lack of 
architecture and the need for further work in order to be able to perform 
immunohistochemistry. Though as a sub specialist area the development of cell blocks (a 
technique that produces a formalin fixed paraffin embedded block for IHC, similar to 
that used for histology and processed in the same manner) has brought cytological 
diagnosis forward and its role as a diagnostic tool is increasing.  
 
Figure 1.2: Pictures demonstrating the preparation of a cytology slide. The cells are 
suspended in an alcohol based fixative fluid before being spun onto a circular area of the 
slide using a centrifuge and a stencil. This is then stained using a Papanicolaou (PAP) stain 
before microscopy. (A) the specimen is transferred into a spinning tube and spun down, (B) 
the glass slide is placed into the centrifuge container to focus the cells onto a spot, (C) the 
sample that has been spun down into a pellet is now placed into the centrifuge container, (D) 
the centrifuge is closed, (E) after the centrifuge the slide is placed into the auto-stainer, (E) a 
PAP stained slide.  
 
1.1.1 Pathology Services in the UK 
 
The last Government led review of pathology in the UK took place in 2006. This was 
undertaken as a seminal paper to highlight the need to improve UK pathology services. It 
recognised UK pathology deals with over 17 million slides covering both histology and 
cytology a year (Carter, 2006). The majority of NHS based hospitals have a pathology 
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department, though over recent years pathology as a speciality is being forced to 
streamline departments and merge to form large specialised centres, where possible, to 
reduce the cost of the service (Carter, 2006). This has followed the subspecialisation of 
surgery, which has resulted in a hospital specialising in, for example, cardiothoracic 
surgery. This is highlighted by Blackpool Victoria Hospital, which covers all lung 
resection specimens for Lancashire and South Cumbria (shown in Figure 1.3), 
comprising over 1.7 million patients (Healthier Lancashire and South Cumbria, 2016). 
This results in a department dealing with specimens for patients over a large 
demographic area of the UK and the need for crosslinking computer systems to allow 
important clinical information not to be missed is crucial.  
 
Figure 1.3: The Lancashire and South Cumbria geographical area as dictated by the 
regional sustainability and transformation partnership (STP) (Healthier Lancashire and 
South Cumbria, 2016) 
 
Pathology is also facing a recruitment crisis. There are more Consultants retiring than 
trainees both within the training programme and completing training. This has led to 
some departments relying on out-sourcing cases for reporting to private firms. These 
firms provide a diagnostic service on a pay scale depending on the complexity of the 
case. Within the NHS itself, a routine biopsy from the GI tract costs around £60 
(Shepherd et. al., 2014). Other options being trialled to improve staffing levels, involves 
the training of biomedical scientists (BMS) to perform some roles normally done by a 
pathologist. This often includes cut up (the selection of tissue of from areas of interest 
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from a large specimen in order to process into tissue blocks for examination) and in some 
cases reporting basic specimens with strict guidelines (Lishman and Sturdgess, 2017 ). 
This has been met with some resistance, as the BMS is not a medically trained 
professional and opened a large debate into who should be allowed to undertake various 
roles within the laboratory.  In the United States of America, their histopathology 
departments are run in a similar fashion with hospital based pathologists paid for the 
work performed via insurance companies as opposed to the NHS.  
 
1.1.2 Pathology Worldwide 
 
Within the wider developing world, histopathology services are rudimentary at best. 
There is a marked shortage in staff. Within North America and Europe there are from 14-
40 pathologists per million populations, whereas in the developing world this ranges 
from 0-low single digits. For example Tanzania has 15 pathologists for 38 million people 
(Benedikttson et. al., 2007). Services such as the American Forces Institute have been 
cut, again reducing availability of the developing world to histopathology services 
(Humphreys et. al., 2010). Training in these regions is also variable, along with many 
hospitals relying on machines donated from the Western world, which may not be fit for 
purpose in developing countries with marked climate differences (Benedikttson et. al., 
2007). To compound this, within these parts of the world, cancer diagnostics often occurs 
at a late stage and treatment is unlikely to be readily available. Therefore offering an easy 
to use technology is likely to aid diagnostics greatly, especially if the technology is low 
cost to run (Benedikttson et. al., 2007). Additions to diagnostics within this forum could 
revolutionise diagnosis, however, without the treatment to follow on, its use is again 
limited.  
 
1.1.3 Pathology Moving Forward 
 
Within the developed world, in an effort to ever specialise departments and to meet the 
growing demand for ‘personalised medicine’, pathologists are tending to work in a niche 
market of a single organ system to accommodate the need for in-depth specialist 
knowledge.  Compounding this there is a new Government aim of a cancer diagnosis 
within 4 weeks of visiting your GP by 2020 (Karakusevic et. al., 2016). This again 
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highlights the need for fast, accurate diagnostics. There are two complicating factors to 
this; one is the increasing demand and pressure on overstretched and under resourced 
pathology departments, and secondly the impending recruitment crisis within pathology 
as fewer trainees apply and the aging consultant body retires (RCPath, 2015). To help 
combat this, new diagnostic tools are required to aid the pathologist in ensuring accurate 
diagnostics whilst improving and decreasing turn around times. This aids the pathology 
department by improving workflow and allows other areas of clinical work to meet the 
new Government targets of 4 weeks to diagnosis by providing the diagnosis is a timely 
manner (Karakusevic et. al., 2016).  
A tool to allow the clinician to make an accurate diagnosis in clinic without the need for 
a biopsy, leaving the pathologist to focus on the resection and staging may be very 
beneficial. However, given tumours can change their appearances following chemo-
radiotherapy, a biopsy prior to treatment, if this is the patient’s first port of call, may still 
be required. Being able to re-examine a biopsy in the context of examining the resection 
specimen or subsequent biopsies can be very helpful in challenging cases. 
 
1.2 Cancer 
 
Over 350,000 people are diagnosed with cancer each year; of these over 50% comprise 
breast, prostate, lung or bowel cancer (CRUK A, accessed 1/12/16). The vast majority of 
these patients will require samples to pass through a histology department for diagnosis. 
New statistics show that 1 in 2 people born after 1960 will be diagnosed with some form 
of cancer in their lifetime, demonstrating the importance of innovative new technology to 
assist already busy pathology departments (CRUK B, accessed 3/11/17).   
 
1.2.1 Primary brain tumours  
 
Primary central nervous system (CNS) tumours comprise approximately 3% of all 
cancers, of which less than 5% are hereditary. Almost half of these tumours are 
astrocytic in origin, with another 20% meningothelial in origin. Of the astrocytic 
tumours, glioblastomas are more common in men, whereas mengingiomas are more 
common in women. For the latter this is thought to be due to the oestrogen driver of 
	   	   	  9	  
some of the meningiomas (CRUK C, accessed 3/11/17, CRUK D, accessed 3/11/17, 
Ellison et. al., 2013).  
Around half of all patients are alive one year after diagnosis, showing the relatively poor 
outcome of the majority of primary CNS tumours. These tumours present with a range of 
features, including; epilepsy, focal neurological defects and non-specific features such as 
mood change.  
Diagnosis is often made initially intraoperatively using a smear preparation by a 
Neuropathologist (see Figure 1.4). This affords the surgeon more information on the 
tumour such as its lineage and can help plan the extent of the resection. Following on 
from this the tissue is then formalin fixed to provide a definitive specimen on which to 
perform immunohistochemistry and to grade the tumour according to the World Health 
Organisation (WHO) grading system for CNS tumours (Ellison et. al., 2013). 
 
Figure 1.4.: Photomicrograph of a H&E stained brain smear, demonstrating the lack of 
architecture seen in a smear preparation. It highlights the cells and nuclei but no tissue 
structure is seen.  
 
1.2.1.1 Astrocytomas 
 
Astrocytomas are glial in origin, and usually occur in the 3rd-4th decades of life. They 
arise within either; the neural stem cells, progenitor cells or differentiated glial cells. 
They are graded based on WHO recommendations from 1 to 4, with 1 and 2 comprising 
low-grade tumours and 3 and 4 high grade (Louis et. al., 2016). Grade 4 corresponds to a 
glioblastoma. Grades 2 – 4 are most common in adults within the cerebrum. Numerous 
genetic mutations occur with early mutations within isocitrate dehydrogenase 1 (IDH1) 
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and tumour protein 53 (p53), and allelic loss in chromosome 10 common in 
glioblastomas. Up to 50% of all gliomas are glioblastomas at diagnosis. Of the lower 
grade tumours 50-70% progress to glioblastomas, usually over 3-5 years. This 
transformation is associated with increasing genetic abnormalities, examples of which 
can be seen in the pathway below (Figure 1.5) (Ellision et. al., 2013). 
	  
 
Figure 1.5: A pathway demonstrating the different mutations seen in primary and 
secondary glioblastomas based on the WHO Classification system (Louis et. al., 2016). 
 
Radiologically, astrocytomas of differing grades show different appearances. These are 
again different to those seen within metastasis. This rule, can however, be broken with 
metastasis mimicking primary tumours and vice versa. Radiologically, primary brain 
tumours are usually seen as peripherally enhancing lesions (see Figure 1.6). 
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Figure 1.6: Radiological images of a low grade astrocytic tumour (A) demonstrating a non 
enhancing, ill defined lesion and a high grade astrocytic tumour (glioblastoma) (B) showing 
a peripherally enhancing lesion (Ellision et. al., 2013).  
 
Pathologically as the grade of the tumour increases, so does the cellularity, 
pleomorphism of the cells, mitoses, necrosis and vascular proliferation (Figure 1.7). This 
enables the pathologist to grade the tumour, providing important information to the 
Clinician to guide treatment and prognosis.  
 
Figure 1.7: Photomicrograph of a glioblastoma demonstrating palisading tumour necrosis 
(black arrow) and vascular proliferation (arrow head).  
 
 
A	   B	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1.2.1.2 Meningiomas 
 
Meningiomas arise from the mengingothelial cells within the leptomeningies and can 
occur anywhere in the CNS. The site will often determine the ease and completeness of 
resection. Up to 15% of those thought to be completely resected will recur. The 
incidence of these tumours increases with age with a female:male ratio of 3:2. They are 
associated with oestrogen dependant carcinomas of the breast and endometrium. A wide 
range of histological patterns are seen as cells can have either epithelial or mesenchymal 
differentiation, with the WHO grading these from 1 -3 see Figure 1.8 below) (Ellision et. 
al., 2013). 
 
	  
Figure 1.8: Photomicrograph of a meningioma demonstrating cleared nuclei and whorls, 
indicative of meningothelial cells. The arrow indicates a whorl, within which the nuclei show 
clearing.  
 
1.2.1.3 Metastatic Brain tumours  
Metastatic brain tumours are usually the end point in a persons’ journey through cancer. 
The number of metastatic brain tumours identified each year is difficult to quantify, 
however they out number primary tumours by roughly 3:1, with the majority of 
metastases from primary lung tumours (Davis et. al., 2012, Huang et. al., 2013, Renfrow 
et. al., 2013). Interestingly, less than 9% of colorectal tumours metastasize to brain, in 
contrast to melanoma, which shows a predilection for the CNS (Sanghvi et. al., 2017). 
Whilst 80% of patients have a known primary, for some patients, the identification of 
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metastasis may be the initial presentation of the primary tumour (Bekaert et. al., 2017). It 
is thought that the number of brain metastases is higher than reported as some may go 
undiagnosed. Most metastasis are found at the grey white matter junction (these are areas 
with a dual blood supply). They are usually discrete masses though occasionally show a 
more diffuse, infiltrative growth pattern mimicking primary CNS tumours. For those who 
undergo metastectomy for diagnosis or symptom relief, the tissue, once removed is sent 
for histopathological analysis to determine the origin of the primary tumour. 
In order to reach a diagnosis this often comprises a mix of morphological appearances 
and IHC tests. The combination of IHC tests enables the pathologist to give either a 
single or group of organs from which the primary tumour likely arises. Morphologically 
these tumours can look remarkably similar (see Figure 1.9). For example, when 
differentiating adenocarcinomas from melanomas a combination of epithelial and 
specific protein markers are used (please see also Table 1.1). These include; anti-
epithelial cell adhesion molecule (Anti-EpCam/BerEP4), a marker of epithelial cells and 
therefore expressed in the majority. Cytokeratin 7 (CK7) and cytokeratin 20 (CK20), 
these are cytokeratin’s expressed in different patterns throughout glandular and 
transitional epithelial tissues within the body. The pattern of CK7 and CK20 helps to 
localise the primary tissue site, for example in lung tumours CK7 is positive and CK20 
negative. This is a similar pattern to that seen in the upper GI tract. However in the lower 
GI tract CK7 is negative and CK20 positive. This is then followed with more specific 
markers, such as homeobox protein CDX-2 (CDX-2), which indicates origin in the GI 
tract, or thyroid transcription factor 1 (TTF1), which would suggest a primary lung 
tumour. There is some overlap with staining hence some lung adenocarcinomas will 
express CDX-2, when they demonstrate a more intestinal phenotype. The combination of 
staining patterns allows the user to determine primary site, in combination with clinical 
and radiological information. For melanoma, these stains will be negative and a more 
limited range of stains is positive, these include S100 protein and melanoma antigen 
recognized by T cells 1 (Melan A). The table below highlights the positive and negative 
staining patterns of lung and colorectal adenocarcinomas and melanoma when tested for 
a panel of immunohistochemical stains.  
	   	   	  14	  
 
Figure 1.9: Photomicrographs of brain metastasis from colorectal and lung 
adenocarcinomas and a melanoma metastasis. (A) is a metastasis from a colorectal 
adenocarcinoma (H&E ×200 objective); (B) is a metastasis from a lung adenocarcinoma 
(H&E ×200 objective); and, (C) is a metastasis from a malignant melanoma (H&E ×200 
objective). 
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Table 1.1: A representative immunohistochemical panel for the differentiation of lung and 
colorectal adenocarcinomas from melanoma. (Key: +=positive, -=negative, +/-=variable)  
 
Immunohistochemical 
Stain 
Lung 
Adenocarcinoma 
Colorectal 
Adenocarcinoma 
Melanoma 
BerEP4 + + - 
CK7 + - - 
CK20 -/+ + - 
TTF1 + - - 
CDX-2 -/+ + - 
S100 - - + 
Melan A - - + 
 
1.2.2  Lung Carcinoma 
 
In 2014 there were 46,403 people were diagnosed with lung cancer; of these 5-8% where 
still alive after 5 years (CRUK E, accessed 3/11/7, CRUK F, accessed 1/5/17). The 
development of lung cancer is multifactorial. Whilst the contribution from tobacco and 
smoking is no longer disputed, there are a growing proportion of tumours, up to 10-15%, 
developing in women who have never smoked. These tumours are increasingly 
adenocarcinomas, harbouring specific genetic mutations, with over half of all lung 
cancers in women being adenocarcinomas. However, the majority of cases (over 90%) 
are in adults over 40 years, and most common in men (CRUK E, accessed 3/11/17).  
Histologically, lung cancer is divided primarily into small cell and non-small cell 
carcinoma. This is done on the basis of morphology and immunohistochemical testing. 
The distinction is important for two main reasons; firstly the chemotherapy regimes 
differ greatly and secondly with the advent of molecular pathology, the genetic mutations 
are tested for on the basis of the histological diagnosis as a means to stratify those most 
likely to harbour treatment targetable mutations.  
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Non-small cell carcinoma is further subdivided into either squamous cell carcinoma, or 
adenocarcinoma. This is often done with the help of IHC as squamous cell carcinoma 
and adenocarcinoma demonstrate different staining patterns due to their different cells of 
origin (see Table 1.2). Approximately three quarters of all lung adenocarcinomas express 
TTF1, making this IHC stain very valuable. Half of all lung tumours in women are 
adenocarcinomas.  
Table 1.2: A representative immunohistochemical panel for the differentiation of non small 
cell tumours of the lung into lung adenocarcinomas and squamous cell carcinomas (Key: 
+=positive, -=negative, +/-=variable) 
 
Tumour CK7 TTF1 CK5/6 p40/p63 
Adenocarcinoma + + - - 
Squamous cell 
carcinoma 
-/+ - + + 
 
1.2.3  Colorectal Adenocarcinoma 
 
Colorectal cancer is the most common malignancy in northwest Europe and North 
America. It affects 1:14 men and 1:19 women during their lifetime, with most over the 
age of 75 (CRUK G, accessed 3/11/17). Survival has more than doubled in the last 40 
years with over 57% alive at 10 years (CRUK H, accessed 3/11/7).  There are many 
contributing factors to the development of colorectal cancer. These can be split into 
environmental; including diet, as diets high in animal fats and red meat have been shown 
to increase risk though this relationship is complex, and genetic; for example familial 
adenomatous polyposis (FAP) and Lynch syndrome.  
The presenting features often include; change in bowel habits, rectal bleeding, weight 
loss or urgent hospital admission with bowel obstruction. Widely used as part of the 
diagnostic work up, is carcinoembryonic antigen (CEA) level. This marker is known to 
be increased in patients with colorectal cancer, and levels return to normal following 
surgery. They are then shown to increase on recurrence. However, this has its limitations. 
It is not appreciably increased in the development stages of colorectal cancer nor is it 
specific. CEA has found to be increased in a range of cancers, including; stomach, lung 
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and pancreatic cancer. Colorectal cancer most often metastases to the liver and lymph 
nodes with brain metastases being relatively rare.   
As the development of colorectal cancer has become more understood with the adenoma 
carcinoma pathway (please see Figure 1.10), the development of a screening test has 
been possible. Faecal occult blood testing is now commonplace in the over 60’s in 
England and is increasing the number of cancer detected earlier, enabling improved 
outcomes (Public Health England, 2015).  
As for lung cancer, colorectal cancer has its own targetable mutations. Testing for 
mismatch repair genes and Kirsten rat sarcoma virus (KRAS) testing is now 
commonplace for colorectal cancer cases in order to guide treatment.  
 
 
Figure 1.10: The adenoma/carcinoma sequence in the development of colorectal carcinoma. 
(Kumar et. al., 2010). 
 
1.2.4  Melanoma 
 
A melanoma is a malignant tumour of the melanocytes, most commonly occurring in the 
skin. Melanocytes are found in the basal layer of the epidermis, this is the innermost 
layer of the epidermis closest to the dermis. There are many types of malignant 
melanoma but the four major types are: lentigo maligna melanoma which is found on 
chronically sun-damaged skin and is most common in older generations that have had 
much more sun exposure, they are commonly elevated from the skin once they invade 
and have a brown colour; acral lentiginous melanomas occur on the soles of the feet, 
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palms and under the nails and are the most common form of melanoma in Asian and 
Afro-Caribbean population; superficial spreading malignant melanoma (SSMM), which 
can occur in any age group, are most common in the middle-aged population, they 
appear flat to the skin or slightly raised with an irregular border and can be a variety of 
colours including brown, white and blue; finally, nodular melanomas can occur on any 
body surface and invade early, they can occur in any age range but are most common in 
middle age, are raised from the skin and most commonly black in colour. 
Melanoma is a cancer on the increase worldwide. It almost exclusively affects 
Caucasians with approximately 9,000 new cases of melanoma diagnosed in the UK each 
year. Although skin cancer is more common in the over 50s, melanoma is the most 
common cancer in the 15-34 age group. The highest rates of melanoma in the world are 
found in Australia and New Zealand (CRUK I, accessed 3/11/17, CRUK J, accessed 
3/11/17). 
 
1.3 Personalised medicine/Molecular pathology 
 
The advent of molecular pathology has allowed various tumour types to be sub-classified 
further and for the production of genetically targeted therapy. One of the first tumours to 
benefit was breast cancer with the discovery of Herceptin (NHS choices, accessed 
23/1/17). This led to changes in breast cancer reporting and the requirement for all cases 
to be sent for hormone status analysis, including Her-2 status, the gene targeted by 
Herceptin. Breast cancer is now moving forward again with at risk patients, defined 
based upon the stage of their disease, being tested using a tool called Oncotype Dx. This 
is a genetic test, performed in the USA, examining activity of 21 pre-defined genes, 
which gives a risk stratification as to the risk of recurrence or new primary and the 
benefit to chemotherapy (Genomic Health Inc., accessed 12/12/17). This is now in 
widespread use within the NHS. Other examples include the ground breaking changes in 
lung cancer using anaplastic lymphoma kinase (Alk) and epidermal growth factor 
receptor (EGFR) mutation status analysis and therefore allowing targeted treatments, 
which in some cases have been shown to extend life by 9-12 months respectively 
(Lindeman et. al., 2013, Vincent et. al., 2012). For lung cancer, this is a marked 
improvement, given 5 year survival has only increased from 5% to 8% in the last 40 
years (CRUK F, accessed 1/5/17). This has driven the drug companies to find new 
targets for potential therapies. One such target is programmed death-ligand 1 (PDL1); 
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this has multiple immunohistochemistry tests depending on which drug company is 
funding the test, though concordance between them is not known (Cree et. al., 2016). 
This requires uniformity, especially if it is to be in general use in departments around the 
country. The main challenge can be for the NHS to keep up with the pace of 
development and for NICE to approve these new drugs. They are often very expensive, 
given the research and development required, which can lead to a rejection on the 
grounds NICE do not feel it meets their cost effectiveness levels. This has recently led to 
a spate of crowd funding for treatment and more people looking abroad for new ground-
breaking therapies. Therefore in order to support the development of targeted medicine, 
not only do new mutations need to be identified, but easy, quick, reliable and importantly 
cheap methods for their identification are required. 
 
1.4 Patient centred care 
 
Healthcare has come a long way from the old model of the doctor and patient interaction 
where the doctor takes on a paternal role and dictates the patients’ treatment plan.   The 
patients of the 21st century are taking a much more active role in their diagnosis, 
treatment and management. A study by the King’s fund demonstrated that as medical 
professionals we are not reaching far enough to help patients understand their disease and 
hence treatment options available to them (Mulley et. al., 2012). A recent study has also 
shown that even with a 1% risk of a cancer diagnosis, patients would want a referral for 
further investigations (Banks et. al., 2014). Giving someone a cancer diagnosis is a major 
life changing moment for them and their families. The importance of the setting and 
delivery of the information cannot be underestimated. In a description of patient 
preferences it was shown that the most important factors to the patient were time spent 
talking and ability to ask questions, be treated as an individual and to feel the doctor was 
supporting them (Thorne et. al., 2010). All of these factors together help form the basis 
of the doctor-patient relationship moving forward and the memories the patient takes 
away of their diagnosis. It is crucially important that this is done well to help the patient 
moving forward and to develop the level of trust needed to help treat the person 
successful. A recent report from The Brain Tumour Charity highlighted the importance 
of recognition of symptoms with 62% of people being diagnosed as an emergency 
following repeated visits to GPs and doctors and wide ranging referral patterns. The 
majority of diagnoses were done by neurologists, with only 60% rated as having very 
good or excellent communication skills (MHP Health, 2013). Correcting these statistics 
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would be a crucial step towards early diagnosis and building trust with patients through 
communication.  
For many years we have understood the importance of informed consent, however, how 
well informed are patients? How much do they understand of the treatment options given 
and how are their decisions being made and to that end how much do medical 
professionals guide the decisions. Decisions regarding treatment both given and received 
are made on an individual basis with the best information available at the time. The 
importance of the way risks are presented either as figures or pictorial representations are 
hugely important as patient understanding is the basis upon which an informed choice 
can be made. An understanding of their disease and how it progresses is also crucial to 
enable a truly informed choice (Elmore et. al., 2010). Patients are likely to search for 
information surrounding their diagnosis and often bring this to their physician to discuss 
treatment options (Lewis N. et. al., 2009). Patients also benefit from interactions with 
others with similar cancers and can find experiential information and support from these 
sources invaluable (Hartzler et. al., 2011). However, alongside this there must be a 
human element, experiences both of the doctors and patients will also play a role no 
matter how small. Gattellari et. al. (2001) showed how by giving patients increased roles 
in the decision-making process anxiety levels were decreased and satisfaction levels 
increased (Gattellari et. al., 2001). Alongside this, a study by Wessels et. al. (2010) 
demonstrated good concordance between doctors and patients surrounding treatment 
preferences. Though patients’ valued expertise of the health professional higher than 
doctors thought they would (Wessels et. al., 2010). In an interesting study from the 
doctors’ perspective, Shepherd et. al. (2011) interviewed doctors treating a variety of 
cancers to discuss their views on patient involvement in treatment decisions. It 
highlighted that the doctors recognised the need for patient involvement in areas where 
there was a choice to be made, such as the treatment of low grade lymphomas where 
many treatment options are available and in cases of disfiguring surgery, for example a 
mastectomy. Yet they note how if the situation is clear cut, i.e. emergency surgery, there 
is much less patient involvement. Interestingly they found that the type of cancer also 
influenced patient based decision making, as those with breast cancer were far more 
likely to want to be involved in treatment decisions due to the high profile of their 
cancer, the nature of the surgery and the push for women to be more informed (Shepherd 
et. al., 2011). Along-side this Keating et. al. (2010) found patient influence on a 
treatment decision varied depending upon the evidence behind a decision. In situations 
where there was good evidence for or against and when there was equivocal evidence, 
patients played a larger part in decision making. However, when there was no evidence 
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or in the treatment of metastatic disease physicians took the decision making control 
(Keating et. al., 2010). Involved in all these studies there are many confounding factors. 
Underpinning it all in a number of cases is the fact that the patient does not wish to be 
involved in the decision and trusts the doctor to manage their disease appropriately. The 
flip side of this is the growing number of patients who wish to understand their disease, 
make informed choices and position themselves at the cutting edge of treatment to reach 
for a cure.  
Also important to consider is the impact carers have upon patient decisions. Zhang et. al. 
(2010) have conducted several studies looking at differing choices made by the patient 
and their care-giver. They report how carers are more likely to push for continued 
treatment until side effects become too great, and how they are more willing to discuss 
palliative situations. Whereas the patient is more likely to agree with the doctor on 
stopping treatment which is no longer working, and are more reluctant to discuss 
palliative care (Zhang et. al., 2010). At the opposite end of the spectrum to this are the 
elderly people living alone with terminal cancer. There are often feelings of ‘being a 
burden’ and not wanting to impose upon medical professionals’ time. They may feel it is 
difficult to access care without someone to help them to get to appointments or their GP 
(Hanratty et. al., 2013). Finally, Dow et. al. (2010) showed Lamont and Siegler’s 
original paradox (patients are more willing to discuss end of life care with a physician 
they have never met) still holds true, they also found that over half of patients would 
actually prefer to discuss this with their oncologist if they must have such a conversation 
(Dow et. al., 2010). This must be brought into consideration when planning future cancer 
diagnostic and treatment aids.  
Two interesting reviews encompassing studies between 1966-2009 left more questions 
than answers by demonstrating how patients often wished to be more involved in 
decision making, their perception of involvement varied and they also wished for 
different levels of involvement depending on where they were in their cancer journey. 
This also varied by cancer with colorectal cancer reporting the lowest active involvement 
(6%) and prostate the highest (as high as 84%) (Hubbard et. al., 2008, Tariman et. al., 
2010). This shows how difficult it is for doctors to gauge level of involvement in 
decision making, or indeed what treatment the patient would want when deciding for 
them in certain situations. Alongside this, after treatment consultations with patients 
regarding whom they would like to manage their follow up care resulted in over half 
(52%) indicating they would rather remain seeing a cancer specialist than their primary 
care physician, as they felt they are better placed to understand their cancer, their care 
and any future management required (Hudson et. al., 2012). It has also been 
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demonstrated that a patients’ need for information remains at a high level during 
treatment at follow up appointments, particularly when patients have a low literacy level 
(Douma et. al., 2012). Finally, a study by Atherton et. al. (2013) demonstrated that 
patients one year on from a cancer diagnosis reported lower quality of life scores in both 
physical and emotional domains when they perceived they had less input in their 
treatment decision than they wanted (Atherton et. al., 2013).  
This places a greater emphasis on the need for doctors to involve patients in decisions 
regarding their treatment as perhaps it improves mood and possibly outcome. When 
combined this makes the area a minefield for doctors and researchers alike. However, 
what is clear is there is a growing number of patients’ for whom their diagnosis and their 
subsequent treatment is an area over which they like to have an impact upon any 
decisions made. For this reason involving patients in the first steps of research is 
becoming an essential part of investigating cancer and developing diagnostic and 
clinically useful tools to aid future diagnostics and management.  
 
1.4.1 Patients Perception of Diagnosis and Screening 
 
Screening for cancer has made large steps towards reducing the number of late stage 
cancers found and aims to reduce the associated mortality. Patients’ perception of 
screening and their experiences play a role in their attendance and adherence to a 
screening programme. It is also possible that their emotional state prior to the initiation 
of the screening programme can dictate their adherence (Hinojosa-Lindsey et. al., 2013). 
Of great importance is the need to listen to patients. Providing information, awaiting their 
decision and then dismissing this in favour of a personal opinion does not adhere to the 
belief of an informed choice (Lin et. al., 2012). 
Colorectal cancer has involved patients in several of its diagnostic steps. First in the 
uptake of screening, Miller et. al. (2011) tested the use of a web based multimedia 
programme at increasing the uptake of colorectal cancer screening and found an 
increases in expressing a screening preference (84% vs. 55% p<0.0001), and increase in 
readiness to receive screening (52% vs. 20% p=0.0001) and an increase in ordering and 
completing the screening tests (Miller et. al., 2011). This group also performed a follow 
up study analysing a different population against a non-interactive format and again 
found that there was an increase in uptake up to 24weeks post exposure to the web media 
(Ruffin et. al., 2007).  However, Smith et. al. (2010) used a leaflet and DVD to inform 
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patients about colorectal cancer screening and found that whilst this increased patient 
knowledge (6.50 vs. 4.10 out of 12) and informed decision making, it led to a reduction 
in the uptake of screening (51% vs. 65%) (Smith et. al., 2010).  Schroy et. al. (2012) 
were also able to demonstrate a modest (8%) increase in colorectal cancer screening rates 
when using a decision aid (Schroy et. al., 2012). Jibara et. al. (2011) looked specifically 
at the Hispanic population in the USA and found that colorectal cancer screening rates 
were lower amongst people who had lived in the USA for a longer time period and were 
more fearful of colonoscopy (Jibara et. al., 2011). This emphasises the point that careful 
explanation of the procedure is required to increase the uptake of screening, though it 
may also lead to some people failing to take on the screening test. Following on from this 
many studies have been conducted around the screening tests used, most importantly the 
use of colonoscopy versus the use of computed tomography colonography (CTC). CTC 
involves the patient undergoing a CT scan whilst the bowel is insufflated with gas. The 
main focus of this research is the public perception and acceptability of traditional 
colonoscopy to see if CTC is preferable and would therefore increase uptake. There are 
several studies highlighting the preference of the general population towards CTC, with 
Pooler et. al. (2012) questioning those undergoing CTC. The majority of which found it 
acceptable and 30% stated they would not have attended screening had only traditional 
colonoscopy been the chosen method (Pooler et. al., 2012). Ghanouni et. al. (2012) used 
focus groups to gauge public perception; pre discussion preference was for CTC (75%), 
however following an explanation of both procedures, the risks, benefits and sensitivity 
the final outcome showed an almost identical split with 46% preferring colonoscopy and 
42% CTC (Ghanouni et. al., 2012). This highlights the importance of clear explanation 
and spending time ensuring basic understanding (all terms used such as ‘bowel prep’ 
were discussed prior to the focus groups and procedural explanations) to allow for an 
informed discussion and final decision.  Howard et. al. (2011) demonstrated patients 
preferred a colonoscopy over CTC in a population who had experienced both using a 
discrete choice preference. They showed an increase in number of patients preferring 
traditional colonoscopy based upon the risk of missing a polyp in CTC and the need for a 
second investigation if CTC found a lesion. The main limiting factor was bowel 
preparation, with a large increase in patients favouring CTC if minimal bowel 
preparation was possible (Howard et. al., 2011). Similar results were also found by 
Imaeda et. al. (2010) with 62% choosing colonoscopy and only 10% CTC (Imaeda et. 
al., 2010). 
These studies highlight the need for patient information and discussion. They 
demonstrate, taking colorectal cancer as an example, that whilst CTC is less invasive and 
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more acceptable to patients on the surface, once the procedure is explained alongside 
traditional colonoscopy the latter increases in popularity. This is mainly due to the need 
for one investigation instead of two as colonoscopy can be used for diagnosis and 
treatment, reducing the need for repeat visits to hospital which has obvious benefits. The 
other factor to come out of these studies is the increase in uptake of screening when 
patients have greater medical input into their decision and perceive benefits from the 
screening programme (Hawley et. al., 2012).   
Studies comparing faecal occult blood tests to either flexible sigmoidoscopy or total 
colonoscopy have also demonstrated patients are more willing to undergo the latter based 
upon risk data when this is clearly explained (Hol et. al., 2010, Wong et. al., 2010). 
Overall, the most important factor within this is by increasing patient knowledge 
surrounding screening tests, for example in colorectal cancer, you enable them to make 
an informed choice (Jerant et. al., 2013). This provides an interesting insight into patient 
decision-making, which can be of use to the researcher. Whilst it may appear that non-
invasive tests are of great benefit, patients place the need for a quick, accurate diagnosis 
and balance of risk over that of an invasive test.  
Decision aids aimed solely at the elderly population are rare. Two studies, one by Lewis 
et. al. (2010) and the other Mathieu et. al. (2007) have both developed tools in colorectal 
and breast cancer to demonstrate the pros and cons for screening. Lewis et. al. (2010) 
showed that whilst knowledge increased from 4% to 41% (p<0.01), only 7 people 
changed their minds (5 against and 2 for) (p=0.76) (Lewis et. al., 2010). Mathieu et. al. 
(2007) also showed an increase in patients making an informed decision (48.8% up to 
73.5% p<0.01), however there was no change in the participation in screening (Mathieu 
et. al., 2007). I think this demonstrates that whilst knowledge is increased, which is 
certainly important, it does not impact upon screening choices in the elderly population. 
There are other factors at play that these studies have not identified that drive peoples 
decision with regards screening. Lewis et. al. (2013) followed up their study by 
demonstrating that physicians look at the health of their elderly patients prior to 
recommending colorectal cancer screening (Lewis et. al., 2013). This demonstrates one 
hurdle to the screening policy for elderly patients and would represent a barrier to the 
uptake of diagnostic innovations if used in a screening capacity.  
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1.4.2 Treatment Options 
 
The King’s report highlighted the importance of obtaining a patients perspective on their 
treatment and what treatment they would like to receive (Mulley, 2012). Treatment for 
many cancers involves surgery. This can range from excision of skin cancers to major 
internal surgery involving removal of one or more organs or large portions of the 
gastrointestinal tract. This surgery is not without risk nor does it leave the patient without 
noticeable differences in their lives. Surgery for gastro-oesophageal cancers involves 
removal of part of the oesophagus and/or the stomach depending on its location. This 
then affects the way patients eat and digest their food. It is major surgery involving 
opening of both the chest and abdomen and has a lengthy recovery time along with risk 
of numerous complications. It is therefore important patients are well counselled before 
surgery. A study of post-operative oesophagectomy patients by found that they valued 
quality of life and cure rates over the hospital in which they had surgery and the 
surgeons’ reputation. They found it more important they knew and trusted their surgeon. 
The doctors surveyed also gave similar results (Thrumurthy et. al., 2011). This study 
serves to demonstrate the factors patients find important when being counselled for such 
life changing operations and gives an insight into the factors they find important when 
making life-changing decisions.  Although, on the flip side a study of men who 
underwent radical prostatectomy for prostate cancer stated that the consequences, 
including urinary incontinence and sexual dysfunction, were acceptable in view of curing 
the cancer (Eliat-Tsanani et. al., 2013).  
When it comes to the use of pre-operative chemo and radiotherapy it has been shown that 
patients value outcome in terms of function. Kennedy et. al. (2011) conducted interviews 
to determine if people would accept pre-operative therapy based upon the attached side 
effects, including sexual dysfunction. They demonstrated that 54% of patients would 
only accept pre surgical therapy if the risk of local recurrence was <5%, interestingly 8% 
said they would not accept pre surgical therapy even if the risk of recurrence was 0% 
(Kennedy et. al., 2011). A study by Lee et. al. (2012) in breast cancer patients showed 
18% did not receive the treatment they preferred when asked (mastectomy versus breast 
conserving surgery). The study also highlighted the information gap with patients not 
understanding the important differences in the two treatment modalities such as the 
difference in margin positivity in breast conserving surgery versus a mastectomy (Lee et. 
al., 2012). Whilst this study was conducted post-surgical intervention and it is to be 
expected patients will forget some of the information provided; only 26-45% of patients 
could recall the difference in margin positivity which is an important factor in the final 
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determination of treatment (Lee et. al., 2012). It is important that patients receive full and 
clear information provided in both oral and written forms in order for them to be able to 
retain this information and make a balanced decision. It is also disappointing that so 
many people stated they did not receive the treatment they wanted as it is important that 
the patients’ beliefs and choices are strongly represented when planning cancer 
treatment.  
Chemotherapy and radiotherapy form the basis for treatment for many cancers, with or 
without surgery. They both have side effects and may affect patient quality of life. Some 
chemotherapy drugs are more toxic than others and therefore cause more side effects. 
Studies surrounding patients’ perception of toxicity versus survival have shown patients 
are willing to accept the toxic side effects of chemotherapy to attempt curative treatment 
or to lengthen life, even if this is for a short time only (Duric and Stockler, 2001, Duric 
et. al., 2008). Brotherston et. al. (2013) reported that 69% of patients chose chemo-
radiotherapy over radiotherapy alone to prevent a difference in survival rate of <5%. 
Even though 80% of patients said based upon their experiences they would wish to avoid 
chemotherapy (Brotherston et. al., 2013). In a study looking at older breast cancer 
patients they showed where the patient would accept chemotherapy for life extension 
<12months they were 3.9 times more likely to receive chemotherapy than those who 
would only accept treatment for a benefit of >12months. Good communication also 
demonstrated a higher chemotherapy rate, as did attending the appointment with a family 
member (Mandelblatt et. al., 2010, 2012). Gerber et. al. (2012) looked at lung cancer 
patients to examine their comprehension and attitudes towards maintenance 
chemotherapy versus a treatment break. They found through focus groups that the 
patients were able to weigh up the pros and cons and understand the concept of 
maintenance chemotherapy and discuss their thoughts surrounding it and the reasons 
behind this option for treatment (Gerber et. al., 2012). I think this demonstrates how 
patients are interested in their treatment options and when it is carefully explained they 
are able to weigh up the risks and benefits and come to a conclusion that fits best with 
them. Be this a treatment break allowing them time to feel better without chemotherapy 
side effects or continuing with maintenance therapy and feel they are possibly able to 
extend their lives. In addition to this a study by Zafar et. al. (2013) of colorectal cancer 
patients with metastatic disease found that 82% of patients that consulted an oncologist 
received chemotherapy. Interestingly a group of patients felt that chemotherapy was 
unlikely to extend their life or improve their symptoms yet they still received treatment 
(Zafar et. al., 2013). This raises interesting questions surrounding the basis of the 
patients’ decision; did they defer to the oncologist whom recommended treatment or 
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whilst they believed the views they expressed did they hope they may confer some 
benefit from the treatment? The importance of hope is also expressed in a study by 
Tomlinson et. al. (2011) which looked at parents of children with palliative cancer and 
physicians. They found that parents were much more likely to opt for chemotherapy in a 
palliative situation than a physician (p<0.0001) and that this held true even if the 
chemotherapy would reduce survival time and quality of life. Parent ranked ‘hope’ and 
‘quality of life’ as the most important factors in making this decision (Tomlinson et. al., 
2011). Interestingly the views held by the parents are very similar to adults with 
palliative cancer and their carers. This is something very important to be considered 
when discussing treatment with families and ensuring their thoughts and wishes are 
translated when planning treatment.     
Carey et. al. (2012) conducted a study focused on haematological patients as they 
believed concordance with treatment decisions may be different in this patient population 
as compared to the solid cancers. They found 46% of patients preferred a passive role in 
treatment planning and that 56% reported they had an exact match between their 
preferred and perceived involvement in treatment planning (Carey et. al., 2012).  
In patients with low risk cancers such as basal cell carcinomas (BCC), the treatment 
takes two common themes, surgery or imiquimod cream. A study by Tinelli et. al. (2012) 
used a discrete choice experiment to determine which patients preferred. They showed all 
patients, with and without previous experience of BCC treatment preferred imiquimod as 
it would not cause a scar (Tinelli et. al., 2012).   
This demonstrates that patients overall are often happy to accept high risks and side 
effects in order to improve outcome. What is concerning and difficult is to ensure 
understanding and how many patients say they did not receive the treatment they wanted. 
It would be interesting to understand how they had come to this conclusion. As perhaps 
pre-treatment counselling may help them come to terms with the risks they are agreeing 
to and accepting as often people as a whole hope they will be the lucky one. 
 
1.4.3 Clinical Trials  
  
Patients enter clinical trials for many different reasons: the hope for a cure, helping 
others or simply prolonging life. Jenkins and Fallowfield (2000) conducted a study using 
a questionnaire to assess cancer patients’ perception of clinical trials. Overall, 72% 
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accepted entry to a trial, with the two main reasons given being ‘helping others (23.1%) 
and ‘trust in the doctor’ (21.1%) (Jenkins and Fallowfield, 2000). This raises an 
interesting dilemma surrounding clinical trials as it demonstrates how powerful the 
doctors’ suggestion of a trial can be. Brown et. al. (2011) developed a tool to aid patients 
being recruited to a clinical trial in order to help them ask questions and gain sufficient 
information to make a decision (Brown et. al., 2011). The National Cancer Research 
Institute figures from 2010 show that 1 in 6 adults diagnosed with cancer enter a clinical 
trial (NCR Institute, 2010).  Dear et. al. (2012) also report anecdotal evidence that a 
website giving information regarding clinical trials helped to increase rates of discussions 
about trials, though they did not find this statistically significant, nor did they find an 
increased rate of uptake of clinical trials after visiting the site (Dear et. al., 2012).  
Important in the development of these aids such as online websites is the need to consult 
the end user. Patients are best placed to comment on the ease of use and accessibility of 
information and can provide valuable insights to the developer hopefully to improve use 
over time (Atkinson et. al., 2011).  
There is also a move towards keeping patients informed of the outcomes of clinical trials. 
In a study by Mancini et. al. (2010) an internet website method of giving out results was 
trialled. They found that there was a significantly greater understanding of the results in 
the Internet group (18.8% vs. 5.6%, p=0.039), however the preferred method of obtaining 
trial results remained in a consultation with an oncologist. They also found that patients 
felt more comfortable discussing positive trial results with family, but were more 
reluctant to discuss negative results, and were more likely to discuss these to obtain 
reassurance (Mancini et. al., 2010).  When people enter trials it is important they are 
informed how and when the results will be available. Whilst a proportion will choose not 
to access them it remains an important source of information for patients regarding any 
treatment or intervention they may have received.   
 
1.4.4 Outside of Cancer 
 
Cancer treatment is not the only area of medicine involving patients in research. An 
interesting study carried out by Jayasooriya et. al. (2011) demonstrated that patients 
when provided with an information booklet detailing the management options for 
asymptomatic carotid stenosis (a leading cause of ischaemic strokes) with the risks 
discussed, a split in treatment decisions almost identical to that seen in a New England 
Journal of Medicine online poll completed by Clinicians was seen. From the patient 
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survey 22% chose carotid artery stenting compared to 19.5% of Clinicians, 48 % patients 
chose best medical therapy compared to 48.5% of Clinicians and 30% of patients chose 
carotid endarterectomy compared to 32% of Clinicians (Jayasooriya et. al., 2011). The 
patient groups may have different reasons for their choices such as ‘not wanting a scar’ 
(Jayasooriya et. al., 2011) as compared to the Clinicians, however involving patients in 
decisions regarding their care can only help improve outcomes as they will be making 
the choice they are more likely to be able to manage after weighing up the risks to their 
health.  
 
1.4.5 Moving forward, involving patients earlier 
 
These studies in a variety of settings using combinations of focus groups, web based 
multimedia and questionnaires have all demonstrated how increasing patient knowledge 
leads to an increase in uptake of testing, with more invasive tests such as colonoscopy, 
increasing in preference as the risks and benefits as compared to other tests are 
explained. The use of visual aids, including decision boards, helps to impart knowledge 
to patients and aid understanding. This can allow for more effective discussion with 
clinicians as increasing the number of appointments to allow for greater discussion is not 
always possible (Politi et. al., 2012). Allowing patients to dictate the future direction of 
medical research is a beneficial process allowing researchers to circumvent the need to 
determine if their new technology will be acceptable to patients and clinicians. It is also a 
crucial step in allowing patients to understand disease, the importance of screening tests 
and demonstrating whilst a test may be invasive it may be the best way to reach a 
diagnosis reducing time to diagnosis and multiple investigations. This understanding for 
researchers also enables them to target tools for use both during screening, diagnosis and 
intra operatively by taking on board the needs of the Clinician as well as patient 
preference. This helps bridge the gap between the laboratory and the hospital as well as 
allowing each group a greater understanding of each other’s role along with potential 
benefits and pitfalls of any new diagnostic tool.  
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1.5 Cancer diagnosis  
 
1.5.1 Patient Pathway 
 
Patients attend their GP for any number of reasons; ranging from a well person check to 
sinister symptoms suggestive of an underlying malignancy. There is a clearly defined 
patient care pathway for suspected cancer, which is site specific and aims to pre select 
high risk patients and move them to treatment within 62 days (NICE, 2005). This has 
been in place for over 20 years, yet no currently proposed plans improve it, nor is the 
target consistently met (NHS Interim Management and support, accessed 12/1/18). 
Looking at the current patient referral pathway (please see Figure 1.11), it is possible to 
see areas that could be improved with new technology and streamline the process further, 
such as reduced turnaround times within pathology departments. However, integrating a 
new test to aid or perform diagnostics can pose significant challenges to scientists and 
developers alike (Srivastava and Gopal-Srivastava, 2002). For example, the path to 
introducing a new biomarker, as suggested by Cancer Research UK (CRUK) contains 
many hurdles over which a new marker is required to jump in order to demonstrate its 
superiority in the field of clinical medicine (see Figure 1.12, CRUK K, accessed 
12/1/18).  This pathway is challenging as most biomarkers used in current clinical 
practise, for example Ca125 may aid diagnosis but are not used as a stand alone test. 
Correlation with pathology and radiology is always required. That said one of the most 
important questions it asks is ‘does the use of the biomarker reduce cancer mortality’ 
(CRUK K, accessed 12/1/18). It is well known that early cancer diagnosis saves lives, 
importantly for the current state of the NHS, earlier cancer diagnosis can, in the long 
term, also save money.  Therefore the aim of any new biomarker or diagnostic tool must 
be to improve mortality. The question then becomes at which point in the diagnostic 
pathway can a new tool such as spectroscopy be targeted. Many studies have been 
performed using spectroscopy in a variety of formats to diagnose many forms of cancer.  
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Figure 1.11: The current patient pathway with areas new technology could target to 
improve the time taken within the pathway (Bury et. al., 2018) 
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Figure 1.12: The CRUK new biomarker roadmap to aid scientists in introducing new tests 
(CRUK K, accessed 12/1/18).  
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1.5.2  New Diagnostic Tools 
 
Patients who attend their GP practise with symptoms such as abdominal pain are 
expecting some form of examination and investigation. This predominantly occurs within 
secondary care, with pathways developed to allow timely diagnosis whilst providing 
patients time to come to terms with their diagnosis. Many people find blogging a useful 
way of explaining to others about their form of cancer and use it as a coping mechanism. 
It becomes evident when reading them that there is a point at which a person becomes 
concerned, they are attending their doctor as they feel unwell and are worried (Pancreatic 
Cancer UK, 1/5/17). The diagnosis still comes as a shock and surprise, but then reading 
their experiences of the current diagnostic pathway and involvement with the cancer 
specialist nurses it is possible to see everybody’s role working as it has been designed 
and guiding a patient through their cancer diagnosis and treatment. To take a diagnosis 
back to an unsuspecting person attending for a well person check may be a step to far. In 
order for any tool to become common use it would clearly need to have high sensitivity 
and specificity. It would in essence become a screening test and the need to then 
understand if the test was detecting ‘cancer’ as a whole or a specific form becomes 
crucial.  
Interestingly researchers in Swansea have developed a technique that detects changes in 
the proteins on red blood cells which it says can be used to detect oesophageal cancer 
(Thompson, accessed 1/10/16). This has not yet been published, however it offers an 
exciting insight into the possibility of the holy grail of biomarkers; one that can detect 
small quantities of mutated proteins and link this to a cancer diagnosis. This does 
however bring back the question of what are these tests being devised in laboratories all 
around the world capable of? This example has focused on oesophageal cancer and time 
will tell if this is possible to detect, and if so, if this is specific to this cancer type or has a 
more general ability to detect the presence or absence of ‘cancer’. The potential of the 
so-called “liquid biopsy” (a blood test) has been under investigation for many years and 
includes a company in the USA called ‘Grail’, with the board of directors listing an ex 
Google team member (Grail, accessed 1/10/17). There is also a team in Cambridge 
working on a fluorescence endoscopic tool to detect oesophageal malignancy (Fitzgerald, 
accessed 1/10/17). I think this is where the potential of new technology lies. The patient 
has already attended the hospital and is expecting an investigation as opposed to a 
diagnosis provided to an unsuspecting patient who went to their GP for another reason. 
The potential of the Swansea research could again be placed into secondary care as an 
aid to diagnostics or a monitoring tool to perhaps replace the need for repeat CT scans.  
	   	   	  34	  
The importance lies in what the tool is expected to detect, cancer as a whole, or a specific 
form of cancer? If the aim is the later, will this be all types of cancer or confined to the 
top ten/twenty types of cancer? The writer believes the later is impossible and 
impractical. To be able to train a diagnostic tool to detect all forms of cancer is unlikely 
to be possible. Some are incredibly rare, for example, thymic cancer. In 2014, breast, 
prostate, lung and bowel cancer accounted for over half of all new cancer diagnoses 
(CRUK A, accessed 1/12/16). Therefore, perhaps a tool to detect these may be useful. 
However, others may be too few in number to offer a reasonable sensitivity and 
specificity.  
 
1.5.3 Developing a new diagnostic tool – for screening and beyond 
 
The WHO identifies the need for a screening test to be sensitive and specific.  For cancer 
diagnostics, it must focus on those cancers, which are most prevalent in the general 
population (Andermann et. al., 2008). Therefore any test developed using spectroscopy is 
most useful within high-risk cancer groups, for example breast and lung cancer, due to 
the high number of new diagnoses and the known benefit to early surgery. Those cancers 
such as brain tumours with a much lower prevalence rate are more likely to benefit from 
intraoperative aids then diagnostics given the lack of a defined pathway for patients to 
follow for screening. This is to enable any system to be adequately trained and develop a 
robust algorithm to provide high sensitivity and specificity. It is worth remembering the 
introduction of faecal occult blood testing (FOBT) has identified many patients at risk of 
colorectal cancer and directed them for further, more invasive, diagnostic testing. The 
FOBT is non-specific. However, it has been used as a method to find those at increased 
risk of cancer and direct them to a more invasive procedure (usually colonoscopy). The 
uptake for bowel cancer screening initially was just over half of those invited (Logan et. 
al., 2012). This has not prevented its use, and in fact, in studies its use has been shown to 
reduce mortality by 16% in those offered screening and 25% in those accepting 
screening, and on-going analysis of the bowel cancer screening programme has 
continued to support its use (Logan et. al., 2012). From this we can see a new point of 
care test does not require the perfect sensitivity and specificity wanted in an ideal world. 
If the test is meant as an indicator to lead onto further, more definitive diagnostic testing, 
i.e. a colonoscopy as follows the FOBT, lower accuracy can be accepted. The importance 
is the test is acceptable to patients and they therefore enrol in screening. If you compare 
the cervical cancer screening programme, they use risk versus benefit to prioritise 
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detecting cervical intraepithelial neoplasia (CIN) and cervical cancer. CIN is divided into 
grades 1 to 3 depending on the level of dysplasia in the epithelium, which is spilt into 
thirds; bottom third grade 1, middle grade 2 and full thickness grade 3. They aim to 
detect CIN 2 and above with a higher sensitivity and maintain a high specificity rather 
than focus on human papilloma virus (HPV) changes and CIN1 (Smith and Patnick, 
2013). This is also seen in breast cancer screening with 2-3 women avoiding death from 
breast cancer from every 1000 women that are screening for 20 years (Loberg et. al., 
2012).  
Hence spectroscopy may be able to play a role as an indicator, alerting the clinician to 
the possible presence of a cancer. Though, if this is the route sought, an investigation 
plan must be produced. A whole body computed tomography (CT) exposes a patient to a 
large volume of radiation, equating to roughly 6 years of background radiation 
(Radiation info, accessed 1/12/17). Therefore the test would need to provide an 
indication of the site of the tumour in order to allow focused diagnostic investigation 
without exposing the general population, who may in fact be well, to a large dose of 
unnecessary radiation. Whole body CTs are also not without risk and the possibility of 
picking up multiple incidental findings that themselves induce worry and require follow 
up without ever resulting in actual illness is of the order of 30% (Lumbreras et. al., 
2010). Aside from CT scanning, invasive tests, such as colonoscopy are themselves not 
without risk, though this risk is often considered minimal, with one non screening 
population study finding a 0.5% risk of serious event (Lumbreras et. al., 2010).  
Therefore careful consideration is required to determine what spectroscopy is able to 
detect and how accurate this is. Can it be definitive and therefore the next treatment steps 
are planned, histology confirmation is not required. Or is it remaining at the suggestive 
phase, such as prostate specific antigen (PSA) and Ca125, indicating a possibility and 
giving a hints as to the primary location to allow directed investigation.  This decision 
requires a dialogue between the scientist and the clinician. The clinician must be clear on 
what is required and at what threshold it would be accepted. Just as the scientist must 
explain the techniques capabilities and limitations, what can be offered and in a 
reasonable time frame? Given the prevalence of some of these tumours, it perhaps makes 
sense to focus these new diagnostics tests, at least initially, on the majority of cancers 
being diagnosed, e.g. breast and colon cancer.    
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1.5.4 Point of care testing 
 
With the point of care (PoC) industry projected to be worth over 36 billion US dollars by 
2021, the development of new diagnostic tests is moving at pace (Market and Market, 
accessed 1/12/16).  Cancer research UK has spent 15 million pounds in the last financial 
year (15/16) in order to develop 3 hubs within which research into early diagnostics will 
be focussed (CRUK L, 2016). Spectroscopy as a technique has been in use for many 
years, predominantly within a research setting in the context of the medical world. Many 
studies have been performed using various cancer types with varying success. Medpally 
et. al. (2017) looked a serum of prostate cancer patients using Raman to try to improve 
throughput and remove the use of expensive substrates whilst still improving on the 
sensitivity and specificity of the current PSA test (Medipally et. al., 2017). However, for 
their normal controls they used a mix of men and women over a different (lower) age 
range to that of their cancer patients. How useful this ‘normal’data is could be open to 
debate, firstly as woman cannot get prostate cancer and secondly, given the younger age 
range of the control population, it may be that other contributing factors that develop as 
people age providing the difference between the two groups and not the presence of a 
cancer. Other studies, such as that by Owens et. al. (2014) have shown a 93.3% accuracy 
to use infrared (IR) and 74% accuracy with Raman spectroscopy when classifying 
patients with ovarian cancer based on whole blood testing (Owens et. al., 2014). This 
requires minimal sample preparation as well as a small amount of blood to test. Given 
this is a pilot study, much larger studies would be required to validate this technique. 
However, these figures do sit amongst others produced by different research groups, such 
as that demonstrated by Hands et. al. (2014) They obtained sensitivities and specificities 
up to 87.5% and 100% respectively when using attenuated total reflectance-Fourier 
transform infrared spectroscopy (ATR-FTIR) on serum from normal and patients with 
glioblastomas. This was used in conjunction with Bioplex assays (Hands et. al., 2014). It 
provided a diagnosis within 5 hours, which is much quicker than current techniques. 
These studies are both detecting changes in different proteins, some of which encode 
oncogenes (Owens et. al., 2014). However given the small scale of the study it is clear 
much larger, controlled studies would be required to move this technique forward. 
Indeed it may be difficult given the low prevalence of brain tumours to introduce this as 
a screening test.  
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1.6 Diagnostics 
 
1.6.1 Clinical Use 
 
Within clinical use are various tools to support and guide cancer diagnosis. Starting with 
clinical examination, which enables a clinician to carefully examine a patient and 
determine if any masses are palpable. Moving on from this are blood tests to look for 
specific tumour markers within the blood such as PSA and CA125. These tools are 
neither specific nor sensitive but can add support to the clinical examination and raise 
suspicion levels. Next is radiological imaging, in the form of plain xray, ultrasound scan 
or CT scan. This can enable visualisation of any tumours and metastasis. To complete 
this there is the gold standard of a biopsy. This is often required prior to surgery to 
enable the patient to make an informed decision and in the case of metastatic disease 
allows the oncologist to target chemotherapy.  
 
1.6.2 Pathological Diagnosis 
 
As discussed above, to support the diagnostic process a pathologist has many tools to 
hand. Starting firstly in the cut up room with the ability to examine and dissect the 
specimen. This then allows the production of H&E stained slides. In complex cases, 
immunohistochemistry or molecular techniques may be required to provide a definitive 
diagnosis. However in a small number of cases this may still not yield an answer. This is 
especially true in challenging small biopsies, hampered by the limited tissue available. 
Also prevalent within histopathology is inter-observer error. Given the subjectivity of 
some areas of pathology, such as dysplasia in Barrett’s oesophagus, which at the low-
grade end of the spectrum can often cause discussion amongst expert pathologists. For 
example, Coco et. al. (2011) found a kappa score of 0.44 for 6 experts looking at 
dysplasia in Barrett’s oesophagus (Coco et. al., 2011). Kappa scores are used to assess 
agreement between observers, taking into account agreement occurring by chance. 
Scores usually range from 0 to 1, with 0 indicating a chance results and 1 perfect 
agreement. Scores below 0 do not often occur in clinical fields (Sim et. al., 2005). 
Therefore, this highlights relatively poor agreement between the pathologists. In order to 
well train any new diagnostic tool concordance from histopathology experts will be 
crucial. 
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1.6.3 New methods 
 
Multiple techniques are currently in development, with varying degrees of success. This 
ranges from smart phone apps to whole genome testing (Balch, Genomics England, 
accessed 1/5/17). In order for these to be introduced into clinical practise they must be 
cost efficient and aid the clinical diagnostic process. One such technique that has been in 
the spotlight recently is vibrational spectroscopy. This encompasses many different types 
of spectroscopy, developed to better aid diagnostics. It is expensive to set up, but once 
running can offer cheap, reagent free results, in a short time span, most importantly faster 
than immunohistochemistry and a specialist opinion. If confirmed, faster than a H&E and 
tissue processing, possibly even taking it one step further back into the clinical domain 
allowing diagnosis whilst the patient waits in a clinic room.  
In recent years the use of next generation sequencing (NGS) has been increasing with the 
costs associated starting to fall. The main challenges now are the interpretation of the 
information obtained; how should this be used and how the variety of genetic differences 
and missense mutations interact in order to produce the clinically evident disease 
(Landsverk and Wong, 2013). This next step is now required in order to determine the 
utility of sequencing beyond single gene testing, as has previously been done, in order to 
determine specific changes (Organisation for Economic Co-operation and Development, 
2011).  
Also increasing is the number of biomarkers detected by “omics” research. Again, many 
challenges are being encountered; none more crucial than funding. Which biomarkers 
should be studied and who is footing the bill are crucial to progression (Armstrong et. al., 
2014). It is difficult to engage clinicians and sell the benefits of a new biomarker without 
determining and proving its utility. Evidence based medicine is at the heart of medical 
training and without evidence of benefit to the patient it can be difficult to secure funding 
and garner enthusiasm (Armstrong et. al., 2014, Byrne et. al., 2015). These new 
biomarkers however, do herald the new era of personalised medicine and with them new 
treatments can be developed that target specific markers found in specific patients 
(Armstrong et. al., 2014). As time progresses and these areas of research expand it is 
likely NGS and novel biomarkers will form the new basis for cancer treatment.  
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1.7 Vibrational spectroscopy 
  
Vibrational spectroscopy comprises two main complimentary techniques; Raman 
spectroscopy and infrared spectroscopy. These provide information regarding molecular 
structure and produce a ‘fingerprint’ of the tissue or fluid analysed. Comparison of these 
fingerprints allows differentiation of, for example, tumour or tissue types. Infrared 
spectroscopy uses polychromatic light to detect the point at which bond vibration occurs 
within a sample, whereas Raman uses monochromatic light to detect inelastically 
scattered photons. Each component of the specimen, for example proteins, vibrate at a 
different wavelength allowing the production of the distinctive fingerprint (Butler et. al., 
2016).  An example of a Raman and infrared spectra of polystyrene is shown in figure 
1.13 below.  
 
Figure 1.13: Example of Raman and infrared spectra of polystyrene showing the different 
appearances of both techniques on the same material. (Raman = blue, Infrared = red) 
(School of Chemistry, accessed 1/5/17). 
 
One success of spectroscopy its low running costs. This includes the use of aluminium 
foil wrapped glass slides. These have been found to be as effective as calcium fluoride 
slides and cost markedly less, increasing the price of a simple glass slide very little (Cui 
et. al., 2016).  The same team also produced a tool kit called iRootlab in order to enable 
easy analysis of spectra within a MATLAB environment. This provides benefits given 
technique and analysis can be optimised and reproduced in order to unify analysis 
(Trevisan et. al., 2013).  It does however require agreement throughout the field on the 
best method for analysis, which while attempted by Butler et. al., has yet to be accepted 
across the board (Butler et. al., 2016). 
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Spectroscopy, in a medical context, can be used to analyse either tissue or biofluids. 
There is a large body of research showing use of both mediums with improving results.  
Body sites examined have included skin, oesophagus, ovary and cervix with varying 
degrees of success (Barr et. al., 2011, Kendall, et. al., 2010, Lyng et. al., 2007, Gajjar et. 
al., 2012). The differentiation of normal tissue/fluid vs. cancer has been done with high 
degrees of accuracy, for example; Gajjar et. al. (2013) separated serum from ovarian and 
endometrial from normal with accuracies of 96 and 81% respectively (Gajjar et. al., 
2013). Whilst some studies have started to compare differing tumour types, such as 
primary and metastatic brain tumours, the analysis has focused on direct questions, i.e. 
normal versus primary tumour, normal versus metastasis (Hands et. al., 2016).   
Also in development are spectroscopic driven tools to aid the surgeon. Liu et. al. (2012) 
trialled a wearable device fitted with near infrared fluorescence for surgeons operating on 
a mouse model to determine if this could  be used to delineate tumour from non tumour 
more accurately than the human eye. It was found to be useful as a 2D model, but was 
unable to fully assess topography in a timely manner, therefore whilst it added some 
information, crucial parts were missed out. It was also a bulky system that based on 
pictures would take some training for a surgeon to operate with one eye covered by the 
device (Lui et. al., 2012). There are many other tools also in development using 
nanoparticles loaded into “Spectropens” (a combined near-infrared laser and detector) to 
allow surgeons to visualise tumour cells more readily. These have shown promise in the 
laboratory and only time will tell if these techniques can be brought effectively into the 
clinical arena (Patlak, 2011).  
Spectroscopy has been used to demonstrable effect within the laboratory, however 
translational studies moving into the clinical forum have been few and far between. In 
order for this technology to move forward, engagement with the medical world is 
required to move this technology into an area from which patient and clinicians can 
benefit.  
 
1.7.1 Nanoparticles 
 
Nanoparticles, specifically metallic nanoparticles, can also be used in conjunction with 
vibrational spectroscopic techniques. The nanoparticles, made of gold or silver, are 
placed on top of the tissue or fluid being analysed and have been shown to enhance the 
Raman signal. This is known as surface enhanced Raman spectroscopy (SERS). Within 
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biological samples this enhancement is seen at the level of one or two orders of 
magnitude, which whilst not as great as that seen on non-biological samples still offers 
an improvement in signal (Fogarty et. al., 2014). This can therefore possibly aid with 
distinguishing the small differences seen within samples.  
 
1.7.2 Towards a molecular future 
 
One of the roles for spectroscopy, is in either frozen section work or treatment follow up. 
Targeting the tissue that would have previously been sent for frozen section and instead 
using spectroscopy to analyse it in the theatre would save at least half an hour. It would 
also allow multiple points to be examined and hopefully give answers as accurately as a 
pathologist. It may not be able to determine tumour type, as often occurs with a lung 
mass, but would be very useful to delineate tumour margins from inflammation. 
Alternatively as a tool to monitor treatment follow up, as biomarkers such as CA125 are 
inherently subjective, Moss et. al. (2005) found 80% of women in their study had raised 
CA125 due to reasons other than ovarian malignancy (Moss et. al., 2005).  There are also 
many cancers for which there is no marker, and therefore a tool that allows scan free 
follow up would be greatly beneficial. It would free up radiology scan spaces for new 
diagnostic work and reduce the exposure of patients to radiation.  
Thus far spectroscopy has been used in a controlled manner, studies have been 
performed on blood and tissue of known cancer types and control populations, with 
varying success (Mitchell et. al., 2014). Suggestions have been raised about its use in 
cancer of unknown primary diagnostics, however, no studies have yet been performed on 
multiple cancer types and controls in order to determine if spectroscopy can detect the 
different cancer types and determine a primary location (Hughes and Baker, 2016).  It 
would be interesting to see the results of a study combining multiple types of cancer 
versus a control population. Following on, it would also be interesting to determine if 
spectroscopy could be able to define the primary tumour site from a number of 
adenocarcinomas or squamous cell carcinomas of various origin sites as current 
morphological and immunohistochemical methods struggle, particularly with the latter. 
Krafft et. al. (2006) demonstrated they could differentiate between brain tumour 
metastasis from a variety of locations, they also found large overlap between the lung 
and colorectal cancer metastasis. They did find greater differences with the renal cell 
carcinoma metastasis as compared to the lung and colorectal cancer (Krafft et. al., 2006). 
This is not surprising as these tumours have markedly different morphological 
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appearances histologically, different immunohistochemical profiles and are from a 
different cell lineage. Gajjar et. al. (2012) has shown that it is possible to differentiate 
between brain tumours of different lineage. They examined normal brain, meningiomas, 
gliomas and metastasis and using ATR-FTIR were able to separate these tumour types 
into groups (Gajjar et. al., 2012).  
Therefore, defining the remit for spectroscopy and setting expectations is crucial and will 
benefit both the clinical and scientific worlds.  
 
1.8 Conclusion 
 
Overall, it is clear there is room for improvement in the cancer diagnostic pathway. 
However, there is still time required for patients to come to terms with their diagnosis 
and to understand and consent to treatment moving forward. Given the pressure on the 
NHS and the volume of patients any tool that can assist and perhaps remove the need for 
a step, such as a follow up scan after treatment, are greatly beneficial. Therefore careful 
planning of where a new technique will best fit within the diagnostic pathway is almost 
as crucial to its survival and uptake as the sensitivities and specificities it offers. On-
going discussions between the scientific and clinical communities are the foundations 
required to develop tests and techniques that can benefit patients and provide clinicians 
with the tools they need to improve services. Techniques that imitate those available, but 
provide less data may add to the pathway as opposed to reducing and improving it and 
therefore may add a cost too great for the NHS and NICE to justify. Whereas carefully 
focused developments to aid tools already in use may unlock crucial information to help 
improve cancer treatment and improve mortality.  
Therefore, it was felt important to consider if new PoC testing was wanted and where it 
may fit into the patient pathway. To start the patient pathway was considered (see Figure 
1.11) and developed into a correspondence (See appendix 9.1). This then led to the 
development of several studies, incorporating varying elements of the current diagnostic 
pathway, to determine how viable the use of new technology, in this case vibrational 
spectroscopy, was as compared to current techniques (see Figure 1.14).  
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 Figure 1.14: The overview of the PhD project, demonstrating how the components fit 
together to investigate the use of vibrational spectroscopy within the clinical field.  
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1.9 Aims and objectives  
 
Aim: The aim of this thesis was to address both the use of vibrational spectroscopy in the 
diagnosis of cancer and how to develop this technology for clinical use. 
 
Objectives of the Research: 
Theme 1: 
o Understand what makes a test acceptable to a patient and useful to a Clinician 
o Establish patient and Clinician preferences surrounding cancer diagnosis  
o Examine where new technology would fit into the clinical environment  
 
Theme 2: 
o Develop proof of concept for diagnosis of primary and metastatic brain tumours using a 
combination of  
§ Formalin fixed paraffin embedded tissue 
§ Fresh frozen tissue 
§ Plasma and serum  
 
Theme 3: 
o Taking theme 1 output in conjunction with theme 2 to develop a working prototype for 
spectroscopic diagnosis of brain tumours on fresh tissue. 
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Chapter 
2 
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2. Patient and Clinician Involvement Study 
 
Declaration of Work 
 
To Whom it May Concern, 
 
Dr Danielle Bury designed the study, questionnaire and paperwork with in put 
from Dr Michelle McManus and Dr Matthew Baker. Dr Bury completed the 
application for the National Research Ethics via the integrated research 
application form and answered all questions following submission. 
Dr Bury arranged and undertook all focus groups, recording and transcribing each 
anonymously. She also publicised the questionnaire, gaining assistance from local 
cancer specialist nurses for input into their support groups and canvasing local 
doctors. She then performed analysis of both questionnaire and focus groups, 
putting together the closing report form for the South West Wales Ethics 
committee and a paper for publication of the results with the support of Prof F 
Martin.  
 
 
Signed 
 
 
 
…………………………….                  ………………………….. 
Prof F L Martin         Dr D Bury 
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Introduction: 
Healthcare has come a long way from the old model of the doctor and patient interaction 
where the doctor takes on a parental role and dictates the patients’ treatment plan. The 
patients of the 21st century are taking a much more active role in their diagnosis, 
treatment and management. This study was designed to involve both Patients and 
Clinicians within the early steps of research project development. A combination of 
questionnaire and focus groups were used to determine thoughts surrounding time taken 
to cancer diagnosis and cancer diagnosis, as well as more general thoughts on screening 
and were they felt new diagnostic tools would be helpful. A copy of the questionnaires 
used is available within appendix 9.5  This qualitative approach was used to build an 
understanding of both Patients and Clinicians thoughts and ideas as to areas that could 
benefit from additional input from new diagnostic tools such as spectroscopy. A wide 
range of cancer support groups and clinicians, not just brain tumours were targeted to 
allow the study to explore limitations of cancer diagnosis within a variety of cancers and 
identify if there were any common themes through which the use of vibrational 
spectroscopy could be targeted. 
 
Method: 
In order to assess both patient and clinician views this study was conducted using both a 
questionnaire and focus group approach. This was to allow short answer questions in the 
form of the questionnaire and to allow expanded discussion via the focus groups. Ethical 
approval from the South-West Wales research ethics committee, reference 13/WA/0411 
was granted for the study on 20/1/14 (available within appendix 9.4). 
The survey was designed to use a combination of attitude scale questions using a 7 
point-Likert scale, with additional questions allowing further exploration of key issues 
and grouping variables, such as demographic information. Open questions at the end of 
the survey were used to allow participants to give any additional free responses. The 
questionnaire was released on “Smart Survey” and distributed to medical professionals 
via medical trainee representatives and consultants. This allowed the survey to reach as 
wide a range of medical professionals at varying stages of their careers as possible. For 
patients, it was distributed via cancer specialist nurses from Lancashire Teaching 
Hospitals NHS Trust who work with support groups or advertised posters within the 
Rosemere Cancer Centre. The opening page displayed an explanation of the study, with 
consent for inclusion in the study being confirmed by completion of the questionnaire. 
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No names or identifiable details were obtained. 
Focus groups were held at Lancashire Teaching Hospitals NHS Trust for consultants and 
at the University of Central Lancashire for patients. Patients were offered £10 as a 
gratuity for attending. Prior to the focus groups information was provided and any 
questions answered. All participants were consented with a pre-approved consent form 
prior to starting and focus groups were recorded and then transcribed anonymously to 
remove identifiers. As the idea was to allow free discussion around the topic of new 
technology in healthcare, questions were left open and kept to a minimum and used only 
to guide discussion. 
Analysis was performed on the questionnaire answers to identify the most commonly 
selected responses and the free text ‘other’ boxes were ordered to look for common 
themes. Following transcription of the focus groups they were read and themes 
identified. These were then viewed in context with the questionnaire responses to allow 
conclusions to be drawn. 
 
Results: 
Overall 72 doctors completed the questionnaire and 6 attended during one of 2 focus 
groups. The patient questionnaire was completed by 93 people but the focus group was 
only attended by 1 person.  Several patients were invited but cancelled due to ill health or 
lack of transport. 
Clinicians: 
Medical professionals ranged from foundation trainees to senior and retired consultants, 
from 26-66 years old, with responders equally split between male and female (48.6% and 
51.4%). The majority identified themselves as British (66%) with 93% working full-
time. The respondents predominantly work as Consultants with 61% dealing with cancer 
every day and 29% in regular contact with cancer patients. Approximately half are 
involved with cancer care. Of the total, 94% worked within a hospital environment. This 
may have led to bias within the results, given the high number of hospital based 
physicians. However, as the majority of patients are diagnosed and treated by hospital 
based physicians they are likely to be able to discuss limitations surrounding cancer 
diagnosis more accurately. General Practitioners were invited to complete the survey, 
however uptake was low.  
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Up to 54% of clinicians have previously attended screening with those who have not 
stating they are not yet old enough to be called for screening. They felt a hospital doctor 
should give a cancer diagnosis (94%), with up to half recognising a GP could give a 
cancer diagnosis. However, they felt overall a hospital consultant, who had organised the 
investigations and would be involved with further management and hence able to discuss 
treatment options and answer questions would be the most appropriate person. A GP 
would be helpful in providing assistance should time be an issue. They thought on the 
whole (69%) that patients would want their cancer diagnosis from a hospital doctor. 
It was thought the areas requiring improvements focussed around the time taken to give 
the diagnosis (48%) and explanation of diagnosis and treatment plan (48%). Only 25% of 
respondents felt there was need for improvement in the method of diagnosis. 
When the prospect of a new screening tool was raised, 68% would recommend it, 
providing it fulfilled Wilson’s Criteria for screening and not just be a means to detect 
cancer without any survival benefits (i.e. a disease must have a early phase that can be 
detected allowing for effective treatment to prolong life) (CRUK N, accessed 11/12/17). 
Clinicians felt the investigations suggested for cancer diagnosis, ranging from a clinical 
examination to a biopsy under general anaesthetic would have different acceptability’s to 
a patient, from 82% down to 15%, as the investigations became more invasive (Figure 
2.1a). This was interesting, when compared to the patients’ results as both found 
different investigations acceptable (Figure 2.1b).  Patients also found investigations more 
acceptable than clinicians thought they would be (Figure 2.1a and 2.1b). 
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Figure 2.1: Which investigations are found acceptable and which are not? (by acceptable we 
mean you would be willing to accept the investigation and do not feel it is unreasonable 
when looking for cancer). (A) The clinicians’ responses to which investigations they felt 
patients found acceptable. (B) The patient responses to which investigations they found 
acceptable. The scale ranges from unacceptable – 1 – to acceptable with no concerns – 10. 
 
Clinicians felt that a cancer diagnosis should be expected within a week (43%) or a 
month (48%), however 52.8% would like a diagnosis before feeling unwell. They 
thought overall patients would be best-informed regarding risks and complications of 
treatment, see Figure 2.2. 
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Figure 2.2: The clinicians’ responses to the level at which they felt a patient is fully informed 
regarding their diagnosis and management. 
 
Moving forward, clinicians felt early diagnosis along with improved molecular testing 
for new genetic alterations would best aid patients. Similar topics were also brought up 
within the focus groups. They felt the best use of a tool such as spectroscopy would be as 
an adjunct or replacement of frozen sections. As the turnaround, whilst often around 30 
minutes, can leave surgeons waiting whilst the patient is on the operating table and if 
further sampling is required this can greatly increase the length of the operation and the 
patients’ general anaesthetic. 
One of the main concerns raised was the cost of bringing the equipment into the 
mainstream and the need for National Institute of Clinical Excellence (NICE) approval. 
They also felt that allowing home testing for cancer was a step too far. They felt that 
some patients may take any suggestion of a cancer diagnosis and not realise the 
sensitivities and specificities attached and end up committing suicide based on the result. 
This they thought would be unacceptable and that cancer diagnostics should remain with 
a health care professional. 
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Patients: 
In comparison, the patient questionnaire which was completed by almost equal numbers 
of men (43%) and women (56%), ranging in age from 18-81 years, of which people 
worked in a variety of jobs demonstrated similar findings, but a greater willingness to 
accept investigations than the doctors thought (see Figure 2.1). Their main concern was 
the need for an early and accurate diagnosis and if an invasive investigation was 
required, then it was needed. Of the people completing the survey, 43% were employed 
full time. Employment ranged from unemployed to company directors with a ranging pay 
scale. Over half had experience of cancer, with one third personal and 50% close family. 
Screening had been attended previously by 43%, with reasons for non-attendance 
ranging from “not yet eligible”, to “don’t see the benefit” and those unaware screening 
programmes exist. The GP was still the most visited healthcare professional at 60%, with 
most people visiting a healthcare professional every 3 months (Figure 2.3). This may 
have been impacted by follow up times often provided within clinics, which are often set 
at 3 months.  
 
Figure 2.3: Patient responses to how often they saw a healthcare professional. This 
encompassed nurses through to doctors. 
 
When asked where they would like to receive a cancer diagnosis, 53% said in hospital 
and only 14% their GP. This was based on hospitals being able to provide more 
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information and likely to have done the investigations. When asked who they would like 
to give the diagnosis, multiple answers were allowed, 72% said a hospital-based 
consultant and 43% their GP (Figure 2.4). Interestingly, the cancer specialist nurses, who 
are seen as having more time to sit and discuss things, where chosen more than a 
patients’ GP (46% to 43% respectively). It was felt the GP would not have sufficient 
knowledge to be able to discuss the diagnosis and treatment plan moving forward. 
However, people did say they wanted an answer quickly after investigations and 
therefore if time constraints were applied their GP would be an acceptable option. 
 
Figure 2.4: Patients responses to whom they feel should give a cancer diagnosis. 
Respondents were allowed to select as many answers as they felt appropriate.  
 
Patients felt cancer diagnosis could be improved by increasing the time taken and 
ensuring the explanation is given in an empathetic manner, with clear guidance on next 
steps and treatment. 
When screening was suggested 77% said they would be interested in attending as most 
would want to know if they had cancer. The majority of patients (82%, see Figures 2.1b 
and 2.5) where happy to accept all levels of intervention required to reach a cancer 
diagnosis. They felt this was necessary to achieve the end goal of an accurate diagnosis. 
Even though as one person described, ‘I had all of the above tests and found the four 
endoscopies the worst but would endure them again.’ and several said ‘I would have any 
test’ qualified with ‘if there was any chance of catching cancer early’ and ‘either of the 
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invasive tests would put me off but investigation of a suspected cancer is worth the 
inconvenience’. 
 
Figure 2.5: Patient responses to investigations they would not want during a diagnostic 
pathway. 
 
Just under half of the group (46%) felt a diagnosis should be reached within a week of 
seeing a specialist (see figure 2.6), and half believed they could be fully informed and 
understand all aspects of diagnosis and treatment provided (see figure 2.7). Therefore 
this is an area that targeted vibrational spectroscopy may be able to develop, enabling the 
patient to have an earlier diagnosis.  
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Figure 2.6: Patients were asked ‘At what point would you EXPECT diagnosis of cancer to 
occur? Please select ONE response’. The majority expected a diagnosis within a week of 
seeing a specialist doctor. 
 
Figure 2.7: Patients were asked ‘ Do you think you are fully informed and/or can access 
information about’ a range of topics, including impact of quality of life, diagnosis and 
complications. Over half felt they were well informed of all risks and complications.  
 
The focus group consisted of only one patient who was very open about their cancer 
experience. The lack of other participants does make the results hard to draw conclusions 
from. However the main points to come through were again similar to those within the 
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questionnaire focussing on the need for clear, open and honest explanation and ensuring 
of understanding and the need for empathy. They felt the oncologist was one of the best 
people they met whom had been the most open with them. They too would want a 
diagnosis from a specialist consultant not their GP as they did not know their GP well 
and felt the consultant knew more about their cancer. The suggestion of a home test for 
cancer was met with reluctance, with the suggestion that its use and outcome would be 
very person dependant and that perhaps cancer diagnosis was best remaining in the 
hospital forum. 
Discussion: 
The questionnaire and focus group responses have all shown the crucial need for time 
and clarity when giving patients a cancer diagnosis. Whilst this has been an area where 
medical training has been focused over many years it still clearly needs work and 
remains at the heart of a persons’ cancer journey. The most interesting point was the 
acceptance of investigations by patients. The range of results given shows how even 
some relatively simple investigations are considered less acceptable. Whilst the medical 
profession is trying to move ever closer to patient centred care and allowing the patient to 
make a decision, a large proportion of people are willing to accept whatever investigation 
is felt necessary by the medical team. As one respondent said ‘if the specialist believed it 
to be the most effective way of diagnosing cancer early, I would accept it’ along with 
others who stated ‘whatever it takes’. The doctor is still in the most powerful position, 
yet I am not sure they all realise how willing patients are to undergo these investigations 
if required. Especially given the results above where they felt some investigations may 
not be as accepted by patients. There was quite a disparity between what the doctor 
believed was acceptable and what the patient felt was. It would be interesting to know if 
the patients have experienced these investigations, the responses clearly show some have, 
as perhaps the doctor may be more aware of the investigation and what is required. It 
would be interesting to repeat the work and identify what a patient understood by the 
investigation and how many had experienced it and understand the impact that had upon 
acceptability. It does however demonstrate to the medical profession the importance of 
any comment made and how despite the drive for patient involvement in care the 
emphasis is still placed on the medical recommendation. 
Of interest, most patients would still rather receive a cancer diagnosis in secondary care, 
even with the time constraints placed upon it and the likelihood of having not met the 
doctor previously. Within primary care they have often used a GP much more often and 
may have a rapport with them, yet they recognise the treatment plan and prognosis is 
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more likely to be developed in secondary care. The use of clinical nurse specialists 
cannot be understated. They were chosen more often than a GP to give a cancer 
diagnosis. They are often seen as having more time to sit and talk to patients and explain 
a diagnosis. As their role develops it is crucial this time is kept, as they are often a great 
source of support for patients. 
The main limitations of study surrounded number of both Patients and Clinicians 
involved, particularly within the focus groups. The Patient focus group was attended by 
only 1 person, therefore the data obtained is limited. Recruitment for this part of the 
study was challenging, if it were repeated providing transport for Patients may aid the 
number of people attending. This was also an issue with the questionnaire. It was 
available in paper format, but this was not requested at all. Some questionnaires were 
started and not completed, which may be due to the length and number of questions. 
These were not included in to the analysis. Questionnaires do not allow for lengthy 
discussions around thoughts and feeling and provide only a limit snap shot based on 
either a selection or short response question. Perhaps if the study were to be repeated it 
would be useful to perform the questionnaire first, then invite open discussion within 
focus groups based on the ideas arising out of the questionnaire answers (Beiske, 2002).  
The results also highlight both slides are aligned with the need for screening and early 
cancer detection. Whilst it is concerning some small patient areas are not aware of 
screening pathways, overall the government drives surrounding cervical and colorectal 
cancer, for example, and the need for screening have increased uptake (CRUK N, 
accessed 11/12/17). The two groups were also both reluctant for a home-based test. Both 
describe the risks associated and the need for careful evaluation and avoiding 
unnecessary worry and potential harm. Again this is a very interesting point. The patient 
group recognised similar concerns to medics surrounding this and the potential risk to 
life if a patient became very upset based upon the results without a clear understanding of 
the accuracy of an investigation. It again highlights the need to involve patients early in 
research as whilst an at-home diagnostic tool may sound like a positive development in 
the laboratory, it may not actually be a positive idea in reality. Nor may patients be 
willing to use it. 
Conclusion: 
Overall this study has highlighted disparities between patient and clinician thoughts 
surrounding cancer diagnosis and treatment. It has also highlighted areas where both are 
aligned in thoughts on new diagnostics, showing that whilst a test may seem 
unacceptable, most would be willing to undertake it. It has demonstrated that any new 
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development within cancer diagnostics is likely to be most beneficial within secondary 
care as this is where patients felt they were most likely to receive information of benefit 
and understand their treatment plans moving forward. Demonstrating whilst a GP is 
crucial in supporting patients following diagnosis, most would still rather receive a 
diagnosis in a secondary care setting. 
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3. Fresh Frozen Primary Brain Tumours 
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Introduction 
 
Brain tumours account for 3% of all tumours diagnosed annually, with incidence rates 
increasing approximately 15% over the last decade (CRUK D, accessed 3/11/17). Whilst 
they comprise a small proportion of all cancer diagnoses per year, the difficulty of 
complete removal of the tumour is inherent. High-grade tumours can be infiltrative and 
when operating within the brain, the risk of removing crucial structures in a bid to free 
the patient of the tumour yet risk leaving them with significant neural deficit is ever 
present. Up to 75% of tumour resections are thought to leave behind viable tumour 
(Hollon et. al., 2016).  This study was designed to look at the potential of vibrational 
spectroscopy to be able to provide an intraoperative method of diagnosing tumours that 
would allow the surgeon to determine if tissue was in fact tumour and improve the ability 
to resect malignancy. Current techniques include the use of 5-aminolevulinic acid (5-
ALA). This uses a fluorescent compound to fluoresce tumour cells to enable the surgeon 
to visualise them more easily. This allows real-time feedback and does not rely on repeat 
imaging on the operating table (Hadjipanavis et. al., 2015.). This has a high success rate 
but can prove difficult at the edge of tumours where normal brain tissue can appear a 
similar lighter colour to that of neoplastic tissue (Hadjipanavis et. al., 2015, Galli et. al., 
2017). 
 
Both Raman and ATR-FTIR spectroscopic methods were used to detect non-tumour 
brain tissue from a variety of primary brain tumours using brain tissue that had been 
frozen after receipt from the surgical theatre. This was placed upon calcium fluoride 
slides and defrosted prior to use. Fresh frozen tissue was used to mimic as closely as 
possible fresh brain tissue and reduce artefact from paraffin embedded tissues.  
 
Methods 
 
Ninety-six cases of fresh frozen brain tissue comprising primary brain tumours both 
gliomas of varying grades and meningiomas, along with normal brain were selected from 
the Brain Tumour North West tissue bank, with ethical approval (NRES14/EE/1270). 
This tissue has been retrieved from the patient and then snap frozen on arrival within the 
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histopathology department. Sections are cut within a cryostat machine to ensure tissue 
remains frozen, sections are allowed to defrost prior to spectral acquisition. This tissue 
was chosen for analysis as it has not previously been formalin fixed and therefore is 
closest to fresh tissue allowable given the number of cases tested. The cases used in the 
study are shown in table 3.1 below, categorised by tumour type. 
 
Table 3.1: Tumour samples selected for analysis, broken down by tumour type and WHO grade. 
 N WHO 
Grade 1 
WHO 
Grade 2 
WHO 
Grade 3 
WHO 
Grade 4 
No Grade 
All Cases 96 25 11 14 33 5  
Normal brain 8 N/A N/A N/A N/A N/A  
Gliomas 54 1 6 11 33 3  
Meningiomas 34 24 5 3 N/A 2 
 
Ten-µm-thick frozen sections were cut and placed onto 25 × 25 × 1 mm Raman-grade 
calcium fluoride-coated slides (Cyrstan Ltd). A matched 4-µm-thick section stained with 
haematoxylin and eosin (H&E) was then cut to allow viable tumour areas to be marked 
and confirmed. This allowed points within the tumour tissue to be tested using 
spectroscopy, to prevent any contaminating spectra from background brain tissue or 
necrotic areas. Following this, spectrochemical measurements were performed using both 
Raman and ATR-FTIR spectroscopy, focussed on the viable tumour areas. 
 
Raman spectroscopy 
 
Spectra were taken from 20-25 random points within the tumour tissue area using a 
Horiba Jobin-Yvon LabRAM HR800 spectrometer. An air-cooled CLDS point mode 
diode 785 nm laser with a single edge filter (cut off to 100 cm-1) and an output power of 
300 mW. This was done with a confocal hole of 100 µm at a grating of 300 gr/mm and a 
×50 objective. For each spectrum, 2 accumulations each over 30 seconds were acquired. 
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ATR-FTIR Spectroscopy 
 
The ATR-FTIR spectroscopy measurements were performed on an Agilent Cary-600 
Series FTIR spectrometer. Measurements were taken in transmission mode with 32 co-
added scans over a range of 4000-400 cm-1 and a resolution of 4 cm-1. A background scan 
was taken prior to each sample with the same settings. Twenty random points were 
selected within each viable tumour area. 
  
Computational analysis 
 
Data collection and manipulation, was performed within a MATLAB R2014b 
environment (MathWorks Inc., USA) using PLS Toolbox 7.9.3 (Eigenvector Research 
Inc., USA) with specimens first assigned to training, validation and test groups using the 
Kennard-Stone algorithm, a method of dividing data into training, validation and test 
groups (see Table 3.2). Of the samples, 70% were placed into training and 15% each into 
validation and test groups. This method was chosen as it has been previously shown to be 
effective in spectral analysis (Lima et. al., 2015). Youden’s index was also calculated to 
determine the significance of the results, with 1 meaning no false positives or negatives 
and 0; occurring by chance.  
 
Table 3.2 Number of samples within the training, validation and test groups based on the 
application of the Kennard-Stone algorithm. 
Class Training Validation Test 
Normal 111 24 24 
Meningioma 466 100 100 
Glioma 739 158 159 
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Pre-processing using Savitzky-Golay smoothing followed by multiplicative scatter 
correction (MSC), baseline correction, and vector normalization were performed. The 
spectra were cut from 1800-500 cm-1 [see Supplementary Information (SI) Figures S1 
and S5)]. Following on from this, principal component analysis with linear discriminant 
analysis (PCA-LDA) or quadratic discriminant analysis (PCA-QDA), and genetic 
algorithm with LDA (GA-LDA) or quadratic discriminant analysis (GA-QDA) were 
performed in order to determine the best analytical method (Lima et. al., 2015). The 
training samples were used for model construction and the test set for the final 
classification evaluation. The optimum number of variables for GA-LDA/QDA was 
performed based on the average risk 𝐺 of misclassification, which is calculated in the 
validation set as: 
 
𝐺 = !!! 𝑔!!!!!!          
 (1) 
 
where 𝑁! is the number of validation samples and 𝑔! is defined as 
 
𝑔! = !! !!,!!(!)!"#!(!)!!(!) !! !!,!!(!)         
 (2) 
 
where 𝐼(𝑛) is the index of the true class for the nth validation object 𝑥!; 𝑟! 𝑥!,𝑚!(!)  is 
the squared Mahalanobis distance between object 𝑥! (of class index 𝐼(𝑛)) and the sample 
mean 𝑚!(!) of its true class; and 𝑟! 𝑥!,𝑚!(!)  is the squared Mahalanobis distance 
between object 𝑥! and the sample mean 𝑚!(!) of its wrong class (28). The GA routine 
was carried out during 40 generations with 80 chromosomes each. Crossover and 
mutation probabilities were set to 60% and 10%, respectively. Moreover, the algorithm 
was repeated three times, starting from different random initial populations. The best 
solution (in terms of the fitness value) was employed. LDA and QDA were employed to 
the PCA scores and GA selected variables as follows (Siqueira et. al., 2017): 
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𝐿!" = 𝐱! − 𝐱! !𝚺!""#$%!! 𝐱! − 𝐱! − 2 log! 𝜋!      (3) 
 𝑄!" = 𝐱! − 𝐱! !𝚺!!! 𝐱! − 𝐱! + log! 𝚺! − 2 log! 𝜋!     (4) 
 
where 𝐿!" and 𝑄!" are the LDA and QDA classification scores, respectively;  𝐱! is the 
measurement vector containing the input variables for sample i; 𝐱! is the mean 
measurement vector for class k; 𝚺!""#$% is the pooled covariance matrix between the 
classes; 𝚺! is the variance-covariance matrix of class k; and 𝜋! is a prior probability 
term, defined as the ratio between the number of samples in class k and the total number 
of samples in the training set. 
 
Results 
 
Raman Spectroscopy 
 
From the 96 cases, 1911 spectra were collected. During pre-processing 30 spectra were 
removed due to poor quality, observed by a Hotelling T2 versus Q residuals test. As in 
Table 2, tumours were classified by type rather than grade. Following pre-processing 
(figure 3.1) there were 159 spectra in the training class, 666 in the validation class and 
1056 in test class. Firstly, comparison was done between normal and tumour tissue, 
grouping both meningiomas and gliomas together (Figure 3.2, Table 3.3). This 
demonstrates that 94% of the cases were correctly classified as either tumour or non-
tumour brain tissue, with a sensitivity (i.e. the number of actual positives identified as 
positive) of 98.8% and specificity (i.e. the number of actual negatives identified as 
negative) of 41.7%. 
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Figure 3.1: Pre-processed mean Raman spectra, averaged spectra for each tumour type.  
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Figure 3.2 Discriminant function plots to demonstrate the separation of normal versus 
tumour (Meningioma and glioma) using Raman spectroscopy. (A) Principal Component 
Analysis-Linear Disciminant Analysis, (B) Principal Component Analysis-Quadratic 
Discriminant Aanalysis, (C) Genetic Algorithmn- Linear Disciminant Analysis, (D) Genetic 
Algorithmn- Quadratic Discriminant Aanalysis. 
 
Table 3.3 Results for classification models for normal versus tumour (meningioma and 
glioma) using Raman spectroscopy. Highlighted in red is the best classification model. 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 93.3 94.0 91.5 91.8 
Sensitivity (%) 98.4 98.8 97.3 97.7 
Specificity (%) 37.5 41.7 29.2 29.2 
PPV (%) 94.4 94.8 93.7 93.7 
NPV (%) 69.2 76.9 50.0 53.8 
Youden’s Index 0.36 0.41 0.27 0.27 
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Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 85.5 91.4 93.3 
PCA-QDA 93.4 94.3 94.0 
GA-LDA 84.3 90.7 91.5 
GA-QDA 86.6 91.8 91.8 
 
Following on from this the model was tested to determine if it could identify; meningioma from 
glioma (figure 3.3, table 3.4), normal from meningioma (figure 3.4, table 3.5), normal from glioma 
(figure 3.5, table 3.6) and normal from meningioma from glioma (figure 3.6, table 3.7). When asked 
to determine tumour by type the overall classification accuracy fell to 63.1%. Normal brain tissue was 
still detected with an accuracy of over 90%.  
 
Figure 3.3: Discriminant function plots to demonstrate separation of meningioma versus glioma using 
Raman spectroscopy. ((A) Principal Component Analysis-Linear Disciminant Analysis, (B) Principal 
Component Analysis-Quadratic Discriminant Aanalysis, (C) Genetic Algorithmn- Linear Disciminant 
Analysis, (D) Genetic Algorithmn- Quadratic Discriminant Aanalysis. 
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Table 3.4: Results for classification models for meningioma versus glioma using Raman spectroscopy. 
Highlighted in red is the best classification model.  
 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 67.1 66.7 67.4 66.7 
Sensitivity (%) 83.4 94.3 88.5 89.8 
Specificity (%) 41.6 23.8 34.7 30.7 
PPV (%) 68.9 65.8 67.8 66.8 
NPV (%) 61.8 72.7 66.0 66.0 
Youden’s Index 0.25 0.18 0.23 0.21 
 
Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 67.5 68.9 67.1 
PCA-QDA 70.5 67.3 66.7 
GA-LDA 73.4 73.1 67.4 
GA-QDA 75.8 72.0 66.7 
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Figure 3.4: Discriminant function plots to demonstrate the separation of normal versus 
meningioma using Raman spectroscopy. (A) Principal Component Analysis-Linear 
Disciminant Analysis, (B) Principal Component Analysis-Quadratic Discriminant Aanalysis, 
(C) Genetic Algorithmn- Linear Disciminant Analysis, (D) Genetic Algorithmn- Quadratic 
Discriminant Aanalysis. 
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Table 3.5: Results for classification models for normal versus meningioma using Raman 
spectroscopy. Highlighted in red is the best classification model.  
 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 89.6 90.4 88.8 95.2 
Sensitivity (%) 98.0 99.0 97.0 95.0 
Specificity (%) 54.2 54.2 54.2 95.8 
PPV (%) 90.0 90.1 89.9 99.0 
NPV (%) 86.7 92.9 81.2 82.1 
Youden’s Index  0.51 0.53 0.51 0.91 
 
Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 92.0 89.4 89.6 
PCA-QDA 94.5 88.6 90.4 
GA-LDA 92.0 90.2 88.8 
GA-QDA 91.3 98.4 95.2 
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Figure 3.5: Discriminant function plots to highlight the separation of normal versus glioma 
using Raman spectroscopy. (A) Principal Component Analysis-Linear Disciminant Analysis, 
(B) Principal Component Analysis-Quadratic Discriminant Aanalysis, (C) Genetic 
Algorithmn- Linear Disciminant Analysis, (D) Genetic Algorithmn- Quadratic Discriminant 
Aanalysis. 
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Table 3.6: Results for classification models for normal versus glioma using Raman 
spectroscopy. Highlighted in red is the best classification model.  
 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 90.1 91.7 90.6 88.4 
Sensitivity (%) 99.4 100 98.1 96.2 
Specificity (%) 29.2 37.5 41.7 37.5 
PPV (%) 90.2 91.3 91.7 91.0 
NPV (%) 87.5 100 76.9 60.0 
Youden’s Index  0.29 0.38 0.40 0.34 
 
Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 79.7 87.2 90.1 
PCA-QDA 90.2 91.7 91.7 
GA-LDA 82.7 90.0 90.6 
GA-QDA 76.8 88.9 88.4 
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Figure 3.6 Discriminant function plots to demonstrate the separation of normal versus 
meningioma versus glioma using Raman spectroscopy. (A) Principal component analysis – 
linear discriminant analysis, (B) Genetic Alogorithmn-Linear  discriminant analysis. 
 
Table 3.7 Results for classification models of normal versus meningioma versus glioma using 
Raman spectroscopy. 
 Normal Meningioma Glioma 
PCA-LDA GA-LDA PCA-LDA GA-LDA PCA-LDA GA-LDA 
Accuracy 
(%) 
92.9 92.6 69.5 68.4 63.6 62.4 
Sensitivity 
(%) 
33.3 29.2 33.7 36.6 86.6 82.8 
Specificity 
(%) 
98.4 98.4 89.5 86.2 35.2 36.8 
PPV (%) 66.7 63.6 64.2 59.7 62.7 62.6 
NPV (%) 94.1 93.7 70.7 70.9 67.7 63.0 
Youden’s 
Index  
0.32 0.28 0.23 0.23 0.22 0.20 
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Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 59.0 62.5 63.1 
GA-LDA 66.1 68.9 61.7 
 
ATR-FTIR Spectroscopy 
 
The process was then repeated for ATR-FTIR spectroscopy. From the 96 cases, 1919 
spectra were collected; again during pre-processing 38 spectra were removed due to poor 
quality, observed by a Hotelling T2 versus Q residuals test. Spectra were divided as 
above. Following pre-processing (figure 3.7) there were 159 spectra in the training class, 
666 in the validation class and 1056 in the test class. As for the Raman spectra, firstly, 
normal was compared to tumour (meningioma and glioma) with GA-QDA providing the 
best results, with a classification accuracy of 97.2% (Figure 3.8, Table 3.8). The 
sensitivity was 100% and specificity 66.7%. Following on from this the model was tested 
to determine if it could identify; meningioma from glioma (figure 3.9, table 3.9), normal 
from meningioma (figure 3.10, table 3.10), normal from glioma (figure 3.11, table 3.11) 
and normal from meningioma from glioma (figure 3.12, table 3.12). 
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Figure 3.7: Mean pre-processed IR spectra 
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Figure 3.8 Discriminant function analysis to demonstrate the separation of normal versus 
tumour (meningioma and glioma) using IR spectroscopy. (A) Principal Component 
Analysis-Linear Disciminant Analysis, (B) Principal Component Analysis-Quadratic 
Discriminant Aanalysis, (C) Genetic Algorithmn- Linear Disciminant Analysis, (D) Genetic 
Algorithmn- Quadratic Discriminant Aanalysis.. 
 
Table 3.8 Results of classification models for normal versus tumour (meningioma and 
glioma) using IR spectroscopy, with the best classification model highlighted in red. 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 92.1 87.1 94.1 97.7 
Sensitivity (%) 98.1 87.1 100 100 
Specificity (%) 12.5 87.5 16.7 66.7 
PPV (%) 93.7 98.9 94.1 97.5 
NPV (%) 33.3 33.9 100 100 
Youden’s Index 0.11 0.75 0.17 0.67 
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Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 81.1 92.9 90.5 
PCA-QDA 93.3 86.2 84.5 
GA-LDA 91.5 95.4 92.9 
GA-QDA 96.7 97.9 97.2 
 
 
 
Figure 3.9: Discriminant function analysis to demonstrate separation of Meningioma versus 
Glioma using IR spectroscopy. (A) Principal Component Analysis-Linear Disciminant 
Analysis, (B) Principal Component Analysis-Quadratic Discriminant Aanalysis, (C) Genetic 
Algorithmn- Linear Disciminant Analysis, (D) Genetic Algorithmn- Quadratic Discriminant 
Aanalysis. 
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Table 3.9: Results for classification models for meningioma versus glioma using IR 
spectroscopy. Highlighted in red is the best classification model.  
 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 74.5 74.1 81.5 82.2 
Sensitivity (%) 97.5 88.1 94.3 92.5 
Specificity (%) 38.0 52.0 61.0 66.0 
PPV (%) 71.4 74.5 79.4 81.2 
NPV (%) 90.5 73.2 87.1 84.6 
Youden’s Index 0.36 0.40 0.55 0.59 
 
Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 75.4 69.4 74.5 
PCA-QDA 74.7 72.1 74.1 
GA-LDA 88.0 84.9 81.5 
GA-QDA 89.2 88.0 82.2 
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Figure 3.10: Discriminant function analysis to demonstrate separation of Normal versus 
meningioma using IR spectroscopy. (A) Principal Component Analysis-Linear Disciminant 
Analysis, (B) Principal Component Analysis-Quadratic Discriminant Aanalysis, (C) Genetic 
Algorithmn- Linear Disciminant Analysis, (D) Genetic Algorithmn- Quadratic Discriminant 
Aanalysis. 
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Table 3.10: Results for classification models for normal versus meningioma using IR 
spectroscopy. Highlighted in red is the best classification model.  
 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 86.3 95.2 83.9 96.8 
Sensitivity (%) 100 95.0 100 99.0 
Specificity (%) 29.2 95.8 16.7 87.5 
PPV (%) 85.5 99.0 83.3 97.1 
NPV (%) 100 82.1 100 95.5 
Youden’s Index 0.29 0.91 0.17 0.87 
 
Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 89.3 91.1 86.3 
PCA-QDA 95.8 91.9 95.2 
GA-LDA 89.5 91.9 83.9 
GA-QDA 96.5 98.4 96.8 
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Figure 3.11: Discriminant function analysis to demonstrate separation of normal vs glioma 
using IR spectroscopy. (A) Principal Component Analysis-Linear Disciminant Analysis, (B) 
Principal Component Analysis-Quadratic Discriminant Aanalysis, (C) Genetic Algorithmn- 
Linear Disciminant Analysis, (D) Genetic Algorithmn- Quadratic Discriminant Aanalysis. 
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Table 3.11: Results for classification models for normal versus glioma using IR 
spectroscopy. Highlighted in red is the best classification model.  
 
 PCA-LDA PCA-QDA GA-LDA GA-QDA 
Accuracy (%) 80.6 73.4 88.7 94.4 
Sensitivity (%) 95.0 74.0 100 96.0 
Specificity (%) 20.8 70.8 41.7 87.5 
PPV (%) 83.3 91.4 87.7 97.0 
NPV (%) 50.0 39.5 100 84.0 
Youden’s Index 0.16 0.45 0.42 0.84 
 
Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 76.9 90.7 86.9 
PCA-QDA 92.1 80.2 82.0 
GA-LDA 92.1 94.5 92.3 
GA-QDA 96.2 95.6 96.2 
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Figure 3.12 Discriminant function analysis to demonstrate separation of normal versus 
meningioma versus glioma using IR spectroscopy. (A) principal component analysis – linear 
discriminant analysis, (B) Genetic Alogrithmn-linear discriminant analysis. 
 
Table 3.12 Results of the classifcation models for normal versus meningioma versus glioma 
using IR spectroscopy. 
 Normal Meningioma Glioma 
PCA-LDA GA-LDA PCA-LDA GA-LDA PCA-LDA GA-LDA 
Accuracy 
(%) 
90.8 95.8 73.1 83.4 64.0 79.2 
Sensitivity 
(%) 
8.3 50.0 26.0 56.0 96.2 98.1 
Specificity 
(%) 
98.5 100 98.9 98.4 22.6 54.8 
PPV (%) 33.3 100 92.9 94.9 61.4 73.6 
NPV (%) 92.1 95.6 71.0 80.4 82.4 95.8 
Youden’s 
Index 
0.07 0.50 0.25 0.54 0.19 0.53 
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Correct 
Classification (%) 
Training Validation Test 
PCA-LDA 62.8 61.7 64.0 
GA-LDA 83.1 84.0 79.2 
 
As the classification model becomes more complex, the accuracy drops; for example, 
when comparing if the classification model could correctly identify normal versus 
meningioma versus glioma the accuracy fell to 79.2%, however this was still above that 
achieved with the Raman spectroscopy (63.1%). FTIR also gave higher accuracy results 
when comparing tumour to no tumour, 97.7% compared to 94%. This may be due to the 
water content within the frozen samples interfering with the Raman spectra.  
 
Discussion 
 
The ability of vibrational spectroscopic techniques to detect brain tumours with both 
blood components (Owens et. al., 2014, Gajjar et. al., 2013, Hands et. al., 2014, Hands 
et. al., 2016) and formalin-fixed tissue (Gajjar et. al., 2012) has been previously 
demonstrated with high accuracy levels. Studies using fresh frozen brain tissue are few 
and far between, with one study within the paediatric field showing an ability to detect 
different tumour types and a second trialling a hand held Raman machine 
intraoperatively slowly moving forward (Auner et. al., 2013, Desroches et. al., 2018, 
Desroches et. al., 2015). This study aimed to compare both Raman and ATR-FTIR 
spectroscopy using fresh tissue, which had previously only been frozen, in order to 
determine which provided the most accurate classification results as a precursor to 
developing a tool for intraoperative detection of primary brain tumours. We have shown 
that as compared to normal brain tissue, ATR-FTIR and Raman spectroscopy can both 
detect normal from tumour tissue with a high degree of accuracy (97.7% and 94%, 
respectively). However, when asked to determine tumour type, the accuracy of both 
techniques drops (79.2 and 63.1%, respectively). FTIR spectroscopy was however, 
considerably higher than Raman, perhaps demonstrating it is better placed to differentiate 
between the tumour types. The accuracy does though remain greatly below that offered 
by a conventional intraoperative smear diagnosis and thus would require improvement in 
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order to be a useful, clinically diagnostic tool. Importantly, the sensitivity when 
comparing normal to tumour is high (87.1-100%), meaning we are not over diagnosing 
tumours. The specificities are lower, though in this situation where a surgeon is aware of 
the presence of a tumour, high sensitivity remains the priority. One limitation of the 
study is the low number of ‘normal’ i.e. non tumour cases tested (n=8) as the majority of 
patients undergoing neurosurgery have a tumour. This is due to the low number of 
normal fresh frozen cases available within the brain bank. Therefore, if used clinically, 
the ability to test more background non tumour brain is likely to improve the 
classification accuracy and specificity. One other consideration is if the use of 
spectroscopy to detect meningiomas is useful. Given the distinctive radiology and 
macroscopic appearances, it may be that surgical tumour detection is limited between 
normal and glial tumours. If mengiomas were to be excluded, this would increase the 
detection accuracy between normal brain and gliomas to over 90% (see table 3.11). 
Finally, glial tumours were detected as a group and not based on their WHO 
classification. This was done due to the relatively small numbers of low grade tumours 
(n=7/54, WHO Grades 1&2). Surgically, this is a useful distinction to make, therefore 
taking this study forward it would be necessary to differentiate the glial tumours into low 
and high grade based upon WHO grades.  
 
Overall, we have shown spectroscopy may have potential in the diagnosis of 
intraoperative brain tumours; however, further work to improve classification would be 
required prior to clinical implementation. Further work to allow for comparison of 
primary to metastatic tumours would also prove useful in providing clinical useful 
information in real time. 
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4. Metastatic Brain Tumours 
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Introduction 
Metastatic brain tumours are usually the end point in a persons’ cancer journey, yet for 
some may represent the initial diagnosis. The background prevalence of metastatic brain 
tumours is difficult to quantify; however, those clinically detectable outnumber intrinsic 
tumours by roughly 3 to 1, with the majority of metastases arising from primary lung 
tumours (Davis et. al., 2012, Huang and Ouyang, 2013, Renfrow and Lesser, 2013). In 
contrast, colorectal tumours comprise 4-8% of metastasis, yet less than 9% of all cases 
metastasise to the brain (Sanghvi et. al., 2017). For those who undergo metastectomy for 
diagnosis or symptom relief, the tissue, once removed is sent for histopathological 
analysis to determine the location of the primary tumour. This study was designed to 
examine the capabilities of spectroscopy, both Raman and ATR-FTIR, in determining the 
primary location of a metastatic tumour. Tumours were chosen, firstly those that 
commonly metastasise to the brain, i.e. lung adenocarcinoma and malignant melanoma. 
Colorectal adenocarcinoma was then used as a tumour with morphologically similar 
appearances to lung adenocarcinoma but differing immunohistochemical profile. This 
was chosen in preference to breast carcinoma, as whilst this morphologically often 
appears different to lung adenocarcinoma, the immunohistochemical profiles of both 
tumours overlap significantly, often providing challenges to the Histopathologist.  
The initial hypothesis was that the two adenocarcinoma groups would show similar 
spectral patterns and therefore would be difficult to differentiate as compared to the 
metastatic melanoma group, which would demonstrate a marked difference. 
Methods 
Formalin-fixed paraffin embedded tissue from twenty-one brain metastasis comprising 
colorectal adenocarcinoma metastasis (n=7), lung adenocarcinomas metastasis (n=7) and 
metastatic melanomas (n=7) were obtained from the Brain Tumour North West (BTNW) 
research tissue bank (RTB – ethics NRES14/EE/1270). Sections (10-µm-thick) were 
placed onto glass slides covered with aluminium foil.  Foil covered slides have been 
previously demonstrated to be as effective as the more expensive CaF2 slides 
significantly reducing the costs of this process (Cui et. al., 2016). These were de-waxed 
prior to spectral acquisition by leaving overnight in fresh xylene. They were then washed 
in fresh xylene for 5 min. Following this, they were immersed in fresh ethanol at 100% 
twice and then 70% ethanol once, for 5 min each, and then allowed to air dry prior to 
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spectral acquisition. H&E-stained slides were viewed to delineate the tumour to be 
examined, to reduce contamination of spectra from background brain tissue. 
Raman spectroscopy 
A Renishaw InVia Raman spectrometer was used to collect 25 spectra per section using a 
785 nm laser at 1200 g mm-1 grating with an acquisition time of 30 seconds for each 
sample. This was over a spectral range of 400-1600 cm-1. A 50× objective with numerical 
aperture of 0.85 was used to focus the laser beam. The spectral sites were selected at 
random moving over the tissue. 
Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy 
ATR-FTIR spectra were collected using a Bruker TENSOR 27 FTIR spectrometer with 
Helios ATR attachment containing a diamond crystal internal reflective element and a 
45° incidence angle of IR beam. A new background spectrum was collected prior to each 
new sample, following cleaning of the crystal with distilled water. For each case 32 scans 
with 8 cm-1 spectral resolution were taken at 10 randomly selected points. The sampling 
aperture was 250 µm × 250 µm and the mirror velocity was 2.2 Hz. 
Computational analyses 
Computational analyses, including principal component analysis (PCA) with linear 
discriminant analysis (LDA) and linear discriminant classifier (LDC) was then 
performed within a MATLAB environment, using the IRootlab toolkit as a user interface 
(Trevisan et. al., 2013). For classification spectra were pre-processed by cutting to the 
region of interest (Raman = 500-1800 cm-1; IR = 900-1800 cm-1), followed by 
polynomial baseline correction and vector normalisation. Spectra were then interrogated 
via PCA-LDA to generate scores plots and cluster vectors to determine points of 
variation between the spectra; PCA-LDC was then applied to calculate the classification 
accuracy as compared to the histopathological result. The top 6 spectral differences 
between the adenocarcinoma and melanoma groups were also determined. 
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Results 
Analysis of the spectra has shown similar results for both Raman and IR spectroscopy. 
They demonstrate similar spectral appearances for both adenocarcinoma groups, with 
significant differences seen to the spectra of the melanoma (figure 4.1). 
 
Figure 4.1 A graph demonstrating the mean pre-processed spectra from each tumour group 
using: (A) Raman spectroscopy (cut to the region of interest, polynomial baseline correction 
and vector normalisation); and, (B) IR spectroscopy (cut to the region of interest, 
rubberband baseline correction and vector normalisation). (KEY: CA=COLORECTAL 
ADENOCARCINOMA, LA=LUNG ADENOCARCINOMA, MM=MELANOMA). 
PCA-LDA was carried out to determine the principal components and thus the factors 
that account for most variance between the three groups in order to classify them. It was 
demonstrated that the groups show a degree of overlap (figure 4.2), which is greatest 
between the two adenocarcinoma groups. The difference to the melanoma group is again 
highlighted. From this, cluster vectors were used to visualise the differences between the 
three groups. It can be seen (Figure 4.3) that the two adenocarcinoma groups are similar 
with small areas of variance. However, the melanoma groups show a marked difference. 
This is particularly demonstrated within panel (D) where melanoma is taken as the 
baseline. This shows how similar adenocarcinomas are despite their different primary 
locations. 
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Figure 4.2 A graph demonstrating the PCA-LDA results for Raman and IR. The left side 
demonstrates the Raman results firstly without (A) and secondly with (B) 95% confidence 
intervals. This is then mirrored for IR, without (C) and with (D) 95% confidence intervals. 
(KEY: CA – COLORECTAL ADENOCARCINOMA, LA – LUNG ADENOCARCINOMA, MM – MALIGNANT 
MELANOMA) 
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Figure 4.3 These graphs show the cluster vectors for Raman and IR. The left side 
displays the Raman results, starting with (A) all the groups, (B) CA is taken as the 
baseline, (C) LA taken as the baseline, (D) MM taken as baseline and (E) compares 
adenocarcinoma vs. MM. This is mirrored on the right for IR. (KEY: CA – 
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COLORECTAL ADENOCARCINOMA, LA – LUNG ADENOCARCINOMA, MM – MALIGNANT 
MELANOMA, ADCA – ADENOCARCINOMA). 
 
 
Figure 4.4 The confusion matrices display the percentage of the results assigned to the 
correct group (green) or another group (red). The Raman results are shown on the left with 
(A) displaying each of the three cancer groups separately, and (B) compares 
adenocarcinoma to MM. On the left are the IR results; (C) displays each of the three cancer 
groups separately and (D) again compares adenocarcinoma to MM. (KEY: CA – 
COLORECTAL ADENOCARCINOMA, LA – LUNG ADENOCARCINOMA, MM – MALIGNANT 
MELANOMA, ADCA – ADENOCARCINOMA). 
A PCA-LDC, giving the classification accuracy for each group as compared to the final 
histological diagnosis, was then performed (Figure 4.4). This was run for three separate 
groups and then two (combining the two adenocarcinoma groups) groups to show the 
difficulty in separating the adenocarcinomas. When using three groups for Raman, the 
classification accuracy is 69% for colorectal adenocarcinoma, 69% for lung 
adenocarcinoma and 72% for melanoma. Using IR this is 60% for colorectal 
adenocarcinoma, 59% for lung adenocarcinoma and 47% for melanoma. If the two 
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adenocarcinoma groups are combined, classification accuracy markedly increases. With 
Raman this improves to 85% for adenocarcinoma and 75.4% for melanoma, and with IR 
96% for adenocarcinoma and 72% for melanoma. This is, however, still below that found 
with traditional histopathology. 
 
 
Figure 4.5 These graphs represent the results of both a one-way ANOVA and student’s t-test 
scores plot for Raman and PCA-LDA. (A) shows the one way ANOVA for Raman with all 
three tumour groups, (B) the student’s t-test for Raman with adenocarcinoma and MM. 
This is mirrored for IR with (C) showing the one-way ANOVA for IR with all three tumour 
groups and (D) the student’s t-test for IR with adenocarcinoma and MM. (KEY: CA – 
COLORECTAL ADENOCARCINOMA, LA – LUNG ADENOCARCINOMA, MM – MALIGNANT 
MELANOMA). 
Following this, a one-way ANOVA was performed for the three groups to assess if the 
differences seen between the spectra were significant. A student’s t-test was performed 
on the merged 2 groups to assess significance due to the small numbers involved (Figure 
4.5). This was performed on the PCA-LDA results using all spectra for each case. For the 
three Raman groups this was P=0.0016 at 95% confidence interval and for IR this was 
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not significant (P=0.08) (table 4.1). For two groups, this was again significant at <0.0001 
for Raman and IR, with a 95% confidence interval (table 4.2). 
Table 4.1 Results of one-way ANOVA for both Raman and IR to determine statistical 
difference between all three groups. (KEY: CA – COLORECTAL ADENOCARCINOMA, LA – 
LUNG ADENOCARCINOMA, MM – MALIGNANT MELANOMA) 
 
 
 
 
 
 
 
 
 
Table 4.2 :Results of a student’s t-test for Raman and IR to determine statistical difference between 
adenocarcinoma and MM. (KEY: MM = METASTATIC MELANOMA, AD = ADENOCARCINOMA) 
Method Group Difference 
between 
means 
95% 
CI 
P-value 
Raman MM 
vs. AD 
0.24+/-
0.01 
0.22 – 
0.27 
<0.0001 
IR MM 
vs. AD 
0.09 +/- 
0.01 
0.08 – 
0.10 
<0.0001 
 
Method Group Mean 
difference 
95% CI P-value 
Raman CA vs. LA 0.03 -0.01 - 0.06 0.1898 
 CA vs. MM -0.23 -0.26 - -0.20 <0.0001 
 LA vs. MM -0.25 -0.29 - -0.22 <0.0001 
IR CA vs. LA -0.02 -0.03 - -0.00 0.0122 
 CA vs. MM -0.10 -0.11 - -0.08 <0.0001 
 LA vs. MM -0.08 -0.09 - -0.06 <0.0001 
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The statistical significance between each group was also calculated using a one-way 
ANOVA (Table 4.1). This highlights the statistically significant differences found 
between adenocarcinoma and melanoma. There is no statistical difference between the 
two adenocarcinoma groups on either Raman or IR spectroscopy. 
To conclude, the significant differences were calculated (figure 4.6) and tentative 
distinguishing wavenumbers assigned to those differences (Table 4.3). This was done to 
examine the points at which the tumours vary and to see which areas accounted for the 
variation. 
 
Figure 4.6 The significant wavenumber differences between the adenocarcinoma groups and 
melanoma. The red line indicates the U wave number curve and the black doted line the 
significance threshold. The X highlights the 6 most significant differences. A: Raman, B: 
ATR-FTIR 
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Table 4.3 The tentative assignments of significant points of difference for Raman and IR, 
using adenocarcinoma vs. melanoma (Movasaghi et. al., 2007, Movasaghi et. al., 2008). 
Method Wavenumber 
(cm-1) 
Tentative assignment 
Raman  1310 
CH3/CH2 twisting or bending mode of 
lipid/collagen 
CH3/CH2 twisting, wagging &/or bending 
mode of collagens & lipids 
 1297 CH2 deformation/Palmitic acid, acyl chains, 
fatty acids 
 1296 CH2 deformation 
 1295 Methylene twisting /CH2 deformation 
 1294 Methylene twisting 
 1293 Cytosine/ Methylene twisting 
IR 1720 C=O 
 1578 Ring C-C stretch of phenyl 
 1481 Amide II 
 1477 CH2 bending of methylene chains in lipids 
/Polyethylene methylene of deformation 
modes 
 1474 CH2 bending of methylene chains in lipids 
/Polyethylene methylene of deformation 
modes 
 1470 CH2 bending of methylene chains in lipids 
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Discussion 
 
Both spectroscopic methods have been shown to be able to classify the different tumours 
by type (i.e., adenocarcinoma vs. melanoma), providing similar results. However, 
accuracy is greatly diminished if it is used to classify the primary origin of the tumour 
type, specifically determining if the adenocarcinoma arose within the lung or colon. 
Minor differences are seen between the spectra of these two tumours (Figure 4.1); 
however, these differences are not statistically significant. This would, therefore, limit 
any clinical use, as it would not be able to provide as much information as traditional 
histopathology with H&E and IHC. These tumour types were chosen specifically to 
provide two similar tumours (i.e. the two adenocarcinomas, that require 
immunohistochemistry to differentiate) alongside one different tumour, both 
morphologically and immunohistochemically (i.e. melanoma). Both lung 
adenocarcinomas and melanomas frequently metastasis to the brain. It may be that such 
new tools may aid the clinician in determining tumour type intra-operatively, i.e. that the 
tumour is a metastasis and not a primary brain tumour, but formal histopathology with 
IHC would still be required for primary tissue origin identification. This, however, is also 
of interest given the marked spectral similarities between adenocarcinomas of different 
primary origins (Figure 4.2). This is useful for Clinicians, as it may help with cancer of 
unknown primaries (i.e. the primary site is unknown and traditional methods such as 
radiology and pathology are failing to determine the primary site) or in aiding the 
surgeon to distinguish a primary from metastatic tumour. 
 
Within this study, confounding factors, such as the number or location of the brain 
metastasis, nor patient factors have been used to contribute to the accuracy of the results. 
As this was a comparison to conventional histopathology, these factors would not impact 
upon microscopy or immunohistochemistry, therefore it was felt not appropriate to be 
added into the diagnostic algorithm. 
 
When evaluating the potential value of spectroscopy as a possible intraoperative tool its 
ability to determine cancer versus no cancer and suggest a tumour type would be 
required. To provide further information to that provided by intraoperative 
neuropathology, spectroscopy would need to differentiate the primary tumour origin for a 
metastasis. However, as can be seen, both Raman and IR spectroscopy are able to detect 
differences between the two tumour types, but not specify the primary tissue origin 
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accurately enough for treatment decisions. As the technique develops, it may replace 
frozen section, often performed intraoperatively to determine if a tumour is primary, i.e., 
has arisen within the brain, or is a metastasis to guide the surgeon in relation to the extent 
of the resection he may perform, as has been suggested previously (Ji et. al., 2013, Ji et. 
al., 2015, Hollon et. al., 2016).  At which point, acknowledgement of a metastasis (from 
a primary tumour) would be the level required with histopathology completing the 
primary tumour origin determination as currently occurs. This would provide a 
potentially useful area for the technology to exploit as frozen section work can be 
challenging and potentially an area for error to be removed by use of spectroscopy. 
However, comparative work to normal brain tissue and primary tumours would be 
required to ensure the technique is able to differentiate all potential results. This study 
has highlighted spectroscopy would not be able to determine primary tissue origin of a 
metastasis in its current form.  
As the technique develops, it may eventually be able to provide additional information to 
support the initial histopathological diagnosis, which may in the future provide treatment 
related or prognostic information once the spectra are fully understood in the years to 
come. 
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5. Detection of Primary and Metastatic brain tumours from 
biofluids 
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Introduction 
 
Blood testing for cancer diagnostics is a popular ideal. It uses an acceptable patient test, 
i.e., a blood test, which is non-invasive and machine analysed, can be run on a mass 
scale, and can target specific markers circulating in the blood. An example is prostate 
specific antigen (PSA) to allow detection of a suspected prostate cancer. For PSA this 
gives a quantitative figure that must be addressed in context with patient age to stratify 
risk. It has its flaws as a significant percentage of prostate cancers are non-secretors, 
meaning that there is no appreciable rise in PSA identifiable to indicate the underlying 
disease process. Conversely, benign conditions such as prostatitis can raise the PSA. 
However, tests such as PSA, or for women, CA125, are commonly used in clinical 
medicine, with beneficial outcomes, providing they are taken in context with the clinical 
and radiological picture. However, their sensitivity and specificity drops when used as a 
screening detection method, hence no mass-screening programme has yet been 
introduced using PSA or CA125. Many tumour types do not have specific blood markers. 
Therefore this study was designed to examine the potential of ATR-FTIR in analysing 
plasma samples from patients with a variety of primary and metastatic brain tumours. 
The metastatic tumours chosen were the same as those within the previous study for 
comparison. This approach aims to investigate whether ATR-FTIR spectroscopy is a 
useful tool to detect tumours within blood plasma when asked to differentiate on a wider-
scale more akin to a typical clinical setting. If accuracy falls in low-grade and metastatic 
lesions against a backdrop of high-grade lesions and controls, this would limit clinical 
use.	  
Methods 
 
Plasma from 50 patients comprising normal, i.e., no known brain tumour (n=10), glioma 
high-grade (n=5) or low-grade (n=5), meningioma (n=10) and brain metastasis patients, a 
mix of lung adenocarcinoma (n=7), colorectal adenocarcinoma (n=7) and malignant 
melanoma (n=6) patients were obtained from the Brain Tumour North West tissue bank 
(BTNW). This was under ethical approval number (RTB - ethics NRES14/EE/1270). 
These were stored at -80°C and defrosted prior to use. From the samples, 50 µl of plasma 
was pipetted onto a glass slide wrapped in aluminium foil. This has previously been 
shown to be as effective as slides such as calcium fluoride-coated windows (Cui et. al., 
2016). 
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The slides were left to dry overnight prior to spectral acquisition. ATR-FTIR spectra 
were collected using a Bruker TENSOR 27 FTIR spectrometer with Helios ATR 
attachment containing a diamond crystal internal reflective element and a 45o incidence 
angle of IR beam. For each case 32 scans with 8 cm-1 spectral resolution were taken at 10 
randomly selected points. A new background spectrum was collected prior to each new 
sample, followed by cleaning of the crystal with distilled water. The sampling aperture 
was 250 µm × 250 µm and the mirror velocity was 2.2 Hz. 
Computational analysis was then performed within a Matlab environment using IRootlab 
toolkit as a user interface (Trevisan et. al., 2013). Spectra were then pre-processed by 
cutting to the region of interest (1850-800 cm-1), followed by polynomial baseline 
correction and vector normalisation. Following this principal component analysis-linear 
discriminant analysis (PCA-LDA) to determine differences between the groups was 
performed, along with PCA-linear discriminant classifier (PCA-LDC) to calculate the 
classification accuracy of each group. Statistical significance was then determined using 
a one-way ANOVA within PRISM statistical analysis software.	  
Results  
 
From the 50 cases 500 spectra (i.e., 10 spectra per sample) were obtained. Following pre-
processing a PCA-LDA was performed to identify if the groups (or categories) are 
significantly different based upon their spectra, along with PCA-LDC to generate 
confusion matrices to look at the accuracy of the spectra in detecting each tumour type. 
This was performed initially looking at normal vs. each tumour group and then 
combining all groups together to determine if they could be differentiated accurately 
from each other, as would occur in a typical clinical setting. 
Figure 5.1 shows normal compared to low-grade and high-grade gliomas. It shows how 
well the spectra are separated based upon them being classed as normal (89%) or high-
grade (98%) with some overlap between low-grade and normal dropping the low-grade 
classification accuracy to 84%. The misclassified high grade spectra were below the level 
of resolution for the analytical method.  
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Figure 5.1 Confusion matrix comparing normal (N) to low-grade (LG) and high-grade (HG) 
gliomas. It shows the accuracy of classification for the three categories, with minimal 
overlap between normal and low-grade tumours. Green-filled circles represent accurate 
classification whereas red-filled circles represent inaccurate classification. 
 
This differentiation between the three groups is statistically significant using a one-way 
ANOVA, as shown in Table 5.1. Similar results are seen for normal vs. meningioma 
categories (88% and 85%, respectively) and normal vs. metastasis categories (96% and 
92%, respectively), though results were mixed for the metastasis group depending on the 
type of primary tumour, with lung adenocarcinoma giving the best accurate classification 
at 63% (Figure 5.2). 
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Table 5.1 A one-way ANOVA showing the differences between each of the normal, high-
grade (HG) and low-grade (LG) glioma groups. 
 
Tukey's multiple 
comparisons test 
Mean 
Difference 
95% CI of 
difference 
Adjusted P-
value 
Normal vs. HG 0.05 0.05 to 0.06 <0.0001 
Normal vs. LG 0.01 0.01 to 0.02 <0.0001 
HG vs. LG -0.04 -0.04 to 
-0.03 
<0.0001 
 
 
Figure 5.2 Confusion matrices for (A) control (N) vs. meningioma (Men); (B) control (N) vs. 
metastasis; and, (C) control (N) vs. the different metastatic groups, colorectal 
adenocarcinoma (CA), lung adenocarcinoma (LA) and melanoma (MM). Green-filled circles 
represent accurate classification whereas red-filled circles represent inaccurate 
classification. 
 
A)                                  B) 
    C) 
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For this spectrochemical approach to be a valid clinical test it is critically important for it 
to be able to differentiate all types of tumour from an initial plasma assessment. 
Therefore, following PCA-LDA for all 5 categories confusion matrices were generated. 
It shows that the accuracy of assigning categories drops significantly for low-grade glial 
tumours, meningiomas and metastasis (Figure 5.3). 
 
Figure 5.3 Three-D scores plot (A) and confusion matrix (B) for all separate categories, 
demonstrating overlap with low-grade gliomas, meningiomas and metastasis. Green-filled 
circles represent accurate classification whereas red-filled circles represent inaccurate 
classification. Key: N, control; HG, high-grade glioma; LG, low-grade glioma; Men, 
meningioma; and, Met, metastasis 
 
Following this, a one-way ANOVA was performed to demonstrate the differences 
between the five categories (Figure 5.4, Table 5.2), which demonstrates statistical 
significance, p <0.001 at the 95% confidence interval. 
A)                                            B) 
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Figure 5.4 A one-way ANOVA was performed looking at the differences between the five 
categories. This demonstrates the first linear discriminant of each spectra (LD1). Key: N, 
control; HG, high-grade glioma; LG, low-grade glioma; Men, meningioma; Met, metastasis 
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Table 5.2 The results of the one-way ANOVA showing statistically significant comparisons 
between each group. LG, low-grade glioma; HG, high-grade glioma; Mets, metastasis to 
brain 
 
Tukey's multiple 
comparisons test 
Mean 
Difference 
95% CI of 
difference 
Adjusted P-
value 
Normal vs. HG 0.05 0.05 to 0.06 <0.0001 
Normal vs. LG 0.01 0.01 to 0.02 <0.0001 
Normal vs. 
Meningioma 
0.03 0.03 to 0.04 <0.0001 
Normal vs. Mets 0.02 0.02 to 0.03 <0.0001 
HG vs. LG -0.04 -0.04 to -0.03 <0.0001 
HG vs. 
Meningioma 
-0.02 -0.03 to -0.02 <0.0001 
HG vs. Mets -0.03 -0.04 to -0.02 <0.0001 
LG vs. 
Meningioma 
0.02 0.01 to 0.023 <0.0001 
LG vs. Mets 0.01 0.00 to 0.01 0.0005 
Meningioma vs. 
Mets 
-0.01 -0.01 to -0.00 <0.0001 
 
However, the classification accuracy drops further if the metastasis category is split by 
primary tumour location, with only the detection of high-grade glioma maintaining >90% 
(figure 5.5). Whilst statistical significance is maintained from normal to tumour category, 
it is lost between certain tumour categories such as the two adenocarcinoma groups. It 
fails also, however, to reach significance for melanoma vs. lung adenocarcinoma, which 
is surprising (Table 5.3). 
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Figure 5.5 A confusion matrix showing the detection rates of all tumours compared to 
control cases with metastasis split into primary tumour site. Green-filled circles represent 
accurate classification whereas red-filled circles represent inaccurate classification. Key: N, 
normal; LG, low-grade; HG, high-grade; Men, meningioma; MM, melanoma metastasis; 
CA, colorectal adenocarcinoma metastasis; LA, lung adenocarcinoma metastasis 
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Table 5.3 Results of a one-way ANOVA comparing the tumours to look for statistically 
significant differences. Highlighted in red are those categories failing to reach statistical 
significance. Key: N, control; LG, low-grade; HG, high-grade; Men, meningioma; MM, 
melanoma metastasis; CA, colorectal adenocarcinoma metastasis; LA, lung adenocarcinoma 
metastasis 
 
Tukey's multiple 
comparisons test 
Mean 
Difference 
95% CI of difference Adjusted P-value 
  Normal vs. LG 0.02 0.01 to 0.02 <0.0001 
  Normal vs. HG 0.05 0.04 to 0.06 <0.0001 
  Normal vs. Men 0.03 0.03 to 0.04 <0.0001 
  Normal vs. MM 0.03 0.02 to 0.04 <0.0001 
  Normal vs. CA 0.02 0.02 to 0.03 <0.0001 
  Normal vs. LA 0.02 0.02 to 0.03 <0.0001 
  LG vs. HG 0.03 0.03 to 0.04 <0.0001 
  LG vs. Men 0.02 0.01 to 0.02 <0.0001 
  LG vs. MM 0.01 0.01 to 0.02 <0.0001 
  LG vs. CA 0.01 -0.00 to 0.01 0.2092 
  LG vs. LA 0.01 0.00 to 0.01 0.0190 
  HG vs. Men -0.02 -0.02 to -0.01 <0.0001 
  HG vs. MM -0.02 -0.03 to -0.01 <0.0001 
  HG vs. CA -0.03 -0.04 to -0.02 <0.0001 
  HG vs. LA -0.03 -0.03 to -0.02 <0.0001 
  Men vs. MM -0.00 -0.01 to 0.00 0.4924 
  Men vs. CA -0.01 -0.02 to -0.01 <0.0001 
  Men vs. LA -0.01 -0.02 to -0.01 <0.0001 
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  MM vs. CA -0.01 -0.02 to -0.00 0.0002 
   MM vs. LA -0.01 -0.01 to -0.00 0.0077 
  CA vs. LA 0.00 -0.00 to 0.01 0.9569 
 
Discussion 
 
In a typical clinical setting, patients present with a multitude of morbidities, real or 
perceived. The clinician’s challenge is to diagnose especially life-threatening conditions 
such as cancer as soon as possible. Given the complexity of the clinical picture, this can 
be time-consuming, inaccurate and expensive. Consequently, there has been great effort 
invested in attempts to develop biomarker-led blood tests for disease. In the last number 
of years, there have been a lot of pilot studies using spectrochemical techniques such as 
ATR-FTIR or Raman spectroscopy to distinguish control and cancer-sourced samples. 
Whilst the results of these studies are promising, many have not been designed with the 
complexity of a typical clinical setting in mind. 
 
Our results demonstrate that ATR-FTIR spectroscopy is able to detect patients with 
intrinsic or metastatic brain tumours using plasma samples from peripheral blood. 
However, this is most effective when used to detect high-grade glial tumours, or when 
asking a specific question, i.e., high-grade vs. low-grade glial lesions or control vs. 
meningioma. Once more tumour types are introduced into a classification algorithm, 
accuracy drops along with the statistical significance of differences between the groups. 
Taking this back into the clinical setting suggested above, with the incidence of brain 
tumours within the general population being 10/100,000 population/year, therefore for 
every positive result there will be many negatives in any given clinic (MacDonald et. al., 
2000). Strokes and epilepsy along with headache disorders make up the majority of clinic 
attendees. In order for this test to be validated it would be crucial to test a wide range of 
disorders to ensure this would not affect the results. It would also not account for patients 
with other underlying cancer(s) and how this could be differentiated. 
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One possible confounding factor that may need to be considered in future work is that it 
is not known if there is tumour involvement of the dura, the exact location of the tumours 
or number of metastasis in the metastatic group. It is also not known how widespread 
metastases are within the body. Therefore the lack of such information may influence 
classification accuracy. 
 
This study has shown that ATR-FTIR spectroscopy could play a role in plasma testing 
for both intrinsic and extrinsic brain tumours; however, this role is of limited value. 
Patients with high-grade intrinsic tumours and metastatic lesions are more likely to be 
detected via the conventional route of GP referral to secondary care or emergency 
admission at which point tumours would be identified. However, one use may be in 
accident and emergency when patients present with concerning symptoms; here, it might 
be used as a screening test for a high-grade glial lesion., as two thirds of patients with a 
high grade glioma attend A&E. The use of ATR-FTIR spectroscopy is unlikely to speed 
up the diagnostic process nor eliminate any of the current steps within the patient 
pathway; therefore, its usefulness as a biofluid screening tool may remain limited. Given 
its apparent weakness for low-grade lesions, for which it would be most beneficial, its 
clinical impact for pre-surgical diagnostics is limited. 
	  
This study demonstrates that ATR-FTIR spectroscopy is able to differentiate brain 
tumour types from blood plasma with a high degree of accuracy. However, this is most 
effective when a direct clinical question is asked. When confounded by increasing 
differential diagnoses, the classification accuracy of the system falls markedly for low-
grade lesions and metastasis. Therefore, this likely makes the use of ATR-FTIR 
spectroscopy within a clinical setting of limited value. Further work is required to 
determine if there is a more appropriate point to harness the use of ATR-FTIR 
spectroscopy within the clincal pathway. 
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6. Fresh brain tumours tested using a hand held Raman 
probe, can it differentiate primary from metastatic 
tumours? 
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Introduction 
 
Brain tumours account for 3% of all tumours diagnosed annually (CRUK D, accessed 
3/11/17). Whilst they comprise a small proportion, the difficulty of complete removal of 
the tumour is inherent. High-grade tumours can be infiltrative and when operating within 
the brain the risk of removing crucial structures in a bid to free the patient of the tumour, 
yet risk leaving them with significant neural deficit is ever present. Up to 75% of tumour 
resections are thought to leave behind viable tumour, though there is a survival benefit to 
improved/complete resection (Hollon et. al., 2016, Broadbent et. al., 2016). Therefore, 
any new technique available to highlight residual tumour, thus improving outcome and 
resection, yet reducing the non-tumour tissue removed would be beneficial. Currently, 
the use of 5-aminolevulinic acid (5-ALA) does allow for fluorescence of tumour cells in 
order to aid resection; however, this is imperfect. It can be difficult to tell apart tumour 
from background fluorescence (Galli et. al., 2017). 
Therefore this novel study was designed to determine the potential of Raman 
spectroscopy using fresh brain tissue taken at the time of surgery and sent for an 
intraoperative smear diagnosis to determine the primary tumour type. The results were 
compared to both the intraoperative smear diagnosis and final fixed paraffin result.  
This was done, as the need to test fresh tissue is crucial, to overcome any spectral 
changes seen due to formalin fixation or freezing artefact (O’Faolain et. al., 2005, Huang 
et. al., 2003). The use of gold nanoparticles in conjunction with Raman spectroscopy has 
previously been shown to improve the Raman signal received, reducing signal to noise 
ratio and thus enhance the spectral quality (Bulter et. al., 2015). Therefore due to the 
small sample size, the use of nanoparticles was performed to maximise spectra.  
 
Methods 
Prior to using the handheld Raman machine, a custom-built box was required to ensure 
darkness when analysing the tissues. As this was being placed into a working laboratory, 
it would not be possible to work in darkness and it would also need to fit into a category 
2 fume hood for work with fresh tissue. With this is mind, a box was custom engineered 
using plywood. A stage was built within this box to allow the slide to be moved in the x 
and y planes with a custom cut out area for the slide to be held securely. This was to 
allow the tissue to be accurately positioned under the probe. A clamp was then secured to 
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the box to allow the probe to be moved in the z plane to allow it to be positioned at the 
correct height above the tissue. Thus allowing movement similar to a conventional light 
microscope. The box was painted with black paint on the inside to minimise reflection of 
any light entering it. It also enabled it to be wiped clean if required (Figure 6.1 and 
appendix 9.11. 
 
A  
B  
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C  
Figure 6.1: The hand held Raman probe with purpose built box in situ in the 
Neuropathology department at Royal Preston Hospital. (A) and (B) show the full set up, 
with (C) highlighting the set up inside the box with example slide.  
 
Fresh brain tissue samples sent to the laboratory for intraoperative smear preparations 
were tested over a 6-month period (table 6.1). Ethics approval was obtained from the 
BTNW brain bank (NRES14/EE/1270). We obtained n=29 samples, which were 
analysed using an i-Raman portable Raman system with BAC100/BAC102 lab-grade 
Raman probe from B&W Tek from Pacer International, with software version 4.1. 
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Table 6.1 Results of both intraoperative smear preparations and final formalin-fixed 
paraffin-embedded tissue for each case tested. 
Case Number Smear Result Paraffin Result 
 
1 Low-grade glioma Glioblastoma 
2 Meningioma Meningioma 
3 Metastasis Ovarian serous 
carcinoma 
4 High-grade glioma Glioblastoma 
5 High-grade glioma Glioblastoma 
6 Meningioma Meningioma 
7 Metastasis Adenocarcinoma 
8 High-grade glioma Glioblastoma 
9 High-grade glioma Glioblastoma 
10 Metastasis Renal cell carcinoma 
11 Metastasis Lung adenocarcinoma 
12 ?no tumour Glioblastoma 
13 Low-grade glioma Astrocytoma Grade 2 
14 Inflammation Astrocytoma Grade 2 
15 Inflammation Astrocytoma Grade 2 
16 Metastasis Ovarian serous 
carcinoma 
17 High-grade glioma Glioblastoma 
18 High-grade glioma Glioblastoma 
19 High-grade glioma Glioblastoma 
20 High-grade glioma Glioblastoma 
21 High-grade glioma Glioblastoma 
22 ?reactive ?Low-grade glioma Low grade glioma 
23 Intermediate-grade glioma Glioblastoma 
24 Low-grade glioma Astrocytoma Grade 3 
25 Lymphoma High grade B cell 
lymphoma 
26 Glioma Astrocytoma Grade 2 
27 No definite tumour Astrocytoma Grade 2 
28 Low- to intermediate-grade glioma Astrocytoma Grade 2 
29 High-grade glioma Glioblastoma 
 
Prior to sample analysis, a small amount of tissue (similar in size to that used for a smear 
preparation) (Ellison et. al., 2013) was placed onto a glass slide covered with aluminium 
foil (Cui et. al., 2016) and 100 µL of 5 µg/mL BioPureTM 20 nm gold nanoparticles 
diluted in PBS was placed onto the sample and left for a few minutes to absorb prior to 
collecting 10 spectra per sample. Gold nanoparticles were used to enhance spectral 
quality. Each spectra had an acquisition time of 30 seconds at a laser power of 75% (see 
appendix 9.11 for set up analysis).  
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Data analysis was then conducted using MATLAB R2014b software (MathWorks Inc., 
USA) with an IRootlab toolkit (Trevisan et. al., 2013). IRootlab was chosen as it 
provides an interface with MATLAB to ensure consistent analysis. The raw spectral data 
was initially pre-processed by cutting the region of interest, 1800-400 cm-1, followed by 
polynomial baseline correction and vector normalisation. Thereafter, 10-fold cross-
validated principal component analysis-linear discriminant classifier (PCA-LDC) was 
applied for classification of the datasets. PCA-LDC uses principal component analysis 
(PCA) as feature extraction method, where the original data is decomposed into a few 
number of principal components (PCs) representing the majority of the information in 
the original dataset. The scores on each PC are then used as input variables for linear 
discriminant analysis (LDA). LDA works by maximizing the between-class variance 
over the within-class variance in order to create a linear decision boundary between the 
classes that provides the optimum class segregation (Santos et. al., 2017). Patient factors, 
including the location of the tumour and biopsy were not considered within this study as 
these factors would be unlikely to directly impact the histopathological analysis and thus 
may unnecessarily complicate the results algorithm. 
 
Results 
 
Over the 29 samples, 290 spectra were collected and analysed. From this, PCA-LDC was 
employed and receiver operating characteristic (ROC) curves generated. This was done 
to determine the classification accuracies of the Raman spectra as compared to both the 
intraoperative smear result and final FFPE histological diagnosis, followed by ROC 
curves to determine the accuracy of the classification model as well as its sensitivity and 
specificity were generated. Low-grade gliomas were considered WHO grades 1 and 2, 
and high-grade gliomas WHO grades 3 and 4. Meningiomas were classed as WHO grade 
1. Metastatic tumours were grouped due to the range of different primary site s within the 
tumours tested, and as intraoperatively ‘metastasis’ is sufficient for intraoperative 
surgical planning. Example spectra are seen in figure 6.2.  
	   	   	  121	  
 
Figure 6.2: Example Raman Spectra, as compared to the smear results. Key:	  N;	  Normal	  brain	  tissue,	  LG;	  
Low-­‐grade	  Glioma,	  HG;	  High-­‐grade	  Glioma,	  Men;	  Meningioma,	  Met:	  Metastasis,	  Ly;	  Lymphoma. 
 
Raman results compared to intraoperative smear preparation 
 
From Figure 6.3 it can be seen that the accuracy for detection of primary brain tumours 
was between 64% and 92%. The algorithm provided the lowest accuracy for meningioma 
(64%) with differentiation of glial tumours proving more robust (92.2 and 89.7%). The 
ROC parameters and curves (Figure 6.4, Table 6.2) demonstrate the sensitivities and 
specificities range from 64%-94% and 91%-100%, respectively, again with meningioma 
falling behind the other tumours for sensitivity. As the area under the curve is >0.8 for all 
tumour classifications it confirms the high accuracy of the classification model and 
presence of statistical significance (P <0.001). This is an important result if this model is 
to provide clinically useful information. With the exception of meningioma the positive 
and negative predictive values are consistently high (Table 6.3), with all negative 
predictive values over 95%. 
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Figure 6.3. Graphical confusion matrix for PCA-LDC model using smear-based results. 
Key: N; Normal brain tissue, LG; Low-grade Glioma, HG; High-grade Glioma, Men; 
Meningioma, Met: Metastasis, Ly; Lymphoma. 
Table 6.2. Figures of merit for PCA-LDC model using smear-based samples. Key: N; 
Normal brain tissue, LG; Low-grade Glioma, HG; High-grade Glioma, Men; Meningioma, 
Met: Metastasis, Ly; Lymphoma, PPV; positive predictive value, NPV; negative predictive 
value. 
Class Accuracy (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
N 98.6 94.4 99.5 97.7 98.8 
LG 96.1 92.2 97.0 88.7 98.0 
HG 90.3 89.7 90.6 83.5 94.4 
Men 94.8 63.9 97.1 62.1 97.3 
Met 95.4 79.2 98.8 93.3 95.8 
Lv 99.6 88.9 100 100 99.6 
 
	   	   	  123	  
 
Figure 6.4; Receiver operating characteristic curves for smear-based samples: (a) Normal 
brain tissue; (b) Low Grade Glioma; (c) High Grade Glioma; (d) Meningioma; (e) 
Metastasis; and, (f) Lymphoma. (AUC: area under the curve). 
 
Raman results compared to FFPE tissue results 
 
When comparing the Raman results to the final FFPE diagnosis, the classification model 
also works with a high degree of accuracy. With the exception of metastatic tumours, the 
accuracy dips slightly for all cases as compared to the smear results (Figure 6.5, Table 
6.3). This may be due to a variety of reasons, including normal brain tissue within the 
biopsy material or areas of necrosis. Given this is not possible to determine 
macroscopically by eye, this remains a limitation of the study. The reduction in 
classification accuracy is to be expected as the neuropathologist has many diagnostic 
tools to aid the final FFPE diagnosis such as tumour morphology, architecture and 
immunohistochemical testing. The ROC graphs though do continue to show the 
reliability and statistical significance of the classification model (Figure 6.6), 
highlighting the ability of Raman spectroscopy to differentiate the tumour types within 
this study. 
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Figure 6.5. Graphical confusion matrix for PCA-LDC model using formalin fixed paraffin-
embedded tissue results. Key: LG; Low-grade Glioma, HG; High-grade Glioma, Men; 
Meningioma, Met: Metastasis, Ly; Lymphoma. 
 
Table 6.3. Figures of merit for PCA-LDC model using paraffin-embedded tissue results. 
Key: LG; Low-grade Glioma, HG; High-grade Glioma, Men; Meningioma, Met: Metastasis, 
Ly; Lymphoma, PPV; positive predictive value, NPV; negative predictive value. 
 
Class Accuracy (%) Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
LG 93.8 88.7 95.4 85.8 96.4 
HG 88.0 82.8 92.8 91.6 85.1 
Men 90.8 91.7 90.8 42.4 99.3 
Met 96.3 78.7 100 100 95.7 
Lv 99.5 86.1 100 100 99.5 
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Figure 6.6. Receiver operating characteristic curves for formalin-fixed paraffin-embedded 
tissue results: (a) Low-grade Glioma; (b) High-grade Glioma; (c) Meningioma; (d) 
Metastasis; (e) Lymphoma. (AUC: area under the curve). 
 
Discussion 
 
Many Raman spectroscopic studies have been performed in recent years with the aim of 
introducing a clinically useful diagnostic tool that is easy to use and reagent-free. Much 
work has been performed towards standardisation of methodology and analysis, as this 
has previously led to criticism as many different techniques have been used (Butler et. 
al., 2016). Previous work within the field has shown good discrimination between 
normal and cancerous tissue. For example, within brain tumours, prostate and ovarian 
cancer we have previously found potential using Raman spectroscopy to differentiate 
normal from tumour within both tissue and biofluids (Owens et. al., 2014, Gajjar et. al., 
2012, Patel et. al., 2011). The aim of this study was to determine if a handheld Raman 
probe could provide comparable results to both an intraoperative smear preparation and 
the final FFPE histological diagnosis. Comparable results would allow for further 
exploration of a Raman based probe for intraoperative use, particularly within the field of 
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neuro-oncology. The use of fresh tissue, within a neuropathology laboratory, testing 
samples sent for smear preparations demonstrates a novel approach within this field, 
moving spectroscopic assessment closer to the patient. 
 
These results demonstrate the ability of a handheld Raman device, when combined with 
gold nanoparticles, to differentiate tumour types from fresh brain tissue. The results are 
comparable to both the intraoperative smear preparations and final FFPE diagnosis, with 
accuracy at detecting a variety of primary brain tumours and metastases ranging from 
63.9-94.4% as compared to the intraoperative smear preparation, and 78.7-91.7% when 
compared to the FFPE diagnosis. With the exception of meningioma the sensitivities and 
specificities are above 75% throughout, with the majority over 90%. The PPV and NPV 
results are also consistently high. These results are also comparable to a recent study 
demonstrating the possible use of Raman to detect tumours prior to biopsy (Desroches et. 
al., 2018). For a test to be clinically useful, especially intraoperatively, a high accuracy, 
PPV and NPV is needed. These results compare well to a study performed on 
intraoperative smears and the final results compared to the FFPE diagnosis, which 
yielded an accuracy of 95.25% with PPV of 95.3% and NPV of 95.1% (Sanjeev et. al., 
2016). This is an important step as it allows the results to be comparative to current 
techniques, possibly demonstrating an improvement. By adequately training the Raman 
probe these results demonstrate a possible improvement on the current method of 
intraoperative smear diagnosis, reducing the human element involved and decreasing 
time to reach a diagnosis. As the accuracy of the Raman probe is slightly reduced when 
results are compared to the FFPE diagnosis for the majority of tumours (see figures 6.2 
and 6.4), the role for conventional neuropathology remains, with this tool focussed 
towards intraoperative diagnosis. 
 
These positive findings indicate the possible benefits to having a handheld Raman device 
present within the neurosurgical theatre. As all tissue was preserved following spectral 
acquisition and fixed to aid final diagnosis, we have also shown that spectral acquisition 
and addition of nanoparticles have not harmed the tissue, nor prevented final histological 
diagnosis. This is an important step when bringing this technology into the clinical field. 
Patient factors were not considered within this study as they were felt unlikely to directly 
influence the histopathological assessment. As the technique is developed, it may prove 
useful to add patient characteristics into an algorithm to improve accuracy, particularly 
within the paediatric field as some tumours are inherent to certain age groups. 
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The strength of these results would suggest a handheld device within theatres, once 
properly trained, would be able to assist surgeons in removing tumour tissue without the 
need for an intraoperative smear preparation. This could reduce surgical time as no result 
is awaited and allow for improved surgical resection as small foci of tumour could be 
identified. Further work would be required to determine the minimum tumour volume 
needed for a positive result. This was not attempted within this study and would be an 
important step moving forward. Mapped margin biopsies would be required with 
histopathological analysis. As the classification model is able to determine tumour type 
this also would allow for further management steps to be completed, such as the addition 
of Gliadel wafers in the case of high-grade gliomas. The use of intracranial 
chemotherapy, such as Gliadel, is recommended by the National Institute for Clincial 
Excellence (NICE) under certain conditions, one of which is the diagnosis 
intraoperatively of a high-grade glioma by a neuropathologist (National Institute for 
Clinical Excellence, 2007). Raman spectroscopy could therefore be used to circumvent 
the need to involve the neuropathologist, streamlining processes within theatre. The 
identification of a metastatic tumour is also important, we have not used the results to 
determine primary tumour origin for metastatic tumours, as this has previously been 
shown to be challenging, particularly for cases such as adenocarcinomas from different 
primary sites (Krafft et. al., 2006). Intraoperatively, the determination of a metastasis 
versus a primary brain tumour is the level required and offered from an intraoperative 
smear preparation. Therefore allowing conventional histopathology and 
immunohistochemistry to determine the primary site of origin is the most logical step. 
 
Determination of surgical margins within breast cancer has been demonstrating using 
Raman spectroscopy (Haka et. al., 2006). If developed, our classification model may also 
allow for other surgical sites to determine presence of absence of tumour 
intraoperatively, again removing the need for intraoperative frozen sections to be 
performed and improve resection clearance. 
 
Overall, this study presents a novel approach to intraoperative brain tumour diagnosis 
and is one of the first studies to report results on intraoperative fresh brain tumour 
samples. The next step is to move this technology into theatre and continue to develop 
the classification model to allow for real time feedback to the surgeon and allow Raman 
technology to reach its full potential. 
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7. Discussion 
 
Brain tumours may account for a relatively small proportion of new cancer diagnoses per 
year (3%); however, their effect can be more devastating than most (CRUK M, accessed 
18/2/18). The presenting symptoms may be vague, leading to multiple visits to a doctor 
prior to diagnosis (MHP Health, 2013) and the risks of surgery are great. The need to 
resect the tumour versus protecting functioning brain tissue is great. Therefore, any new 
medical tool that could potentially aid either diagnostics or intraoperative assessment 
would be clinically useful. 
Through interaction with patients and clinicians the need for new diagnostic tools that 
diagnose cancer faster and more accurately is highlighted. Yet patients wish for their 
diagnosis to remain in secondary care, a crucial factor when considering any new 
diagnostic tool and where it can be targeted (see Figure 1.11). They also demonstrate a 
willingness to accept more invasive investigations than thought by the clinicians; an 
interesting point to consider when developing a diagnostic tool. From the work done with 
patients and clinicians, a series of proof of concept studies were developed to test a new 
innovative diagnostic method, in this case vibrational spectroscopy, to see if it could aid 
and improve the current NICE cancer care pathway (NICE, 2005). 
As the aim of the project was to address the use of vibrational spectroscopy in the 
diagnosis of cancer and how to develop it for clinical use the studies were designed to 
target various points in the current patient pathway using spectroscopy and determine its 
viability as well as comparing the results to the gold standard of histopathology. Brain 
tumours can be either primary, i.e., arise within the brain, or metastatic, i.e., have spread 
to the brain from a primary point elsewhere in the body, e.g., the lung. It was therefore 
important that the studies incorporated a combination of primary and metastatic tumours, 
as these would both be encountered within clinical practise, as metastases outnumber 
primary brain tumours 3:1 (Davis et. al., 2012). A combination of FTIR and Raman 
spectroscopy was used for the studies either alone, or in combination to compare the 
diagnostic accuracy. For each study the accuracy was determined via comparison to the 
final histopathological diagnosis. This was for two main reasons, firstly, it provided a 
constant end point with the possibility to review histopathology slides and understand the 
distribution of the tumour and secondly it provided a constant known result. Other 
factors such as tumour size, distribution and location as well as location of biopsy sites 
were unknown, with review of the radiology beyond the scope of this project, as the 
project was focussed on diagnostics and the ability of spectroscopy to mimic 
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histopathology. Common primary brain tumours were also chosen as they provided 
sufficient tissue and make up the bulk of primary brain tumours. 
The first two studies focussed on tissue based diagnosis towards an aim of either 
intraoperative diagnosis or aiding the pathologist during diagnosis as an alternative to 
immunohistochemistry. The first study was designed to target primary tumours, using a 
combination of both Raman and ATR-FTIR spectroscopy to see which is best able to 
classify common brain tumours using fresh frozen tissue. This would be able to provide 
insight into the ability of spectroscopy to diagnose brain tumours and help set up the later 
study using fresh tissue. It found both forms of spectroscopy were able to differentiate 
non-tumour brain tissue from gliomas and meningiomas. For normal versus tumour, 
Raman spectroscopy was able to correctly classify 94% of the cases, with a sensitivity of 
98.8% and specificity of 41.7%, compared to FTIR spectroscopy which classified with 
an accuracy of 97.2% with sensitivity and specificity of 100% and 66.7% respectively. 
When asked to determine tumour by type (i.e., glioma or meningioma) for Raman the 
overall classification accuracy fell to 63.1% and FTIR spectroscopy accuracy fell to 
79.2%. The results demonstrated that both forms of spectroscopy were able to tell tumour 
from non-tumour tissue but within this study, struggled to differentiate tumour types, 
with accuracies lower than would be required clinically. It highlights that whilst 
spectroscopy has potential, further work surrounding classification of tumour types 
would be needed. 
Following on, metastatic tumours were investigated again using a combination of Raman 
and ATR-FTIR spectroscopy, but this time on FFPE tissue. Metastases from common 
tumours were selected to mimic clinical medicine. Lung adenocarcinomas are one of the 
most common tumours to metastasise to the brain, (Huang et. al., 2013), these were 
compared with colorectal adenocarcinomas in order to provide two metastatic tumours 
with similar phenotype, with the acceptance that colorectal adenocarcinomas are less 
likely to metastasise to the brain (approximately 9%) (Davis et. al., 2012, Huang et. 
al.,2013, Renfrow and Lesser, 2013, Sanghvi et. al., 2017). Melanoma metastases were 
then used to provide a markedly different metastatic tumour, both in tumour lineage, 
morphological appearance and immunohistochemical profile. This was done in order to 
determine if spectroscopy was able to determine the primary origin of a metastatic 
tumour, not just its presence. The two similar tumours were used as it was felt 
spectroscopy would struggle with this, as conventional histopathology requires 
immunohistochemistry in order to differentiate the primary origin. If successful this 
study would have shown the benefit of spectroscopy when compared to conventional 
histopathology and provided additional support to diagnosis. However, whilst both 
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Raman and ATR-FTIR spectroscopy were able to determine the presence of tumour 
tissue, the differences seen from the adenocarcinomas to the melanoma was much greater 
than the differences between the two adenocarcinoma groups. Given the similarities 
between the adenocarcinomas this was to be expected, however the accuracy fell from 
85% and 96% for Raman and ATR-FTIR spectroscopy respectively when identifying an 
adenocarcinoma to 68.7% and 60% for colorectal adenocarcinomas, and 68.6% and 59% 
for lung adenocarcinomas. The identification melanoma was constant around 70% for 
both techniques. Both methods gave results much lower than that offered by conventional 
histopathology with immunohistochemistry and therefore were unlikely to be clinically 
useful or remove the need for histopathological diagnosis. 
The third study looked at moving diagnosis back to the initial phases of patient work-up 
or screening potential, using biofluids, namely plasma as a contrast to the tissue based 
work. There have been suggestions of vibrational spectroscopy based screening test to 
detect cancer (Hughes et. al., 2016) with promising results shown by various studies, 
predominantly using serum. Both Gajjar et. al. (2013) and Owens et. al. (2014) 
demonstrated the ability to detect endometrial and ovarian carcinoma with high success 
81.67% and 71.47% respectively (Gajjar et. al., 2013, Owens et. al., 2014). Hands et. al. 
(2014, 2016) also demonstrated good results with brain tumours, primarily primary 
tumours (Hands et. al., 2014, 2016). This study compared normal (i.e., no known 
tumour) with primary brain tumours (high- and low-grade gliomas and meningiomas) 
and metastatic tumours (lung and colorectal adenocarcinomas and melanomas) using 
ATR-FTIR spectroscopy. This study demonstrated that when asked a specific question 
ATR-FTIR spectroscopy had a high degree of accuracy; for example normal vs. high-
grade glioma vs. low-grade glioma; 89.3% to 84% to 98% respectively. However, when 
the question was expanded, as would be seen in a clinical setting for screening or initial 
diagnostics, to incorporate a more broad question, such as ‘does this patient have a 
tumour, what is it and where is it from?’ the accuracy of detection of the type of tumour, 
primary, secondary (with and without primary location), fell markedly in most areas 
(normal; 85.28%, low-grade glioma; 61.25%, high-grade glioma; 92%, meningioma; 
42.86%, melanoma metastasis; 21.25%, colorectal adenocarcinoma metastasis; 50% and 
lung adenocarcinoma metastasis; 24%. This raises questions about the use of such a tool 
as a screening method, or within a clinic as it would need to be asked a more direct 
question. The location of the tumours within the brain is not known, nor for the 
metastatic cases is the number or location of metastasis (except for the location of one 
within the brain). This could be seen as a weakness to the study, as perhaps the tumours 
that are being detected are those that involve the dura or are in a particular location 
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within the brain. Moving forward with future work it would be interesting to develop a 
method whereby the radiological results could be added to spectroscopic output to 
determine if this provided a more accurate result. However, if taken back to the studies 
initial purpose; to determine clinical usefulness either in clinic or as a screening tool, the 
location of a tumour would not be known and clinically spectroscopy would need to 
detect any tumour, not just those in favourable locations. Conventional radiology would 
still be required to plan surgery and hence spectroscopic detection would not circumvent 
this. In cases were the radiology is known with a suggestion as to the tumour type based 
on radiological appearances, perhaps spectroscopy may play a role as a more direct 
question could be asked. However, this would need to form part of a larger study in order 
to combine radiology, spectroscopy and the final histology. 
The final study was designed to compare a hand held Raman spectrometer to 
histopathological intraoperative smear diagnosis, being the first known study comparing 
the two results using fresh tissue. If successful, this study could demonstrate the ability 
of spectroscopy as a possible intraoperative aid for the surgeon. Recent studies have 
shown it can be used with high accuracy for targeting brain biopsy locations from 
tumour, though these results were developing using spectroscopy for tissue with high 
tumour burden (Desroches et. al., 2018). This study did not put any restrictions on the 
tissue, it was simply that sent for a smear preparation as would be analysed by the 
neuropathologist. Elsewhere there are very few spectrometers within the clinical world 
with one being trialled in London (Optics.org, accessed 22/2/18). Some studies have 
been performed close to the operative theatre; therefore this was an exciting and novel 
experiment to perform (Horsnell et.al., 2010, 2012 Haka et. al., 2009, 2006). A handheld 
Raman spectrometer was therefore placed within the Neuropathology department at 
Royal Preston Hospital. There were several reasons for basing this within the pathology 
laboratory; firstly, it allowed the fresh tissue being sent for intraoperative smear 
preparations to be tested. This meant working on tissue freshly removed from the body 
with no preservatives, nor having been previously frozen or fixed in any way. Secondly, 
as Raman has to be performed with minimal light disruption, it allowed darkness to be 
achieved using a purpose built box thereby not impacting in any way upon surgery (see 
Figure 6.1).  
As the spectroscopy was performed alongside the smear preparation there was also no 
delay in the intraoperative diagnosis thereby extending surgical time. By keeping the test 
within pathology, it allowed the Neuropathologists to see no damage was being done to 
the valuable tissue samples prior to fixation and enabled the development of a standard 
operating procedure (SOP) and safety protocol see Appendix 9.10) for spectroscopy 
	   	   	  133	  
within the lab as well as a bank of spectra from cases consented for research. Running 
the study over several months allowed for the collection of spectra from both primary 
and metastatic tumours. The use of nanoparticles was in order to amplify the Raman 
signal given the use of a small probe and small amount of fresh tissue. The results were 
impressive. The ability to detect the different tumour types when compared to both the 
smear and paraffin results with accuracies ranging from 63-94% and sensitivities and 
specificities from 63.9-100%. It showed good resolution for low- and high-grade glial 
lesions and metastasis. It appeared to struggle most with the meningiomas, though 
accuracy greatly improved as compared to the paraffin report (63 to 91%). Though this 
could also be relatively to the small number of cases (n=2) or presence of necrosis within 
one sample. With the exception of meningiomas the accuracy based upon the smear 
result (Figure 6.3) would allow the use of a hand held intraoperative device in order to 
determine if tissue was neoplastic or not intraoperatively, its cell lineage and high grade 
nature. It may also be able to guide the surgeon as to the type of tumour present based 
upon these results, allowing for further management steps to be taken as would follow an 
intraoperative smear result. As the metastatic tumours came from a variety of origins 
they have not been subdivided for the analysis. However, intraoperatively, there is 
unlikely to be a pressing need to differentiate the primary tumour origin on the table, this 
would be able to wait for a final histological diagnosis. Given the previous results and 
the difficulty to separate adenocarcinomas of different primary origins it would probably 
be an unreasonable expectation to include this within an intraoperative tool and best left 
within the realms of the neuropathologist. Confirming a tumour as glial, meningothelial 
or metastatic is a more viable option. With the ability to differentiate high- and low-grade 
glial tumours in order to aid further management (such as Gliadel, or future therapy) is 
however a step forward (NICE, 2007). It would reduce the surgical waiting time for an 
intraoperative smear result and decrease pressure on ever-busier laboratories and 
pathologists time by removing the need. It would also enable a surgeon to have a result at 
any time of the day/night or weekend not only when the laboratory is open. When tested, 
it may also allow for detection of intraoperative surgical resection margins allowing for 
improved resection rates, particularly within challenging areas of the brain, thus aiming 
to improve long-term survival. 
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7.1 Moving Forward 
 
These studies have highlighted both the strengths and weakness of vibrational 
spectroscopy as a clinically useful and viable tool. They have explored the patient and 
clinician views surrounding cancer and cancer diagnosis with interesting results that have 
enabled further thoughts surrounding what vibrational spectroscopy as a tool may be 
capable of providing to clinical medicine.  
Firstly as a point of care testing device, its limitations are greatly felt to out-way any 
potential benefits. The need for specific clinical queries builds in a significant challenge 
that does not circumvent the need for any of the current steps of the clinical pathway 
therefore providing little benefit for the outlay. Given this would be trained based upon 
final pathological diagnosis, it also is unlikely to improve the current issues surrounding 
interobserver error. Challenging cases are always brought back to the histopathology 
with a clinical discussion surrounding treatment. Whilst spectroscopy may add to this, 
that is likely to be a long term goal not a short impact upon clinical management. 
Ongoing clinical observation of patients with known tumours at risk of recurrence may 
benefit from spectroscopic monitoring. However, this would require much work with 
patients post operatively with recurrent testing and scanning to the point of recurrence to 
see if spectroscopy is able to detect those at risk of recurrent disease prior to it being 
visible on a conventional scan, e.g., MRI. However, if this is unlikely to lead to earlier 
surgical or treatment input, its use is again limited. Within the biofluid study the health of 
patients outside of their cancer diagnosis was not considered. This was not an age-
matched study. Therefore, it is possible other factors such as hypertension or medications 
patients may be taking that also have an impact upon the difference in the spectral results 
seen. This would all need to be considered prior to starting a larger clinical trial using 
spectroscopy. 
Finally, the hand held intraoperative study gave the most promising results. This is an 
exciting step towards clinical inclusion of spectroscopy and highlighted it may be able to 
aid the surgeon and ease workload on pathology laboratories.  It is not known where in 
the tumour these biopsies are taken from, nor the location of the tumour within the brain, 
therefore it is again not possible to correlate with radiological findings. However, the 
tissue sent to the pathologist for an intraoperative diagnosis is what has been tested 
therefore similar results to their diagnosis is exciting. It demonstrates the possibility of 
training a similar system for use intraoperatively to aid the surgeon to enable improved 
resection rates and to target neoplastic tissue more easily and with more confidence. This 
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in turn would hopefully improve survival rates, or at least disease free intervals (i.e., the 
time taken from treatment to recurrence of disease). Therefore moving forward, this 
study should be used to form the basis of a classification model to enable this technology 
to be trialled within the neurosurgical operating theatre. Where possible, if the 
neuropathologists are agreeable, areas tested by the surgeon and deemed cancer or not 
could be placed into separate histology pots to enable matching with the final histological 
diagnosis. The non-neoplastic samples would correspond to areas the surgeon was 
removing based on clinical suspicion, even with the spectral result. This would allow 
improved training of the system and a learning period for the surgical team. If successful, 
the possibilities for this technology include expansion within the field of frozen section 
work. It could enable its use in a multitude of theatre settings, replacing frozen sections 
and providing almost instant feedback and results. 
Overall, this thesis has shown vibrational spectroscopy could have a role to play in the 
field of clinical medicine in the future. The aims and objectives of this PhD have been 
met. The use of a handheld Raman spectroscopic device within the neuropathology 
department at Royal Preston Hospital has had some success. It has shown the ability to 
differentiate some tumour types and match the results given from the intraoperative 
smear provided to the surgeon. It has also developed a platform from which the use of 
spectroscopy within the operating field can be developed and strengthened. It is crucial 
that moving forward clinicians communicate and work closely with those in scientific 
research. Without the ability to develop new diagnostic tools and test them within more 
real world settings, it is unlikely that the technology itself will surpass the human input, 
in conjunction with long standing trusted diagnostic methods. 
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WHO leadership is 
essential for the 
elimination of NTDs
The second director of the Department 
of Control of Neglected Tropical 
Diseases (NTDs) of WHO retired 
at the end of September, 2017. He 
was appointed in 2014 to ensure 
administrative stability after 9 years 
of innovative growth of this WHO 
department, which was established in 
2005 after the retirement of the first 
director.1 Sustaining the momentum 
for elimination of NTDs requires a 
timely appointment of a new director 
to lead an effective Department of 
NTDs in WHO. 
The innovative vision of NTDs was 
developed by WHO between 2003 
and 2005.1 Young talents who are 
managing programmes related to 
NTDs in endemic areas are working for 
elimination of NTDs, and universities 
are researching and teaching about 
NTDs. New agreements between the 
pharmaceutical industry and WHO, 
global partners who are are working 
together against NTDs, and aid 
agencies of countries like the USA, 
the UK, Japan, and, more recently, 
China, have all committed resources 
to assure access to medicines to treat 
NTDs.2 More than 1 billion doses of 
safe, quality-assured, single-dose 
treatments reach at-risk people 
from the poorest urban and rural 
communities of endemic countries 
every year.3 
In April, 2017, 10 years after the 
first WHO partners meeting, health 
ministers, donors, philanthropists, 
and industry representatives met in 
Geneva, Switzerland to confirm their 
support to eliminate NTDs.4 Although 
this meeting was an opportunity to 
review progress, it was also perceived 
as a moment of excessive self-
gratification. Major challenges are 
still ahead including the eradication 
of guinea worm, supplying the 
capacity and resources to expand the 
delivery of preventive chemotherapy, 
and controlling the emergence and 
re-emergence of some NTDs, such 
as hookworm in the south of the 
USA5 or urogenital schistosomiasis 
in Corsica.6
The success of the NTDs programme 
will lead to complacency if the 
immensity of the task ahead and 
the need of WHO leadership are not 
stressed. A WHO department with an 
energetic leader is necessary to gather 
evidence and the scientific community 
behind the control of NTDs, to issue 
new guidance, to highlight the crucial 
role of a central figure to identify 
populations in need, and to logistic-
ally coordinate resources to deliver 
treatments.
The Department of NTDs needs to 
regain the leadership of a complex 
open partnership and to rebuild 
momentum for delivery of the largest 
ever donations of essential medi-
cines, as a component of universal 
health coverage. It is not well known 
that WHO is the only platform through 
which people affected by neglected 
conditions have access to free-of-
charge, quality-assured treatment 
that would not otherwise be available 
(or even manufactured).
The appointment of a new leader to 
direct a specific department for NTDs 
under the current Director General, 
Dr Tedros Adhanom Ghebreyesus, 
who comes from a country that is 
committed to fight NTDs, will be the 
best guarantee to regain momentum 
to eliminate NTDs by 2030, in line 
with the targets set up by the UN 
Sustainable Development Goals. 
We are grateful to Dr Marco Albonico and 
Giulia Savioli for their comments and suggestions.
We declare no competing interests. 
*Lorenzo Savioli, Denis Daumerie
docsavioli@gmail.com
Former Director (LS) and Former Programme 
Manager (DD), Department of Control of Neglected 
Tropical Diseases, World Health Organization, 
Geneva, Switzerland
1 WHO. Accelerating work to overcome the 
global impact of neglected tropical diseases. 
A roadmap for implementation. 2012. http://
www.who.int/neglected_diseases/NTD_
RoadMap_2012_Fullversion.pdf 
(accessed Nov 29, 2017). 
2 WHO. Strategic and technical meeting on 
intensified control of neglected tropical 
diseases: a renewed eﬀort to combat 
entrenched communicable diseases of the 
poor. Report of an international workshop: 
Berlin, 18–20 April 2005. 2006. http://www.
who.int/neglected_diseases/berlinrep.pdf 
(accessed Nov 29, 2017). 
3 WHO Department of Control of Neglected 
Tropical Diseases. Sustaining the drive to 
overcome the global impact of neglected 
tropical diseases. Second WHO report on 
neglected tropical diseases. January, 2013.  
http://www.who.int/neglected_diseases/978 
9241564540/en/ (accessed Nov 29, 2017). 
4 WHO. Global resolve to end neglected 
tropical diseases amid unprecedented 
progress. April 19, 2017. http://www.who.int/
neglected_diseases/news/Global_resolve_to_
end_NTDs_amid_unprecedented_progress/
en/ (accessed Nov 29, 2017). 
5 Albonico M, Savioli L. Hookworm: a 
neglected resurgent infection. BMJ 2017; 
359: j4813.
6 Boissier J, Grench-Angelini S, Webster BL, 
et al. Outbreak of urogenital schistosomiasis 
in Corsica (France): an epidemiological case 
study. Lancet Infect Dis 2016; 16: 971–79.
Are new technologies 
translatable to point-of-
care testing?
The point-of-care testing (PoCT) 
market is rapidly expanding and 
its predicted worth by 2021 is 
US$36·96 billion.1 This market has 
many facets, one of which is tumour 
and cancer markers. To develop a new 
test for clinical use, a biomarker needs 
to be identified and a quick and simple 
detection method developed. This 
biomarker then goes through many 
steps before clinical use including the 
all-important step—can it detect cancer 
earlier than existing methods?
Variants of emerging technologies, 
such as vibrational spectroscopy 
or nuclear magnetic resonance 
spectroscopy, show promise for their 
use in the clinical forum. However, 
the point at which these interventions 
might fit into the diagnostic path-
way remains unclear (appendix). For 
example, many proof-of-concept 
studies have investigated various 
uses of vibrational spectroscopy, 
including biofluids.2 The uptake of 
this technology has been slow in 
the clinical environment3 and it has 
See Online for appendix
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consequences, with identity checks 
potentially giving rise to racial 
profiling, and it must be implemented 
with a comprehensive assessment to 
ensure that denial of health care at one 
point does not result in worse future 
health outcomes. 
Recovery of costs is the main 
justification for these new regulations. 
However, there is little evidence 
regarding the anticipated financial 
saving; it is estimated to be just 
0·00016% of the NHS’s annual 
budget.4 The government’s cost 
recovery assessment fails to value 
the time necessary for staﬀ to review 
identity documents and assess 
eligibility to free care. Confusion about 
eligibility for free care could delay 
diagnosis and treatment, which could 
incur substantial long-term costs to 
the NHS.5 
It’s unclear who will carry out 
identity checks, and how clinicians’ 
roles will be compromised by acting 
as border guards, potentially denying 
care. Doctors of the World have 
launched a campaign for health-care 
professionals to push back against 
these reforms. The new rules for 
upfront immigration checks and 
charges will make the current climate 
of fear among our patients even 
worse. Hospitals should provide a safe 
environment for vulnerable women 
and children, not subject them to 
further intimidation.
The NHS was founded to provide 
comprehensive care to all, regardless 
of their ability to pay. We are seeing 
this sentiment gradually diminish as 
new legislative caveats are introduced, 
risking profit, rather than patients, 
being at the heart of the NHS.  
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not yet improved on existing clinical 
methods, with cases misclassified and 
malignancy missed.4
No clear use has been found that is 
superior to the existing clinical practice 
of intraoperative frozen sections and 
formal histopathological examination. 
Scientists developing these tech-
nologies clearly need direction. With 
the government’s push to reduce the 
time to diagnosis of cancer patients, 
will PoCT be a useful adjunct or are 
the sensitivities and specificities 
suboptimal? The clinical pathway 
allows for a specialist-led, personalised 
plan for patients (appendix) that 
focuses on the individual—PoCT 
puts diagnosis back in the general 
practitioner surgery and places a lot of 
pressure on the physician to deal with 
hopes and expectations handled by 
a practised secondary care team. Not 
only will the physicians’ information 
be limited to a simple indicator of 
PoCT, radiology and an appropriate 
oncology clinician giving treatment 
information will not be available.
Therefore, it is diﬃcult to see how 
technology designed to circumvent 
the diagnostic process and provide 
instant answers fits into the clinical 
pathway. Although point-of-care 
testing is crucial in some areas of 
cancer diagnostics, careful thought 
is required to ensure that valuable 
research funding is correctly dis-
tributed for the development of 
clinically useful tools in the areas that 
need and require them. Appropriate 
allocation will only be possible with 
open communication between 
scientists and clinicians; neither 
professional can make new technology 
work alone.
We declare no competing interests. 
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Changes to NHS charges: 
what does this mean for 
our most vulnerable 
patients? 
August, 2017, saw the introduction 
of new regulations on health-care 
charges to migrants and overseas 
visitors in England.1 Patients who 
are unable to prove entitlement to 
free care will receive an estimated 
treatment bill, which must be fully 
paid before receipt of care, and 
might increase exponentially. Urgent 
treatment, as defined by the treating 
clinician, should be provided and billed 
for afterwards. These regulations are 
the outcome of only 418 responses 
obtained by the Department of Health 
from their consultation exploring the 
extension of charging overseas visitors 
and migrants who use the National 
Health Service (NHS).2 
These measures will increase barriers 
to accessing health care, which leaves 
groups such as refugees, asylum 
seekers, and homeless people at risk of 
not getting the health care they need. 
Evidence shows that this increasingly 
hostile environment is preventing 
such patients from accessing care, the 
majority of whom are entitled to it,3 
and that restricting access to health 
care on the basis of immigration status 
could further compromise the health 
of vulnerable individuals.4 
This new system to check patient 
eligibility could have unintended 
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Phenotyping Metastatic Brain Tumors Applying
Spectrochemical Analyses: Segregation of
Different Cancer Types
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aSchool of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK;
bDepartment of Oncology, University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, UK;
cDepartment of Neuropathology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust,
Preston, UK
ABSTRACT
Metastatic brain tumors represent a significant proportion of tumors
identified intraoperatively. A rapid diagnostic method, circumventing
the need for histopathology studies, could prove clinically useful. As
many spectroscopic studies have shown ability to differentitate
between different tumor types, this technique was evaluated for use
within metastatic brain tumors. Spectrochemical approaches [Raman
and attenuated total reflection Fourier-transform infrared spectros-
copy (ATR-FTIR) spectroscopy] were applied to determine how readily
they may identify the primary site for the metastatic tumor.
Metastases were from primary adenocarcinomas of lung (n¼ 7) and
colorectum (n¼ 7), and for comparison, metastatic melanoma (n¼ 7).
The objective was to determine if Raman or ATR-FTIR spectroscopy
could delineate the origin of the primary tumor. The results demon-
strate that there are marked similarities between the two adenocar-
cinoma groups and whilst Raman and ATR-FTIR can distinguish the
three groups with limited success, classification accuracy is greatly
improved when combining the adenocarcinoma groups. The use of
such techniques in the clinical setting is more likely to be found
intraoperatively, determining the presence of a tumor and suggest-
ing the tumor class; however, traditional histopathology would still
be needed to identify the primary origin of the tumor.
ARTICLE HISTORY
Received 16 April 2018
Accepted 18 May 2018
KEYWORDS
Attenuated total reflection
Fourier-transform infrared
(ATR-FTIR) spectroscopy;
classification; linear
discrimination analysis
(LDA); metastatic brain
tumor; neuro-oncology;
Raman spectroscopy
Introduction
Metastatic brain tumors are usually the end-point in a persons’ battle with cancer, yet
for some may represent the initial diagnosis. The background prevalence of metastatic
brain tumors is difficult to quantify; however, those clinically detectable outnumber
intrinsic tumors by roughly 3 to 1, with the majority of metastases arising from primary
lung tumors (Davis et al. 2012, Huang and Ouyang 2013, Renfrow and Lesser 2013).
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Spectral classiﬁcation for diagnosis involving numerous pathologies in a
complex clinical setting: A neuro-oncology example
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Much effort is currently being placed into developing new blood tests for cancer diagnosis in the hope of moving
cancer diagnosis earlier and by less invasivemeans than current techniques, e.g., biopsy. Currentmethods are ex-
pected to diagnose and begin treatment of cancer within 62 days of patient presentation, though due to high vol-
ume and pressures within the NHS in the UK any technique that can reduce time to diagnosis would allow
reduction in the time to treat for patients. The use of vibrational spectroscopy, notably infrared (IR) spectroscopy,
has beenunder investigation formany yearswith varying success. This technique holds promise as iswould com-
bine a generally well accepted test (a blood test) with analysis that is reagent free and cheap to run. It has been
demonstrated that, when asked simple clinical questions (i.e., cancer vs. no cancer), results from spectroscopic
studies are promising. However, in order to become a clinically useful tool, it is important that the test differen-
tiates a variety of cancer types from healthy patients. This study has analysed plasma samples with attenuated
total reﬂection Fourier-transform IR spectroscopy (ATR-FTIR), to establish if the technique is able to distinguish
normal from primary ormetastatic brain tumours. We have shown that when asked speciﬁc questions, i.e., high-
grade glioma vs. low-grade glioma, the results show a signiﬁcantly high accuracy (100%). Crucially, when com-
bined with meningiomas and metastatic lesions, the accuracy remains high (88–100%) with only minimal over-
lap between the two metastatic adenocarcinoma groups. Therefore in a clinical setting, this novel technique
demonstrates potential beneﬁt when used in conjuction with existing diagnostic methods.
© 2018 Elsevier B.V. All rights reserved.
Keywords:
ATR-FTIR spectroscopy
Bioﬂuids
Brain tumours
Classiﬁcation
Sensitivity
Speciﬁcity
1. Introduction
Blood testing for cancer diagnostics is a popular ideal. It uses an ac-
ceptable patient test, i.e., a blood test, which is minimally-invasive and
machine analysed, can be run on a mass scale, and can target speciﬁc
markers circulating in the blood. Whilst some cancers can be identiﬁed
by the use of biomarkers, there are currently no such markers for pri-
mary or metastatic brain tumours, nor are any biomarkers yet involved
in a mass-screening programme [1]. Brain tumours, both primary and
metastatic, oftenpresentwith a range of non-speciﬁc symptoms. The di-
agnostic process involves a combination of history taking, examination
and radiology to determine the presence of a tumour and its possible or-
igin [2]. There are speciﬁc radiological appearances that can help differ-
entiate between primary andmetastatic brain tumours; however, these
rules do not always hold true [3]. A brain tumour may also be the ﬁrst
presentation of a metastatic cancer from elsewhere within the body;
this accounts for up to a quarter of brain tumours [4]. Currently, a com-
bination of radiological imaging and histology is used to detect the pri-
mary origin of a brain tumour.Whenmetastatic, pathologists can apply
immunohistochemical stains to formalin-ﬁxed parafﬁn-embedded
(FFPE) tissue, within which a combination of positive and negative
stains can help determine a primary site of origin.
Over recent years the potential of vibrational spectroscopy has been
touted as an ‘inexpensive, high throughput and reagent-free’ cancer di-
agnostic tool. In vivo studies have showngreat promiseusingboth tissue
and blood component analysis with detection of cancer vs. non-cancer
in many pilot studies showing promising results [5,6]. When consider-
ing bioﬂuids, predominantly serum has been analysed for brain cancer,
using attenuated total reﬂection Fourier-transform infrared (ATR-FTIR)
spectroscopy, with varying sample methods used [7]. This is due to the
erythrocyte component in whole blood providing a strong interfering
spectroscopic signal, likelymasking the underlying changes seen in can-
cer vs. non-cancer patients [8]. The main limitations of these studies
focus around different methods of sample preparation and analysis.
No universal method of spectral analysis has yet been agreed. Butler
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9.5 Clinician and Patient study approved documents. 
	  
CONSENT FORM – CLINICIAN FOCUS GROUP 
 
Title of Project: Diagnostic Innovation in Cancer 
 
Name of Researcher:  
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated....................  
(version............) for the above study. I have had the opportunity to consider the 
information,  
ask questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time  
without giving any reason, without my legal rights being affected. 
  
 
3. I understand that discussions held during the focus group will be recorded to be 
transcribed  
but this will be done anonymously. I give permission for this to be done.  
 
 
4. I agree to take part in the above study.  
 
 
_____________  ________   _______________ 
 
Name of Participant       Date        Signature  
 
 
_____________  ________   _______________ 
 
Name of Person       Date                   Signature  
taking consent  
 
 
When completed: 1 for participant; 1 for researcher site file.  
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Diagnostic	  Innovation	  in	  Cancer	  
	  
Clinician	  Information	  Leaflet	  –	  Focus	  Group	  
	  
We	  are	  conducting	  research	  into	  Clinician	  preferences	  surrounding	  cancer	  diagnosis	  and	  
we	   would	   like	   to	   invite	   you	   to	   participate,	   however	   you	   are	   under	   no	   obligation	   to	  
become	   involved.	   Below	   is	   some	   information	   relating	   to	   the	   study	   that	  will	   help	   you	  
decide	  whether	  or	  not	  you	  would	  like	  to	  be	  involved.	  	  A	  member	  of	  the	  research	  team	  
can	  be	  contacted	  to	  answer	  any	  of	  your	  questions	  (see	  below).	  
	  
What	  is	  the	  study	  about?	  
At	  the	  University	  of	  Central	  Lancashire	  we	  are	  performing	  research	  into	  cancer	  and	  how	  
to	   diagnose	   it	   and	  we	  would	   like	   to	   discuss	   the	   current	   and	   new	  diagnostic	  methods	  
with	  you	  to	  better	  understand	  a	  Clinician’s	  opinion.	  This	   is	  to	  help	  us	  direct	  our	  future	  
studies.	  	  
	  
What	  is	  the	  aim	  of	  the	  study?	  
The	  aim	  of	   the	  study	   is	   to	   look	  at	  patients	  and	  doctors	  opinions	  of	   the	  current	  cancer	  
diagnosis	  pathway	  and	  possible	  new	  diagnosis	  methods.	  	  
	  
What	  will	  happen	  if	  I	  agree	  to	  take	  part	  in	  this	  research?	  
You	  will	   attend	   a	   focus	   group	   led	   by	   2	  members	   of	   the	   research	   team	  with	   up	   to	   10	  
participants	   to	   discuss	   your	   opinions	   surrounding	   cancer	   diagnosis,	   and	   for	   example	  
where	   it	   should	   take	   place	   and	  who	   should	   be	   delivering	   the	   news.	  We	  will	   start	   by	  
asking	   you	   to	   sign	   a	   consent	   form	   agreeing	   to	   participate.	   This	   is	   to	   allow	   us	   to	  
transcribe	  the	  focus	  group	  anonymously.	  If	  you	  have	  any	  questions	  about	  taking	  part	  we	  
will	  be	  able	  to	  answer	  these	  either	  prior	  to	  the	  focus	  group	  or	  on	  the	  day.	  	  
The	  focus	  group	  will	  start	  with	  a	  short	  presentation	  about	  cancer	  diagnosis	  and	  then	  as	  
a	  group	  this	  will	  be	  discussed.	  We	  will	  record	  the	  conversation	  but	  this	  will	  be	  written	  
up	  anonymously	  and	  then	  the	  tapes	  will	  be	  deleted	  to	  protect	  privacy.	  	  
The	   focus	   group	   will	   last	   for	   up	   to	   2	   hours,	   refreshments	   including	   lunch	   will	   be	  
provided.	  There	  will	  be	  no	  further	  time	  requirements	  beyond	  this.	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What	  happens	  if	  I	  change	  my	  mind?	  
If	  you	  decide	  not	  to	  attend	  the	  focus	  group	  you	  do	  not	  have	  to	  provide	  a	  reason	  and	  we	  
will	  not	  contact	  you	  to	  attend	  a	  different	  day	  unless	  you	  ask	  to	  do	  so.	  On	  the	  day	  if	  you	  
want	  to	  leave	  during	  the	  focus	  group	  you	  are	  free	  to	  do	  so	  without	  explanation.	  If	  you	  
no	  longer	  wish	  for	  us	  to	  use	  your	  comments	  we	  will	  not.	  Once	  the	  focus	  group	  results	  
have	  been	  written	  up	  as	  they	  are	  anonymous	  we	  will	  no	  longer	  be	  able	  to	  remove	  your	  
comments	  as	  we	  will	  not	  know	  which	  they	  are.	  	  
	  
Where	  will	  the	  study	  take	  place?	  
The	   focus	   groups	  will	   be	   held	   at	   Royal	   Preston	   Hospital.	   The	   aim	   is	   to	   run	   the	   focus	  
groups	  at	  a	  convenient	  time	  so	  as	  not	  to	  impact	  on	  clinical	  commitments.	  	  
	  
What	  are	  the	  risks	  associated	  with	  taking	  part	  in	  the	  research?	  
There	  are	  no	  risks	  associated	  with	  taking	  part	  in	  this	  study.	  	  
	  
What	  are	  the	  benefits	  of	  taking	  part	  in	  the	  research?	  
There	  are	  no	  direct	  benefits	  to	  yourself	  from	  taking	  part	  in	  this	  study.	  We	  are	  asking	  you	  
to	  help	  us	  in	  order	  for	  us	  to	  use	  your	  thoughts	  to	  help	  shape	  our	  future	  research.	  	  
	  
How	   will	   we	   ensure	   any	   personal	   information	   used	   during	   the	   research	   is	   kept	  
confidential?	  
If	  you	  come	  to	  a	  focus	  group	  we	  will	  ask	  you	  to	  sign	  a	  consent	  form	  to	  allow	  us	  to	  keep	  a	  
record	   of	   the	   comments.	   We	   will	   however	   not	   identify	   you	   personally	   within	   these	  
notes.	  Your	  consent	  forms	  will	  be	  kept	  securely	  at	  the	  University	  of	  Central	  Lancashire.	  
No	  other	  personally	   identifiable	   information	  will	   be	   collected.	   Your	   taking	  part	   in	   this	  
research	  will	  be	  kept	  confidential.	  	  
	  
Are	  there	  any	  reasons	  why	  I	  might	  not	  be	  eligible	  to	  take	  part	  in	  the	  research?	  
For	  the	  focus	  groups	  we	  require	  Clinicians	  involved	  in	  any	  part	  of	  the	  cancer	  diagnostics	  
pathway.	  	  	  
	  
	  
Complaints	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We	   hope	   you	   take	   part	   and	   find	   our	   study	   interesting.	   However	  we	   realise	   problems	  
may	  arise.	   If	   you	  have	  any	   concerns,	   please	   contact	   the	   researchers	   listed	  below.	  We	  
will	  do	  our	  best	  to	  answer	  any	  problems.	  If	  you	  are	  not	  happy	  with	  the	  outcome	  please	  
contact	  Prof	  R	  Lea	  whose	  details	  are	  available	  from	  Dr	  M	  Baker.	  	  
The	   Rosemere	   Cancer	   Foundation,	   a	   local	   cancer	   charity	   for	   Lancashire	   and	   South	  
Cumbria,	  has	  funded	  this	  study.	  	  	  
	  
	  
This	  study	  will	  form	  part	  of	  Dr	  Danielle	  Bury’s	  PhD	  project.	  	  
	  
As	  with	  all	  studies	  in	  the	  NHS	  it	  has	  been	  looked	  at	  by	  an	  independent	  group	  of	  people	  
who	   form	   the	  Research	   Ethics	   Committee.	   This	   is	   done	   to	  protect	   your	   interests.	   The	  
South	  West	  Wales	  Research	  Ethics	  Committee	  has	  reviewed	  this	  study	  
	  
	  
You	   may	   decide	   to	   withdraw	   from	   the	   study	   at	   any	   time	   without	   need	   for	   an	  
explanation.	  
	  
	  
Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  leaflet.	  	  
	  
	  
For	  further	  information	  or	  to	  confirm	  your	  attendance	  please	  contact	  either	  Dr	  Danielle	  
Bury	  on	  debury@uclan.ac.uk	  or	  Dr	  Matthew	  Baker	  on	  mjbaker@ulcan.ac.uk	  or	   01772	  
893209.	  
	  
Many	  Thanks,	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Dr	  Danielle	  Bury	  and	  Dr	  Matthew	  Baker	  
University	  of	  Central	  Lancashire	  
CONSENT FORM – PATIENT FOCUS GROUP 
 
Title of Project: Diagnostic Innovation in Cancer 
 
Name of Researcher:  
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated....................  
(version............) for the above study. I have had the opportunity to consider the 
information,  
ask questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time  
without giving any reason, without my medical care or legal rights being affected. 
  
 
3. I understand that discussions held during the focus group will be recorded to be 
transcribed  
but this will be done anonymously. I give permission for this to be done.  
 
 
4. I agree to take part in the above study.  
 
 
_____________  ________   _______________ 
 
Name of Participant      Date        Signature  
 
 
_____________  ________   _______________ 
 
Name of Person       Date                   Signature  
taking consent  
 
 
When completed: 1 for participant; 1 for researcher site file. 
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Diagnostic	  Innovation	  in	  Cancer	  	  
	  
Participant	  Information	  Leaflet	  –	  Focus	  Group	  
	  
We	  are	  conducting	  research	  into	  patient	  preferences	  surrounding	  cancer	  diagnosis	  and	  
we	   would	   like	   to	   invite	   you	   to	   participate,	   however	   you	   are	   under	   no	   obligation	   to	  
become	   involved.	   	   Below	   is	   some	   information	   relating	   to	   the	   study	   that	  will	   help	   you	  
decide	  whether	  or	  not	  you	  would	  like	  to	  be	  involved.	  	  A	  member	  of	  the	  research	  team	  
can	   be	   contacted	   to	   answer	   any	   of	   your	   questions	   or	   explain	   any	   details	   further	   (see	  
below).	  
	  
What	  is	  the	  study	  about?	  
At	  the	  University	  of	  Central	  Lancashire	  we	  are	  performing	  research	  into	  cancer	  and	  how	  
to	  diagnose	  it	  and	  we	  would	  like	  to	  discuss	  current	  and	  new	  ways	  of	  diagnosing	  cancer	  
with	  you	   to	  better	  understand	  a	  patients’	  opinion.	  This	   is	   to	  help	  us	  direct	  our	   future	  
studies.	  	  
	  
What	  is	  the	  aim	  of	  the	  study?	  
The	  aim	  of	   the	  study	   is	   to	   look	  at	  patients	  and	  doctors	  opinions	  of	   the	  current	  cancer	  
diagnosis	  pathway	  and	  possible	  new	  diagnosis	  methods.	  	  
	  
What	  will	  happen	  if	  I	  agree	  to	  take	  part	  in	  this	  research?	  
You	  will	   attend	   a	   focus	   group	   led	   by	   2	  members	   of	   the	   research	   team	  with	   up	   to	   10	  
participants,	  all	  with	  personal	  experience	  of	  cancer,	  to	  discuss	  your	  opinions	  of	  cancer	  
diagnosis.	  Examples	  of	   the	  questions	  are;	  where	  diagnosis	   should	   take	  place	  and	  who	  
should	  be	  delivering	  the	  news,	  etc.	  We	  will	  start	  by	  asking	  you	  to	  sign	  a	  consent	  form	  
agreeing	   to	   participate.	   This	   is	   to	   allow	   us	   to	   collect	   the	   results	   of	   the	   focus	   group	  
anonymously.	   If	   you	   have	   any	   questions	   about	   taking	   part	  we	  will	   be	   able	   to	   answer	  
these	  either	  prior	  to	  the	  focus	  group	  or	  on	  the	  day.	  We	  will	  not	  tell	  any	  of	  the	  medical	  
team	  treating	  you	  or	  your	  GP	  that	  you	  have	  taken	  part.	  	  
The	  focus	  group	  will	  start	  with	  a	  short	  presentation	  about	  cancer	  diagnosis	  and	  then	  as	  
a	  group	  this	  will	  be	  discussed.	  We	  will	  record	  the	  conversation,	  but	  this	  will	  be	  written	  
up	  anonymously	  and	  then	  the	  tapes	  will	  be	  deleted	  to	  protect	  privacy.	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The	  focus	  group	  will	  last	  for	  up	  to	  2	  hours,	  refreshments	  will	  be	  provided.	  There	  will	  be	  
no	   further	   time	   requirements	   beyond	   this.	   All	   travel	   expenses	   will	   be	   refunded	   and	  
participants	  will	  receive	  £10	  for	  the	  time	  and	  inconvenience	  experienced.	  	  
	  
What	  happens	  if	  I	  change	  my	  mind?	  
If	  you	  decide	  not	  to	  attend	  the	  focus	  group	  you	  do	  not	  have	  to	  tell	  us	  why	  and	  we	  will	  
not	  contact	  you	  to	  come	  a	  different	  day	  unless	  you	  ask	  to	  do	  so.	  On	  the	  day	  if	  you	  want	  
to	   leave	   during	   the	   focus	   group	   you	   are	   free	   to	   do	   so	  without	   explanation.	   If	   you	   no	  
longer	  wish	  for	  us	  to	  use	  your	  comments	  we	  will	  not.	  Once	  the	  focus	  group	  results	  have	  
been	   written	   up	   as	   they	   are	   anonymous	   we	   will	   no	   longer	   be	   able	   to	   remove	   your	  
comments	  as	  we	  will	  not	  know	  which	  they	  are.	  	  
	  
	  
Where	  will	  the	  study	  take	  place?	  
The	   focus	   groups	  will	   be	   held	   at	   the	  University	   of	   Central	   Lancashire.	   Parking	  will	   be	  
available	  for	  those	  who	  would	  like	  it.	  Three	  focus	  groups	  will	  be	  run	  at	  different	  times	  of	  
the	  day	  so	  people	  at	  work	  will	  be	  able	  to	  attend	  a	  session	  run	  later	  in	  the	  day.	  	  
	  
What	  are	  the	  risks	  associated	  with	  taking	  part	  in	  the	  research?	  
There	  are	  no	  risks	  associated	  with	  taking	  part	  in	  this	  study.	  	  
	  
What	  are	  the	  benefits	  of	  taking	  part	  in	  the	  research?	  
There	  are	  no	  direct	  benefits	  to	  yourself	  from	  taking	  part	  in	  this	  study.	  We	  are	  asking	  you	  
to	  help	  us	  in	  order	  for	  us	  to	  use	  your	  thoughts	  to	  help	  shape	  our	  future	  research.	  	  
	  
How	   will	   we	   ensure	   any	   personal	   information	   used	   during	   the	   research	   is	   kept	  
confidential?	  
If	  you	  come	  to	  a	  focus	  group	  we	  will	  ask	  you	  to	  sign	  a	  consent	  form	  to	  allow	  us	  to	  keep	  a	  
record	  of	   the	  comments.	  We	  will	  not	   identify	  you	  personally	  within	   these	  notes.	  Your	  
consent	   forms	  will	   be	   kept	   securely	   at	   the	  University	   of	   Central	   Lancashire.	  No	   other	  
personally	   identifiable	   information	  will	   be	   collected.	   Your	  part	   in	   this	   research	  will	   be	  
kept	  confidential.	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Are	  there	  any	  reasons	  why	  I	  might	  not	  be	  eligible	  to	  take	  part	  in	  the	  research?	  
For	  the	  focus	  groups	  we	  need	  patients	  over	  the	  age	  of	  18	  years	  who	  are	  able	  to	  consent	  
for	   themselves	   and	   that	   have	   had	   experience	   of	   cancer	   or	   the	   cancer	   diagnostic	  
pathway.	  	  
	  
	  
	  
Complaints	  
We	  hope	   you	   take	   part	   and	   find	   our	   study	   interesting.	   However	  we	   realise	   problems	  
may	  arise.	   If	   you	  have	  any	   concerns,	   please	   contact	   the	   researchers	   listed	  below.	  We	  
will	  do	  our	  best	  to	  answer	  any	  problems.	  If	  you	  are	  not	  happy	  with	  the	  outcome	  please	  
contact	  Prof	  R	  Lea	  whose	  details	  are	  available	  from	  Dr	  M	  Baker.	  	  
	  
The	   Rosemere	   Cancer	   Foundation,	   a	   local	   cancer	   charity	   for	   Lancashire	   and	   South	  
Cumbria,	  has	  funded	  this	  study.	  
	  
This	  study	  will	  form	  part	  of	  Dr	  Danielle	  Bury’s	  PhD	  project.	  	  
	  
As	  with	  all	  studies	  in	  the	  NHS	  it	  has	  been	  looked	  at	  by	  an	  independent	  group	  of	  people	  
who	   form	   the	  Research	   Ethics	   Committee.	   This	   is	   done	   to	  protect	   your	   interests.	   The	  
South	  West	  Wales	  Research	  Ethics	  Committee	  has	  reviewed	  this	  study.	  
	  
If	  you	  decide	  you	  do	  not	  wish	  to	  take	  part	  in	  the	  research	  or	  you	  decide	  to	  withdraw	  
from	  the	  study	  	  
	  
Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  leaflet.	  	  
	  
For	   further	   information	   or	   to	   attend	   a	   focus	   group	   please	   contact	   either	   Dr	   Danielle	  
Bury	  on	  debury@uclan.ac.uk	  or	  Dr	  Matthew	  Baker	  on	  mjbaker@uclan.ac.uk	   	  or	  01772	  
893209.	  
	  
Many	  Thanks,	  	  
	   	   	  171	  
	  
	  
	  
Dr	  Danielle	  Bury	  and	  Dr	  Matthew	  Baker	  
University	  of	  Central	  Lancashire	  
Diagnostic	  Innovation	  in	  Cancer	  
	  
Participant	  Information	  Leaflet	  -­‐	  Questionnaire	  
	  
We	  are	  conducting	  research	  into	  patient	  preferences	  surrounding	  cancer	  diagnosis.	  You	  
have	  been	  identified	  as	  a	  potential	  participant	  in	  this	  research;	  however	  you	  are	  under	  
no	  obligation	  to	  become	  involved.	   	  Below	  is	  some	  information	  relating	  to	  the	  research	  
that	  will	  help	  you	  decide	  whether	  or	  not	  you	  would	   like	  to	  be	   involved.	   	  A	  member	  of	  
the	  research	  team	  can	  be	  contacted	  to	  answer	  any	  of	  your	  questions	  (see	  below).	  
	  
What	  is	  the	  study	  about?	  
At	   the	   University	   of	   Central	   Lancashire	   we	   are	   performing	   	   research	   into	   cancer	   and	  
how	   to	   diagnose	   it	   and	   we	   would	   like	   to	   discuss	   the	   current	   and	   new	   wasys	   of	  
diagnosing	  cancer	  with	  you	  to	  better	  understand	  a	  patients’	  opinion.	  This	   is	  to	  help	  us	  
direct	  our	  future	  studies.	  	  
	  
What	  is	  the	  aim	  of	  the	  study?	  
The	  aim	  of	   the	  study	   is	   to	   look	  at	  patients	  and	  doctors	  opinions	  of	   the	  current	  cancer	  
diagnosis	  pathway	  and	  possible	  new	  diagnosis	  methods.	  	  
	  
What	  will	  happen	  if	  I	  agree	  to	  take	  part	  in	  this	  research?	  
Below	  is	  the	  web	  address	  to	  access	  an	  anonymous	  questionnaire	  online.	  We	  would	  like	  
you	   to	   complete	   this	   questionnaire,	   it	   should	   take	   approximately	   30	   minutes.	   If	   you	  
would	   like	   to	   but	   are	   unable	   to	   do	   it	   online	   or	   need	   it	   in	   a	   different	   language	  please	  
contact	   us	   below	   and	   we	   will	   send	   out	   a	   paper	   copy	   with	   a	   stamped	   addressed	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envelope	  for	  you	  to	  return	  it.	  On	  finishing	  the	  questionnaire	  you	  will	  be	  given	  details	  to	  
access	  the	  results	  of	  this	  study	  when	  it	  is	  finished.	  	  
By	   filling	   in	   the	   questionnaire	   after	   reading	   this	   leaflet	   you	   are	   agreeing	   that	   you	  
understand	  the	   information	  provided	  and	  agree	   to	  us	  analysing	   the	  answers	  you	  give.	  
We	   ask	   if	   you	   do	   not	   agree	   to	   this	   then	   please	   do	   not	   submit	   your	   questionnaire	  
answers.	  
If	   you	   have	   any	   further	   questions	   please	   do	   not	   hesitate	   to	   contact	   us.	   As	   the	  
questionnaire	  is	  completed	  anonymously	  once	  submitted	  we	  will	  not	  be	  able	  to	  retrieve	  
and	  delete	  your	  answers	  as	  we	  will	  not	  know	  which	  they	  are.	  	  
	  
What	  are	  the	  risks	  associated	  with	  taking	  part	  in	  the	  research?	  
There	  are	  no	  risks	  associated	  with	  taking	  part	  in	  this	  study.	  	  
	  
What	  are	  the	  benefits	  of	  taking	  part	  in	  the	  research?	  
There	  are	  no	  direct	  benefits	  to	  yourself	  from	  taking	  part	  in	  this	  study.	  We	  are	  asking	  you	  
to	   help	   us	   in	   order	   for	   us	   to	   use	   your	   thoughts	   to	   help	   shape	   our	   shape	   our	   future	  
research.	  	  
	  
How	   will	   we	   ensure	   any	   personal	   information	   used	   during	   the	   research	   is	   kept	  
confidential?	  
No	   personally	   identifiable	   information	  will	   be	   needed	   to	   complete	   the	   questionnaire.	  
You	  will	  be	  asked	  for	  your	  age	  and	  employment	  to	  allow	  us	  to	  fully	  analyse	  the	  data.	  	  
If	   you	   request	   a	   paper	   copy	   your	   details	   will	   not	   be	   held	   on	   any	   record	   and	   will	   be	  
destroyed	  once	  the	  questionnaire	  has	  been	  sent	  out.	  	  
	  
Are	  there	  any	  reasons	  why	  I	  might	  not	  be	  eligible	  to	  take	  part	  in	  the	  research?	  
We	  require	  patients	  over	  the	  age	  of	  18	  years.	  	  
	  
Complaints	  
We	  hope	   you	   take	   part	   and	   find	   our	   study	   interesting.	   However	  we	   realise	   problems	  
may	  arise.	   If	   you	  have	  any	   concerns,	   please	   contact	   the	   researchers	   listed	  below.	  We	  
will	  do	  our	  best	  to	  answer	  any	  problems.	  If	  you	  are	  not	  happy	  with	  the	  outcome	  please	  
contact	  Prof	  R	  Lea	  whose	  details	  are	  available	  from	  Dr	  M	  Baker.	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The	   Rosemere	   Cancer	   Foundation,	   a	   local	   cancer	   charity	   for	   Lancashire	   and	   South	  
Cumbria,	  has	  funded	  this	  study.	  	  	  
	  
This	  study	  will	  form	  part	  of	  Dr	  Danielle	  Bury’s	  PhD	  project.	  	  
	  
As	  with	  all	  studies	  in	  the	  NHS	  it	  has	  been	  looked	  at	  by	  an	  independent	  group	  of	  people	  
who	   form	   the	  Research	   Ethics	   Committee.	   This	   is	   done	   to	  protect	   your	   interests.	   The	  
South	  West	  Wales	  Research	  Ethics	  Committee	  has	  reviewed	  this	  study.	  
	  
If	  you	  decide	  you	  do	  not	  wish	  to	  take	  part	   in	   the	  research	  at	  any	  time	  your	  medical	  
care	  will	  not	  be	  affected.	  
	  
Thank	  you	  for	  taking	  the	  time	  to	  read	  this	  leaflet.	  	  
	  
To	  visit	  and	  complete	  the	  questionnaire	  please	  go	  to	  XXXXXXX.	  It	  will	  be	  open	  from	  XX	  
to	  XX.	  	  
	  
For	   further	   information	   or	   to	   request	   the	   questionnaire	   in	   a	   different	   format	   please	  
contact	   either	   Dr	   Danielle	   Bury	   on	   debury@uclan.ac.uk	   or	   Dr	   Matthew	   Baker	   on	  
mjbaker@uclan.ac.uk	  or	  01772	  893209.	  
	  
Many	  Thanks,	  	  
	  
	  
	  
	  
Dr	  Danielle	  Bury	  and	  Dr	  Matthew	  Baker	  
University	  of	  Central	  Lancashire	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   1.10     
1.11 Lancashire Teaching Hospitals NHS Trust	  
	  	  	  
	  
	  	   	  
	  
Would	   you	   be	   interested	   in	  
taking	   part	   in	   cutting	   edge	  
research?	  
	  
• We	  are	  looking	  for	  people	  to	  complete	  an	  online	  questionnaire	  about	  
your	  preferences	  around	  cancer	  diagnostic	  testing	  in	  order	  to	  help	  us	  
direct	  our	  research	  into	  the	  development	  of	  a	  new	  diagnostic	  testing	  
device	  to	  help	  patients	  of	  the	  future.	  	  
• You	  must	  be	  over	  18	  years	  old	  to	  complete	  the	  questionnaire.	  
• The	   questionnaire	   will	   take	   approximately	   30minutes	   to	   complete	  
and	  is	  completely	  anonymous.	  
• Completion	   of	   the	   questionnaire	   is	   not	   compulsory	   and	   neither	  
your	  doctor	  nor	  GP	  will	  be	  informed.	  	  
• By	   completing	   the	   questionnaire	   you	   agree	   to	   our	   research	   team	  
analysing	   your	   results.	   As	   this	   is	   all	   done	   anonymously	   and	   once	  
completed	  your	  answers	  cannot	  be	  removed.	  	  
• More	  information	  can	  be	  found	  at	  the	  start	  of	  the	  questionnaire.	  
• For	   further	   questions,	   or	   if	   you	   would	   like	   to	   access	   the	  
questionnaire	  in	  a	  different	  format,	  for	  example	  a	  paper	  copy,	  please	  
contact	   either	   Dr	   Danielle	   Bury	   on	   debury@uclan.ac.uk	   or	   Dr	  
Matthew	  Baker	  on	  mjbaker@uclan.ac.uk	  or	  call	  01772	  893209.	  
• Otherwise	  please	  visit	  XXXXXX	  to	  complete	  the	  questionnaire!	  Thank	  
you	  for	  your	  input	  into	  our	  research.	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This	   study	   has	   been	   reviewed	   by	   the	   South	   West	   Wales	   Research	  
Ethics	  Committee.	  
 
	  
	  
Clinician	  Questionnaire	  
	  
Q1:	  Gender	  –	  Male/Female	  
Q2:	  Age	  (in	  years)	  
Q3:	  Ethnicity	  	  -­‐	  choices	  given	  
Q4:	  Employed	  
	   Full	  time	  
	   Part	  time	  
	   Retired	  
	   Student	  
	   Not	  employed	  
Q5:	  Job	  title	  
Q6:	  Household	  income	  –	  bracket	  figures	  given	  
Q7:	  Have	  you	  ever	  attended	  a	  cancer	  screening	  programme?	  –	  Yes	  or	  No	  
If	  No	  –	  is	  there	  a	  reason	  why	  you	  have	  not	  attended	  a	  cancer	  screening	  programme?	  
Q8:	  Who	  do	  you	  think	  should	  give	  a	  cancer	  diagnosis?	  Please	  select	  as	  many	  as	  	  	  	  	  	  	  are	  
applicable.	  
	   A	  doctor	  in	  a	  hospital	  
	   Your	  GP	  
	   A	  nurse	  
	   A	  clinical	  nurse	  specialist	  
	   Not	  bothered	  
	   Other	  (specify)	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   Who	  would	  prefer	  to	  give	  a	  cancer	  diagnosis?	  Select	  one	  from	  above.	  
Q9:	   From	   your	   experience	   of	   cancer	   diagnosis	   and	   treatment,	   do	   you	   feel	   there	   is	  
particular	  area	  that	  requires	  improvement?	  Please	  select	  as	  many	  as	  appropriate.	  
	   Method	  of	  diagnosis	  
	   Time	  taken	  for	  diagnosis	  
	   Ensuring	  complete	  removal	  of	  cancer	  at	  surgery	  
	   Explanation	  of	  diagnosis	  and	  treatment	  plan	  
	   None	  
	   N/A	  
	   Other	  (specify)	  
	   Please	  explain	  your	  response	  
Q10:	  How	  often	  do	  you	  come	  into	  contact	  with	  cancer	  patients?	  
	   Every	  day	  
	   Once	  a	  week	  
	   Once	  every	  2	  weeks	  
	   Once	  a	  month	  
	   Less	  often	  than	  once	  a	  month	  
Q11:	  How	  often	  do	  you	  diagnose	  cancer?	  
	   Every	  day	  
	   Once	  a	  week	  
	   Once	  every	  2	  weeks	  
	   Once	  a	  month	  
	   Less	  often	  than	  once	  a	  month	  
Q12:	  Are	  you	  involved	  with	  cancer	  treatment?	  
	   Yes	  or	  No	  
Q13:	  Where	  do	  you	  think	  patients	  should	  be	  diagnosed	  with	  cancer?	  
	   At	  home	  
	   GP	  surgery	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   Hospital	  
	   Other	  –	  Please	  specify	  
Q14:	  Where	  do	  you	  think	  patients	  would	  like	  to	  be	  diagnosed	  with	  cancer?	  
	   At	  home	  
	   GP	  surgery	  
	   Hospital	  
	   Other	  –	  Please	  specify	  
Q15:	   If	  we	  were	   to	  offer	  you	  a	  screening	   test	   that	  may	  diagnose	  a	  cancer	   for	  which	  a	  
patient	  had	  no	   symptoms	  and	  did	  not	   know	   they	  had,	  would	   you	   recommend	   this	   to	  
patients?	  Please	  explain	  your	  response.	  
Q16:	  Which	  investigations	  do	  you	  think	  patients	  find	  acceptable	  and	  which	  are	  not?	  (By	  
acceptable	  we	  mean	   you	  would	   be	  willing	   to	   accept	   the	   test	   and	   do	   not	   feel	   it	   is	   an	  
unreasonable	  test	  when	  looking	  for	  cancer).	  On	  the	  scale	  provided	  please	  indicate	  your	  
level	  of	  acceptability	  for	  each	  of	  the	  tests.	  1	  indicates	  ‘Not	  acceptable,	  to	  10	  indicating	  
‘acceptable	  with	  no	  concerns’.	  
	   Xray	  
	   Blood	  test	  
	   MRI	  scan	  
	   CT	  scan	  
PET	   CT	   –	   this	   is	   a	   type	   of	   CT	   scan	   that	   involves	   injecting	   a	   dye	   to	   highlight	   any	  
abnormalities	  –	  not	  all	  cancers	  react	  to	  this	  dye	   	  
Biopsy	  with	   local	   anaesthetic	   (local	   anaesthetic	   is	   the	   use	   of	   a	   drug	  which	   is	   injected	  
into	  the	  biopsy	  site	  to	  make	  it	  numb	  so	  no	  pain	  is	  felt	  during	  the	  biopsy,	  you	  are	  awake	  
during	  this)	  
Biopsy	  with	  general	  anaesthetic	  (this	  is	  a	  biopsy	  where	  you	  are	  put	  to	  sleep)	  
	   A	  physical	  examination	  by	  a	  doctor	  eg	  listening	  to	  your	  chest	  
Q17:	  At	  what	  point	  would	  you	  EXPECT	  diagnosis	  of	  cancer	  to	  occur?	  Please	  select	  one	  
response	  	  -­‐	  time	  scales	  given,	  please	  explain	  your	  response	  
Q18:	   At	   what	   point	   would	   you	   LIKE	   (in	   a	   ideal	   world)	   diagnosis	   of	   cancer	   to	   occur?	  
Please	  select	  one	  response.	  -­‐	  time	  scales	  given,	  please	  explain	  your	  response	  
Q19:	   Do	   you	   believe	   you	   are	   fully	   informed	   and/or	   can	   access	   information	   about:	  
Strongly	  agree	  to	  strongly	  disagree.	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   Risks	  of	  cancer	  
	   Risks	  of	  investigative	  tests	  
	   Risks	  of	  treatment	  
	   Complications	  of	  treatment	  
	   Diagnosis	  
	   Impact	  of	  quality	  of	  life	  
Q20:	  Based	  on	  your	   role	  within	   the	  cancer	   care	  pathway,	  where	  do	  you	   feel	   research	  
can	   most	   benefit	   patients?	   For	   example,	   blood	   test	   diagnosis,	   detecting	   microscopic	  
cells	  at	  surgery	  to	  ensure	  complete	  clearance?	  Etc.	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Diagnostic	  Innovation	  in	  Cancer	  –	  Patient	  Questionnaire	  
	  
Q1:	  What	  is	  your	  gender?	  
	   	  
  Male	  	   	   	  
	     Female	   	  
	  
Q2:	  What	  is	  your	  age	  (in	  years)?	  
	   	  
……………….	  
	  
Q3:	  What	  is	  your	  ethnicity?	  	  
	  
White	  
	   ☐	  British	   	            
	   ☐	  Irish	   	            
	   ☐	  Other	   	            
Asian	  or	  Asian	  British	  
	   ☐	  Indian	             
	   ☐	  Pakistani	             
	   ☐	  Bangladeshi	             
	   ☐	  Any	  other	  Asian	  background	             
Mixed	  
	  
☐	   White	   and	   Black	  
Caribbean	  
          
	  
☐	   White	   and	   black	  
African	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   ☐	  White	  and	  Asian	             
	  
☐	   Any	   other	   mixed	  
background	  
          
Black	  or	  Black	  British	  
	   ☐	  Caribbean	             
	   ☐	  African	             
	  
☐	   Any	   other	   black	  
background	  
          
Other	  Ethnic	  Group	  
	   ☐	  Chinese	             
	  
☐	   Any	   other	   Ethnic	  
Group 
          
	  
☐	   I	  do	  not	  wish	   to	  disclose	  my	  
ethnic	  origin	  
          
	  
Q4:	  What	  is	  your	  employment	  status?	  
	   ☐	  Full	  time	  
	   ☐	  Part	  time	  
	   ☐	  Retired	  
	   ☐	  Student	  
	   ☐	  Not	  employed	  
	  
Q5:	  What	  is	  your	  job	  title?	  
	  
	   ……………………………….	  
Q6:	  What	  is	  your	  household	  income?	  
	  
☐	  Less	  than	  £10,0000	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☐	  	  £10,000	  to	  
£19,999	  
☐	   £20,000	   to	  
£29,999	  
☐	   £30,000	   to	  
£39,999	  
☐	   £40,000	   to	  
£49,999	  
☐	   £50,000	   to	  
£59,999	  
☐	   £60,000	   to	  
£69,999	  
☐	   £70,000	   to	  
£79,999	  
☐£80,000	   to	  
£89,999	  
☐	   £90,000	   to	  
£99,999	  
☐	   £100,000	  
to	  £149,999	  
☐	   £150,000	  
or	  more	  
	  
	  
Q7:	  Do	  you	  have	  experience	  of	  cancer?	  Please	  select	  as	  many	  as	  are	  applicable	  
	  
	   ☐	  Personal	  
	   ☐	  Close	  family	  (eg	  parents,	  children,	  siblings)	  
	   ☐	  Distant	  family	  (eg	  aunts/uncles,	  grandparents)	  
	   ☐	  Friend	  
	   ☐	  None	  of	  the	  above	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Q8:	  Do	  you	  have	  a	  family	  history	  of	  cancer?	  Please	  select	  as	  many	  as	  are	  applicable	  
	  
	   ☐	  1st	  degree	  relative	  –	  this	  may	  be	  your	  mother,	  father,	  brother	  or	  sister	  
☐	  2nd	  degree	  relative	  –	  this	  may	  be	  your	  grandparents,	  aunts/uncles,	  nephews/nieces	  
	  
☐	  Known	  genetic	  abnormality	  –	  have	  you	  ever	  had	  a	  test	  from	  a	  doctor	  that	  has	  shown	  
a	  change	  in	  one	  of	  your	  genes	  that	  gives	  you	  a	  higher	  change	  of	  getting	  cancer?	  
	  
	   ☐	  Not	  applicable	  
	   ☐Other	  (Please	  specify)	  
	   	  
	   …………………………..	  
	  
Q9:	  Have	  you	  ever	  attended	  a	  cancer	  screening	  programme?	  	  
	  
☐Yes	  
☐	  No	  
If	  No	  –	  is	  there	  a	  reason	  why	  you	  have	  not	  attended	  a	  cancer	  screening	  programme?	  
	  
…………………………………………………………………………………………………………	  
Q10:	  If	  you	  needed	  to	  attend	  an	  appointment	  testing	  for	  cancer,	  what	  is	  the	  travel	  time	  
to	  your	  nearest	  hospital	  that	  offers	  cancer	  tests?	  	  
	  
	   ☐	  Less	  than	  30	  minutes	  
	 ☐	  Between	  30	  mins	  to	  an	  hour	  
	   ☐	  More	  than	  1	  hour	  
	 ☐	  Don’t	  know	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Q11:	  On	  average,	  how	  often	  do	  you	  come	  into	  contact	  with	  healthcare	  professionals?	  –	  
by	   this	   we	  mean	   a	   GP,	   a	   doctor	   in	   a	   hospital,	   or	   a	   nurse	   (including	   cancer	   specialist	  
nurse).	  Please	  select	  one.	  
	  
	   ☐	  More	  than	  once	  a	  week	  
	   ☐	  Once	  a	  week	  
	   ☐	  Once	  a	  month	  
	   ☐	  Once	  every	  3	  months	  
	   ☐	  Once	  a	  year	  
	   ☐	  Less	  than	  once	  a	  year	  
	  
Q12:	  Who	  is	  the	  healthcare	  professional	  you	  come	  into	  contact	  with	  most	  frequently?	  
	  
	   …………………………………………………………………………………………………	  
	  
Q13:	  Where	  would	  you	  prefer	  to	  be	  informed	  of	  your	  diagnosis?	  Please	  choose	  one	  	  
	   ☐	  At	  home	  
	   ☐	  GP	  Surgery	  
	   ☐	  Consultant	  Clinic	  
	   ☐	  At	  Optician/dentist/pharmacy	  
	   ☐	  Not	  bothered	  
	   ☐	  Other	  (please	  specify)	  
	  
	   ……………………………………	  
Please	  explain	  your	  response:	  
	  
……………………………………………………………………………………………………………………	  
	  
	   	   	  184	  
……………………………………………………………………………………………………………………	  
	  
……………………………………………………………………………………………………………………	  
	  
Q14:	   Who	   do	   you	   think	   should	   give	   a	   cancer	   diagnosis?	   Please	   select	   as	   many	   as	  
applicable	  	  	  
	  
☐	  A	  doctor	  in	  a	  hospital	  
☐	  Your	  GP	  
☐	  Nurse	  	  
☐	  Clinical	  Nurse	  Specialist	  (a	  nurse	  who	  deals	  solely	  with	  patients	  that	  have	  one	  type	  of	  
cancer	  or	  disease)	  
☐	  Not	  bothered	  
☐	  Other	  (specify)	  	  
	  
…………………………………..	  
	  
Who	  would	  you	  prefer	  to	  give	  a	  cancer	  diagnosis?	  Select	  one	  of	  the	  above	  and	  explain.	  
	  
………………………………………………………………………………………………………...	   	  
	  
…………………………………………………………………………………………………………	  
	  
…………………………………………………………………………………………………………	  
	  
Q15:	   From	  your	   experience	  of	   cancer	  diagnosis	   and	   treatment,	   do	   you	   feel	   there	   is	   a	  
particular	  area	  that	  requires	  improvement?	  Please	  select	  as	  many	  as	  are	  applicable.	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   ☐	  Method	  of	  diagnosis	  
	   ☐	  Time	  taken	  for	  diagnosis	  
	   ☐	  Ensuring	  complete	  removal	  of	  cancer	  at	  surgery	  
	   ☐	  None	  
	   ☐	  Not	  applicable	  
	   ☐	  Other	  (please	  specify)	  
	   	  
	   …………………………………….	  
	  
Please	  explain	  your	  answer:	  
	  
………………………………………………………………………………………………………...	   	  
	  
…………………………………………………………………………………………………………	  
	  
…………………………………………………………………………………………………………	  
	  
Q16:	  If	  we	  were	  to	  offer	  you	  a	  screening	  test	  that	  may	  diagnose	  a	  cancer	  for	  which	  you	  
have	  had	  no	  symptoms	  and	  did	  not	  know	  you	  had,	  would	  you	  take	  up	  the	  offer?	  	  
	  
	   ☐	  Yes	  
	   ☐	  No	  
	   ☐	  Don’t	  know	  
	  
Please	  explain	  your	  response.	  
	  
………………………………………………………………………………………………………...	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…………………………………………………………………………………………………………	  
	  
…………………………………………………………………………………………………………	  
	  
Q17:	  Which	  investigations	  do	  you	  find	  acceptable	  and	  which	  are	  not?	  (By	  acceptable	  we	  
mean	  you	  would	  be	  willing	  to	  accept	  the	  test	  and	  do	  not	  feel	  it	  is	  an	  unreasonable	  test	  
when	   looking	   for	   cancer).	   Please	   indicate	   your	   level	   of	   acceptability	   for	   each	   of	   the	  
tests.	  1	  indicates	  ‘Not	  acceptable,	  to	  10	  indicating	  ‘acceptable	  with	  no	  concerns’.	  
	  
	   ☐	  Xray	  
	   ☐	  Blood	  test	  
	   ☐	  MRI	  scan	  
	   ☐	  CT	  scan	  
☐	   PET	   CT	   –	   this	   is	   a	   type	   of	   CT	   scan	   that	   involves	   injecting	   a	   dye	   to	   highlight	   any	  
abnormalities	  –	  not	  all	  cancers	  react	  to	  this	  dye	   	  
	  
☐	  Biopsy	  with	  local	  anaesthetic	  (local	  anaesthetic	  is	  the	  use	  of	  a	  drug	  which	  is	  injected	  
into	  the	  biopsy	  site	  to	  make	  it	  numb	  so	  no	  pain	  is	  felt	  during	  the	  biopsy,	  you	  are	  awake	  
during	  this)	  
	  
☐	  Biopsy	  with	  general	  anaesthetic	  (this	  is	  a	  biopsy	  where	  you	  are	  put	  to	  sleep)	  
	  
	   ☐	  A	  physical	  examination	  by	  a	  doctor	  eg	  listening	  to	  your	  chest	  
	  
Q18:	  Which	  of	  the	  investigations	  below	  would	  you	  NOT	  want	  to	  have	  if	  you	  were	  being	  
investigated	  for	  cancer?	  Please	  select	  as	  many	  as	  are	  applicable.	  
	  
	   ☐	  Blood	  test	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☐	  Invasive	  test	  eg	  endoscopy	  –	  this	  involves	  a	  camera	  being	  inserted	  for	  example	  into	  
your	  bowel	  to	  look	  at	  the	  bowel	  and	  take	  a	  biopsy	  
	  
☐	  Invasive	  test	  eg	  surgery	  –	  this	  would	  involve	  putting	  you	  to	  sleep	  to	  look	  closely	  at	  a	  
suspected	  cancer	  
	   	  
☐	  Scan	  eg	  MRI/CT	  
	   ☐	  I	  would	  allow	  any	  of	  the	  above	  investigations	  to	  be	  done	  
	   	  
Please	  explain	  your	  response	  
	  
………………………………………………………………………………………………………...	   	  
	  
…………………………………………………………………………………………………………	  
	  
…………………………………………………………………………………………………………	  
	  
Q19:	  At	  what	  point	  would	  you	  EXPECT	  diagnosis	  of	  cancer	  to	  occur?	  Please	  select	  one	  
response	  	  	  
	  
	   ☐	  Before	  you	  feel	  unwell	  
	   ☐	  When	  you	  visit	  your	  GP	  
	   ☐	  At	  first	  medical	  appointment	  with	  a	  specialist	  doctor	  
	   ☐	  Within	  1	  week	  of	  first	  appointment	  with	  specialist	  doctor	  
	   ☐	  Within	  1	  month	  of	  first	  appointment	  with	  specialist	  doctor	  
	   ☐	  I	  would	  not	  like	  to	  know	  
	  
Please	  explain	  your	  response	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………………………………………………………………………………………………………...	   	  
	  
…………………………………………………………………………………………………………	  
	  
Q20:	   At	   what	   point	   would	   you	   LIKE	   (in	   a	   ideal	   world)	   diagnosis	   of	   cancer	   to	   occur?	  
Please	  select	  one	  response.	  	  
	  
	   ☐	  Before	  you	  feel	  unwell	  
	   ☐	  When	  you	  visit	  your	  GP	  
	   ☐	  At	  first	  medical	  appointment	  with	  a	  specialist	  doctor	  
	   ☐	  Within	  1	  week	  of	  first	  appointment	  with	  specialist	  doctor	  
	   ☐	  Within	  1	  month	  of	  first	  appointment	  with	  specialist	  doctor	  
	   ☐	  I	  would	  not	  like	  to	  know	  
	  
Please	  explain	  your	  response	  
	  
………………………………………………………………………………………………………...	   	  
	  
…………………………………………………………………………………………………………	  
	  
…………………………………………………………………………………………………………	  
	  
Q21:	   In	   your	   experience	   (personal	   or	   from	   someone	   you	   know),	   what	   was	   the	   time	  
frame	  from	  first	  visit	  to	  GP	  to	  diagnosis	  of	  cancer?	  	  
	  
	   ☐	  Less	  than	  2	  weeks	  
	   ☐	  2-­‐4	  weeks	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   ☐	  4-­‐8	  weeks	  
	   ☐	  Not	  applicable/not	  known	  
	   ☐	  More	  than	  2	  months	  –	  please	  specify	  
	  
	   …………………………………………………………	  
	  
Q22:	   Do	   you	   believe	   you	   are	   fully	   informed	   and/or	   can	   access	   information	   about:	  
Strongly	  agree	  to	  strongly	  disagree.	  	  
	  
	   Strongly	  
Agree	  
Agree	   Neutral	   Disagree	   Strongly	  
Disagree	  
Risks	  of	  
cancer	  
	   	   	   	   	  
Risks	  of	  
investigative	  
tests	  
	   	   	   	   	  
Risks	  of	  
treatment	  
	   	   	   	   	  
Complications	  
of	  treatment	  
	   	   	   	   	  
Diagnosis	   	   	   	   	   	  
Impact	  of	  
quality	  of	  life	  
	   	   	   	   	  
	  
	  
Thank	  you	  for	  taking	  the	  time	  to	  answer	  this	  survey!	  
	  
If	  you	  have	  any	  concerns	  or	  questions	  about	  this	  survey,	  please	  contact	  the	  researchers	  
listed	  below.	  We	  will	  do	  our	  best	  to	  answer	  any	  problems.	  If	  you	  are	  not	  happy	  with	  the	  
outcome	  please	  contact	  Prof	  R	  Lea	  whose	  details	  are	  available	  from	  Dr	  D	  Bury.	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The	   Rosemere	   Cancer	   Foundation,	   a	   local	   cancer	   charity	   for	   Lancashire	   and	   South	  
Cumbria,	  has	  funded	  this	  study.	  As	  with	  all	  studies	  in	  the	  NHS	  it	  has	  been	  looked	  at	  by	  
an	  independent	  group	  of	  people	  who	  form	  the	  Research	  Ethics	  Committee.	  This	  is	  done	  
to	   protect	   your	   interests.	   The	   South	   West	   Wales	   Research	   Ethics	   Committee	   has	  
reviewed	  this	  study.	   If	  you	  decide	  you	  do	  not	  wish	  to	  take	  part	   in	  the	  research	  at	  any	  
time	  your	  medical	  care	  will	  not	  be	  affected.	  
	  
For	   further	   information	   or	   to	   request	   the	   questionnaire	   in	   a	   different	   format	   please	  
contact	   Dr	   Danielle	   Bury	   on	   debury@uclan.ac.uk	   or	   Dr	   Michelle	   McManus	   on	  
mamcmanus@uclan.ac.uk	   or	   01772	   894154.	   The	   School	   of	   Forensic	   and	   Investigative	  
Sciences	  (FIS)	  office	  can	  be	  contacted	  on	  01772	  895687	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9.6 Brain Tumour North West Ethical Approval 
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9.7 Poster presented at Spec Summer School 2015. 
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9.8 Poster presented at Clir Spec 2017. 
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9.9 Abstract accepted by the American Society of Clinical 
Oncology 
	  
Spectrochemical	   analysis	   highlights	   chemical	   constituent	   similarities	   in	  
adenocarcinomas	  irrespective	  of	  primary	  tissue	  origins	  
	  
INTRODUCTION:	   Identification	   of	   primary	   tissue	   origin	   of	   brain	   metastases	   can	   be	  
histopathologically	   challenging.	   Initial	   diagnosis	   of	   malignancy	   can	   be	   provided	   on	  
intraoperative	  tissue	  smears;	  however,	  it	  requires	  formal	  histopathological	  examination	  
along	  with	   immunohistochemistry	   to	   reach	  a	   final	  diagnosis.	  On	  occasion	   this	  will	   still	  
fail	  to	  determine	  primary	  origin.	  This	  study	  aims	  to	  demonstrate	  if	  Raman	  spectroscopy	  
is	  able	  to	  determine	  primary	  tissue	  origin	  of	  brain	  metastasis	  of	  three	  common	  primary	  
tumours.	  
METHOD:	   Formalin	   fixed	   paraffin	   embedded	   tissue	   from	   twenty	   brain	   metastasis	  
comprising	   colorectal	   adenocarcinomas	   (n=7),	   lung	   adenocarcinomas	   (n=7)	   and	  
melanomas	   (n=6)	   were	   obtained	   from	   the	   Brain	   Tumour	   NorthWest	   tissue	   bank.	  
Sections	  (10-­‐μm	  thick)	  were	  placed	  onto	  glass	  slides	  covered	  in	  aluminium	  foil	  and	  de-­‐
waxed	  prior	   to	   spectral	   acquisition.	   25	   spectra	  per	   section	  were	   collected	   at	   random,	  
using	   a	   785	   nm	   laser	   at	   1200	   g	   mm-­‐1	   grating	   with	   an	   acquisition	   time	   of	   30	   sec.	  
Computational	  analysis	  within	  a	  MatLab	  environment	  was	  then	  conducted.	  	  
RESULTS:	   Following	   PCA-­‐LDC	   analysis,	   classification	   accuracy	   of	   the	   three	   groups	  was	  
colorectal	   adenocarcinoma	   71.3%,	   lung	   adenocarcinoma	   71%	   and	   melanoma	   70%.	   A	  
one-­‐way	  ANOVA	  showed	  statistically	  significant	  differences	  between	  the	  three	  groups,	  
p=0.0014.	   On	   combining	   adenocarcinoma	   groups	   accuracy	   increased	   to	   87.8%,	  whilst	  
melanoma	   fell	   to	   68.9%.	   A	   student’s	   t-­‐test	   confirmed	   statistical	   significance	   between	  
the	  two	  groups,	  p<0.0001.	  	  
CONCLUSION:	   Raman	   spectroscopy	   can	   classify	   different	   tumours	   by	   type,	   though	  
sensitivity	   and	   specificity	   is	   diminished	   if	   used	   to	   classify	   primary	   tissue	   origin	   of	  
adenocarcinomas.	   Therefore	   for	   clinical	   use,	   such	   new	   tools	   may	   aid	   the	   clinician	   to	  
determine	  tumour	  type	   intra-­‐operatively	  but	  classic	  histopathology	   is	  still	   required	  for	  
tissue	   origin	   confirmation.	   Such	   technologies	   may	   provide	   a	   useful	   adjunct	   to	   more	  
conventional	  approaches;	  for	  instance,	  decreasing	  the	  number	  of	  immunohistochemical	  
stains	  required	  to	  determine	  tissue	  origin.	  	  These	  results	  also	  suggest	  strong	  similarities	  
between	  adenocarcinomas	  of	  different	  primary	  origins.	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9.10 Standard Operating Procedure and Risk Assessment for 
Hand Held Raman Probe 
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1. Introduction 
  
Raman spectroscopy is to be compared with light microscopic H&E 
smear examination for the intra-operative diagnosis of brain tumours. 
 
2. Specimen Requirements 
	  
Fresh	  brain	  tissue	  sample	  
	  
3. Principle of the Test 
	  
The	  Raman	  spectra	  produced	  from	  shining	  a	  laser	  through	  a	  piece	  of	  tissue	  is	  unique	  to	  
the	  tissue.	  The	  position	  of	  the	  peaks	  can	  be	  used	  to	  differentiate	  between	  tumour	  and	  
non-­‐tumour	  tissue	  and	  between	  different	  types	  and	  grades	  of	  tumour.	  
	  
4. Health and Safety 
	  
CAUTION	  -­‐	  Laser	  can	  cause	  blindness	  and	  burning	  to	  the	  skin	  and	  clothing	  
Never	  look	  directly	  into	  the	  laser	  beam	  path	  or	  scattered	  laser	  light	  from	  any	  reflective	  
surface.	  	  
Never	  look	  directly	  into	  the	  laser	  source.	  	  
Maintain	  a	  low	  beam	  level	  when	  performing	  experimental	  setup	  to	  prevent	  inadvertent	  
beam-­‐eye	  contact.	  	  
As	   a	   precaution	   against	   accidental	   exposure	   to	   the	   laser	   beam	  or	   its	   reflection,	   users	  
should	  always	  wear	  laser	  safety	  glasses	  with	  sufficient	  attenuation	  for	  the	  laser.	  
Never	  point	  laser	  directly	  at	  skin	  or	  clothing	  	  
	  
Standard	  laboratory	  Health	  and	  safety	  precautions	  must	  be	  adopted	  at	  all	  times.	  For	  full	  
details	  see,	  ‘Safe	  working	  and	  Prevention	  of	  infection	  in	  Clinical	  Laboratories	  and	  similar	  
facilities’	  or	  	  	  	  	  	  	  S	  DI	  SPECHANDLING	  
	  
5. Equipment and Materials 
 
Portable i-Raman spectroscopy machine and probe 
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PC with BWspec software installed 
Laser protection glasses 
Glass	  slides	  covered	  with	  tinfoil	  
BioPureTM	  20nm	  Gold	  Nanoparticles	  
Phosphate	  buffer	  
Pipetters	  and	  tips	  
Vortexer 
 
6. Method 
 
If	  using	  nanoparticles,	  vortex	  BioPureTM	  20nm	  Gold	  Nanoparticles	  solution	  immediately	  
before	  dilution	  
Dilute 2 µL of vortexed nanoparticles with 200 µL phosphate buffer 
 
Turn on computer and login 
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Turn on laser at back of machine (interlock plug and key in desk top 
drawer in Neuro main lab) 
 On/Off power switch to On position 
 Put interlock plug into plug port 
 Insert key and turn to On position 
 
Put tissue on slide coated with aluminium foil. 
If using nanoparticles, cover tissue with 100 µL of freshly vortexed, 
diluted nanoparticle solution. 
Allow tissue to absorb solution for a few minutes. 
 
Open software on PC – BWspec 
‘Online’	   appears	   at	   the	  bottom	   left	   corner	   of	   the	  BWSpec	  main	   screen,	   indicating	  
that	   the	   communication	   between	   the	   i-­‐Raman	   and	   the	   computer	   has	   been	  
established.	  
	  
Put on laser protection glasses 
Remove protective sleeve from end of probe 
Secure probe in black box using clamp 
 
Perform ‘Dark Scan’ 
 Close manual shutter on probe 
 In BWspec change milliseconds field to 30,000 
    Set laser power to 75 
    Set Y axis type to ‘Dark’ 
 Click ‘Dark Scan’ button 
 After scan has completed set Y axis type to ‘Dark Subtracted’ 
 
 
Insert slide into black box, centre laser on tissue using platform screws 
 
Slide manual laser shutter to open 
 
Check probe is over the top of the tissue, approx. 6mm above tissue and 
laser is shining through the tissue 
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Check milliseconds and laser power settings on BWspec haven’t 
changed 
 
Click on ‘Acquire Overlay’ play button to record spectrum 
 
Repeat nine times more to give 10 spectra on graph. Move tissue slightly 
between scans. 
 
Right click in ‘Spectrum List Panel’ 
Save All 
Or File 
 Save All Spectra As – save each spectrum individually 
 Close 
 
 Save as txt and csv file 
 Filename use N17.xxx 
 
Fix fresh tissue analysed with i-Raman with the remaining intra-operative 
sample 
 
Slide manual laser shutter to closed 
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Switch	  off	  laser	  
 Turn key to Off position 
 Remove interlock plug 
 On/Off power switch to Off position 
 
Remove laser from black box by releasing clamp 
Replace protective sleeve on end of probe 
 
Close BW spec software 
 
Log off, turn off computer if no further intra-operative specimens expected 
 
Replace key and interlock plug to drawer, glasses to case 
 
 
7. References 
 
290020077-G i-Raman Manual T:\Pathology-RPH\Neuropathology - 
RPH\Data\Research\RTB Brain CNS\Applications for tissue\Approved\1407 
Danielle Bury\290020077-G i-Raman Manual.pdf 
 
290020175-E-BAC100 BAC102 Lab Grade Raman Probe User Manual 
T:\Pathology-RPH\Neuropathology - RPH\Data\Research\RTB Brain 
CNS\Applications for tissue\Approved\1407 Danielle Bury\290020175-E-BAC100 
BAC102 Lab Grade Raman Probe User Manual.pdf 
 
BioPureTM Gold Nanoparticles Safety Data Sheet 
https://cdn.shopify.com/s/files/1/0257/8237/files/NCX.MSDS-
BioPure.Gold.Citrate.pdf?25143 
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HEALTH AND SAFETY 
 
RISK ASSESSMENT FORM   
	  
Locations – Ward/Department Pathology  
 
Personnel Involved In The Assessment Biomedical scientists and pathologists. 
 
1.11.1.1.1.1.1 Date	  of	  initial	  assessment	  02/03/2017	  
	  
Date of re-assessment 
 
Date of next review 02/03/2018  
 
Assessor   Kate Ashton   Signature  
 
 
Hazard and effect of the hazard. 
 
Biohazard – Fresh tissue 
All unfixed tissue, intra-operative specimens for smears or frozen sections, that are sent to the 
department for processing pose a risk of infection that may not be known. 
Electrical hazard – Portable Raman machine and PC are plugged in to the mains power 
 
Physical hazard – sharps – glass slides and scalpel blade 
Scalpel blades and other dissection equipment are sharp and pose a risk of laceration if not handled 
carefully 
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Laser hazard – Laser can cause blindness and burning to the skin and clothing 
 
 
 
 
Who may be harmed and how. 
List groups of people who are specifically at risk from the significant hazards identified.  
Specify numbers 
 
n All grades of BMS staff - 4 
n Pathologists - 4 
 
 
Is the risk adequately controlled? 
List existing control measures here or note where the information can be found.  E.g. existing 
policies, procedures, work instructions etc.  
 
Biohazard - Wear appropriate PPE (lab coat and/or protective apron and nitrile gloves) when handling 
fresh tissue. Handle inside the category 2 safety cabinet. Clean all equipment with 1% Distel and/or 
70% alcohol before removing from cabinet. 
 
Electrical - All Electrical equipment is CE marked and PAT tested for safety as per the Trust policy. 
Electrical equipment must be isolated from the supply if internal maintenance is to be performed 
during servicing or repair. 
 
Physical – Handle glass slides with care, dispose in a sharps bin if any edges or corners are broken 
and when no longer required. Scalpel blades should be handled with care and removed from handle 
using special box provided in safety cabinet. 
 
Laser – The system has two safety features: a key-activated laser switch and an interlock. These are 
designed to prevent the user from accidentally turning on the laser. To turn on the laser, insert the 
interlock plug and insert the supplied key into the key-switch. Turn the key 90 degrees clockwise to 
turn on the laser. The laser will turn on after a delay of 5 – 10 seconds. The key cannot be removed 
when it is in the ON position.  
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When the safety interlock plug is removed from the system, all electrical power to the laser will be 
turned off. The safety interlock MUST be inserted before the laser can be turned on. Laser emission 
will stop if the interlock is removed while the laser is on. Laser safety glasses should always be worn 
when the laser is in use. 
 
Training – Biomedical scientists and pathologists are trained to handle fresh tissue and sharps safely 
and do so daily. 
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1.11.1.1.1.1.2 Residual	  risk	  rating	  after	  controls	  
 
Biohazard 
P = Probability 1 
C = Consequence 2  
R = Risk Rating PxC 2 
 
Electrical 
P = Probability 1 
C = Consequence 1  
R = Risk Rating PxC 1 
 
Physical 
P = Probability 1 
C = Consequence 2  
R = Risk Rating PxC 2 
 
Laser 
P = Probability 1 
C = Consequence 4  
R = Risk Rating PxC 4	  
 
 
High (>15) 
 
 
Significant 
(8 to 14) 
 
Moderate (4 to 
7) 
 
Low (1 to 3) 
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What further action is necessary to control the risk? 
List the risks which are not adequately controlled and the 
actions you will take to mitigate the risks in so far as is 
reasonable practicable. 
 
None 
 
Date 
to be 
Taken 
 
 
A
cti
o
n 
B
y 
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1.11.1.1.1.1.3 C.	  	  	  Potential	  Consequence	  of	  incident/hazard/estimated	  financial	  loss	   P
.
	  	  
P
r
o
b
a
b
i
l
i
t
y	  5.	   Death	   or	   any	   incident	  where	   there	  
may	   be	   	   grounds	   for	   taking	   legal	  
action	  
Long	   term	  
sickness	  
Major	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9.11 Set up documents for the Hand Held Raman Probe 
 
Prior to using the hand held Raman machine a custom built box was required to ensure 
darkness when analysing the tissue. As this was being placed into a working laboratory it 
would not be possible to work in darkness and it would also need to fit into a category 2 
fume hood for work with fresh tissue. With this is mind a box was custom engineering 
(see figure 1) using plywood. A stage was built within to allow the slide to be moved in 
the x and y planes with custom cut out area for the slide to be held securely. This was to 
allow the tissue to be accurately positioned under the probe. A clamp was then secured to 
the box to allow the probe to be moved in the z plane to allow it to be positioned at the 
correct height above the tissue.  
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Figure 9.1: Pictures showing the production of the box; from initially cutting the wood, to 
routing the slide shape, painting to the finished product in situ in the neuropathology 
department at Royal Preston Hospital.  
	  
The box was painted with black paint inside to minimise reflection of any light entering 
it. It also enabled it to be wiped clean if required.  
Initially frozen tissue from a high-grade glial tumour was selected from the BTNW brain 
bank. This was to ensure no fresh diagnostic material was damaged during the initial 
work up phase. This also allowed comparison of spectra from the tumour at different 
settings on the hand held Raman machine. Different laser power and time periods were 
tested. Raman analysis was performed over a range of exposure times (25-60seconds) 
and laser power (25-100%). The tissue was thawed prior to use and an amount similar to 
that used for a smear (less than 5mm in maximum diameter) was placed onto a glass side 
and compared with a glass slide covered with aluminium foil. This was placed into the 
Raman box for analysis. Spectra were analysed and tissue processed into a smear and a 
separate FFPE block to examine for any diathermy or other tissue damage. 
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Figure 9.2: Graphs demonstrated a variety of laser power and time using fresh brain tissue.  
 
This demonstrated that the aluminium foil being present improved the quality of the 
spectra and also that 30 seconds was the optimum time as the graph did not show 
saturation (straight line seen on 45 second graphs). The power was increased to 75% as 
this did not damage the tissue. At 60 seconds the graph showed marked distortion though 
the tissue was undamaged. A graph comprising just aluminium foil was also taken to 
show this did not interfere with the results. Ten spectra per case were obtained, 
nanoparticles were then added to enhance spectral quality.  
The lack of structural tissue damage was also assessed by a consultant neuropathologist 
(Prof. T Dawson), to ensure he was happy with the tissue post analysis. Once the settings 
were determined a standard operating procedure (SOP) document for the use of the 
Raman machine was produced (above) along with a risk assessment. These were required 
for it to be used within the laboratory with samples.  
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